SI8912489A - Novi IL-2 receptor specifični humani imunoglobulini - Google Patents
Novi IL-2 receptor specifični humani imunoglobulini Download PDFInfo
- Publication number
- SI8912489A SI8912489A SI8912489A SI8912489A SI8912489A SI 8912489 A SI8912489 A SI 8912489A SI 8912489 A SI8912489 A SI 8912489A SI 8912489 A SI8912489 A SI 8912489A SI 8912489 A SI8912489 A SI 8912489A
- Authority
- SI
- Slovenia
- Prior art keywords
- immunoglobulin
- human
- amino acid
- network
- antibodies
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 130
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 130
- 102000010789 Interleukin-2 Receptors Human genes 0.000 title claims abstract description 31
- 108010038453 Interleukin-2 Receptors Proteins 0.000 title claims description 19
- 229940072221 immunoglobulins Drugs 0.000 title abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 30
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims description 87
- 210000004027 cell Anatomy 0.000 claims description 66
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 108010002350 Interleukin-2 Proteins 0.000 claims description 13
- 102000000588 Interleukin-2 Human genes 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 241001529936 Murinae Species 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 102000055277 human IL2 Human genes 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 239000000539 dimer Substances 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 210000001525 retina Anatomy 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 12
- 230000015572 biosynthetic process Effects 0.000 abstract description 11
- 238000003786 synthesis reaction Methods 0.000 abstract description 11
- 108020004511 Recombinant DNA Proteins 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 239000012634 fragment Substances 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 239000012636 effector Substances 0.000 description 8
- 239000002596 immunotoxin Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000002637 immunotoxin Effects 0.000 description 7
- 229940051026 immunotoxin Drugs 0.000 description 7
- 231100000608 immunotoxin Toxicity 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 229940127089 cytotoxic agent Drugs 0.000 description 6
- 239000002254 cytotoxic agent Substances 0.000 description 6
- 231100000599 cytotoxic agent Toxicity 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 108010039491 Ricin Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 2
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- CSOJYIADHHNGRM-UHFFFAOYSA-N (+-)-6-(4-oxo-thiazolidin-2-yl)-hexanoic acid Natural products OC(=O)CCCCCC1NC(=O)CS1 CSOJYIADHHNGRM-UHFFFAOYSA-N 0.000 description 1
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101001009851 Rattus norvegicus Guanylate cyclase 2G Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001474728 Satyrodes eurydice Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000037913 T-cell disorder Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019000 fluorine Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108700028325 pokeweed antiviral Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940002004 the magic bullet Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Zagotovljen je preparat, ki obsega humano-podobne imunoglobuline specifično reaktivne s humanimi IL-2 receptorji, kot tudi postopek za njihovo pridobivanje. Postopek obsega uporabo rekombinantne DNA tehnologije. Preparat je namenjen zdravljenju bolezni, ki jih povzročajo T-celice.ŕ
Description
PROTEIN DESIGN LABS, Inc. USA
US-T/333
NOVI IL-2 RECEPTOR SPECIFIČNI HUMANI IMUNOGLOBULINI
PODROČJE IZUMA
Ta izum se nanaša na tehnike kombiniranja rekombinantne DNA in monoklonalnega antitelesa za razvijanje novih terapevtskih sredstev, ter natančneje na izdelovanje neimunogenih antiteles, ki so specifična za humani interleukin-2 receptor.
OSNOVA PREDMETNEGA IZUMA
Pri sesalcih povzročata imunski odgovor dva tipa celic, ki sodelujeta specifično s tujimi snovmi oziroma antigeni. Eden izmed obeh tipov teh celic, B-celice so odgovorne za proizvodnjo antiteles. Druga vrsta teh celic, celice T, pa vključujejo bogato podskupino celic, ki so namenjene in vivo nadzoru delovanja B-celic ter tudi široki paleti drugih hematopietskih celic, vključno s T-celicami.
Drugi način, na katerega izkazujejo T-celice ta nadzor pa je preko sinteze limfokina, ki je znan tudi kakor interleukin 2 (IL-2), ki je bil originalno imenovan rastni faktor Tcelic. Za primarno funkcijo IL-2 se zdi, da je stimulacija in vzdrževanje T-celic. Nekateri imunologi pa verjamejo, da bi bil IL-2 lahko v samem centru imunskega odgovora (glej, Farrar, J. et al., Immunol. Rev. 63:129-166 (1982), kar je tu navedeno kot referenca) .
Zaradi izražanja svojih bioloških učinkov pa IL-2 sodeluje s specifičnim visoko-afinitativnim membranskim receptorjem (Greene, W. et al., Progress in Hematology XIV, E. Brown ed., Grune in Statton, Nev/ York (1986) na str. 283 ff) . Humani IL-2 receptor je kompleksen večverižni glikoprotein, kjer je ena izmed omenjenih verig, znana tudi kot Tac peptid, dolga okoli 55kD (glej, Leonard W. et al., J. Biol. Chem. 260:1872(1985), kar je navedeno kot referenca). Gen, ki kodira ta protein je bil že izoliran, predstavlja pa 272 amino kislinski peptid, ki vključuje 21 amino kislin signalnega peptida (glej Leonard W., et al., Nature 311:626(1984)). 219 NHž-terminalne amino kisline p55 Tac proteina jasno vključujejo izvencelični del (glej Leonard M., et al., Science, 230:633-639 (1985), kar je navedeno kot referenca).
Mnoge razjasnitve strukture in delovanja humanega IL-2 receptorja so bila dana pri razvijanju specifično reaktivnih monoklonalnih antiteles. Povedano natančneje, je eno mišje monoklonalno antitelo, znano kot anti-Tac (Uchiyama et al., J. Immunol. 126:1393 (1981) pokazalo, da se IL-2 receptor lahko odkrije na T-celicah, da pa je poleg tega tudi na celicah monocit-makrofagne družine, Kuppferjevih celicah jeter, Langerhansovih celicah kože ter seveda na aktiviranih T-celicah. Pomembno je, da preostanek T-celic, B-celice ali makrofagi v cirkulaicji navadno ne kažejo IL-2 receptorja (Hermann et al., J- Exp. Med. 162:1111 (1985)).
Anti-Tac monoklonalno antitelo se uporablja tudi za definiranje limfocitnih funkcij kar zahteva IL-2 sodelovanje in, kot je bilo dokazano, inhibira različne funkcije Tcelic, vključno s sintezo citotoksičnih in supresorskih T limfocitov v kulturi celic. Poleg tega so bile sedaj, na osnovi preučevanja z anti-tac in drugimi antitelesi, razne nepravilnosti v delovanju povezane ravno z neustrezno ekspresijo IL-2 receptorja, do katere pride s pomočjo Tcelic, še posebej odraslih T-celic levkemije.
Nedavno je bilo dokazano, da so IL-2 receptorji res najboljša tarča za nove terapevtske pristope k boleznim, ki jih povzročajo T-celice. Predpostavlja se, da se lahko IL-2 receptor specifična antitelesa, karšna so tudi anti-tac monoklonalna antitelesa, uporabijo le ali kot imunokonjugat (npr. Z Ricin A izotopi in podobno) zaradi učinkovitega odstranjevanja celic, ki nosijo IL-2 receptor. Ta sredstva lahko teoretično odstranijo levkemijske celice, ki ekspresirajo IL-2 receptor, nekatere B-celice ali aktivirane T-celice zajetih v bolezenskem stanju, pa še dovoljujejo zadrževanje zrele normalne T-celice in njihovih prekurzorjev zaradi nadaljnjega omogočanja vzpostavitve sposobnosti vzdigovanja normalnega T-celičnega imunskega odgovora po potrebi organizma. Večina preostalih T-celično specifičnih sredstev lahko uniči v glavnem le vse periferne T-celice, kar omeji terapevtsko učinkovitost takega sredstva. V končni fazi pa ima lahko uporaba ustreznih monoklonalnih antiteles, specifičnih za IL-2 receptor, terapevtsko vrednost tudi pri avtoimunih boleznih, transplantaciji organov ter pri drugih neustreznih odgovorih aktiviranih T-celic. Dejansko so se klinični preizkusi uporabe, npr. anti-tac antiteles že začeli (glej, Waldman T., et al., Cancer Res. 45:625 (1985) ter Waldman T., Science 232:727-732 (1986), kar je tu podano za referenco).
Na žalost pa ima uporaba anti-tac antiteles, kakor tudi drugih nehumanih monoklonalnih antiteles določene pomanjkljivosti, še posebej pri ponovljenih terapevtskih področjih, kot je spodaj pojasnjeno. Tako na primer, mišja monoklonalna antitelesa ne fiksirajo dovolj dobro humani komplement, tako da pri uporabi na ljudeh ni izraženih drugih pomembnejših imunoglobulinskih funkcionalnih karakteristik.
Morda pa je še pomembnejše to, da lahko anti-tac in druga nehumana monoklonalna antitelesa vključujejo znatno zvijanje amino kislinskih sekvenc, ki bodo imunogene, če jih vnesemo v humanega pacienta. Številne študije so pokazale, da je lahko imuni odgovor pacienta, ki se je razvil kot odgovor na antitelesa, dovolj močan, da znatno zniža terapevtsko uporabo antiteles po dokončanem začetnem zdravljenju. Še več, pri zdravljenju različnih bolezni lahko pričakujemo porast v številu različnih mišjih ali drugih antigenskih (za ljudi) monoklonalnih antiteles po prvem in drugem obravnavanju z različnimi nehumanimi antitelesi, naslednje obravnave in celo nevezane terapije pa so lahko neučinkovite ali celo same po sebi nevarne.
Čeprav je bila proizvodnja t.i. humeralnih antiteles (npr. mišja spremenljiva področja povezane s humanimi nespremenljivimi področji) dokazana za uspešno, pa ostaja pomemben problem imunogeničnosti. V splošnem, je bila sinteza humanih imunoglobulinov, ki so reaktivni s humanim IL-2 receptorjem, kakor tudi večjega števila humanih antiteles, zelo težavno z uporabljanjem tipičnih tehnik izdelovanja humanega monoklonalnega antitelesa. Podobno, daje pri sintezi humaniziranih antiteles (glej, npr. EPO publikacijo št. 0239400), nedoločene rezultate tudi uporaba rekombinantne DNA tehnologije, delno zaradi nepredvidljivih afinitet.
Tako torej obstaja potreba po izboljšanih oblikah imunoglobulinov, ki so podobni humanim ter so specifični za IL-2 receptor, ter so pri ljudeh v glavnem neimunogena, ter jih poleg tega lahko pridobivamo ekonomično in z lahkoto na način, ki je predpisan za terapevtsko formulacijo in druge priprave. Predstavljeni izum izpolnjuje vse te in druge zahteve.
OPIS IZUMA
Predstavljeni izum omogoča izdelavo novih preparatov, ki so uporabni na primer pri zdravljenju T-celic, ki povzročajo humane bolezni, preparatov, ki vsebujejo imunoglobuline, podobne humanim in so specifično sposobni blokirati vezaj oči se humani IL-2 na njegov receptor in/ali so sposobni vezanja na p55 Tac protein na humanih IL-2 receptorjih.
Imunoglobulini imajo lahko dva para kompleksov težkih/lahkih verig, navadno pa vsaj en par, ki ima verigo, ki objamejo mišje komplementarno določujoča področja, ki so funkcionalno vezane na humane mrežne področne segmente. Na primer, mišje komplementarno določujoča področja z ali brez dodatnih naravno vezanih amino kislinksih ostankov, se lahko uporabijo za sintezo antiteles na humani IL-2 receptor na afinitetnih nivojih, ki so močnejši od 108M-1.
Imunoglobuline, vključno z fragmenti, ki se vežejo in drugimi derivati tega izuma, lahko pridobimo z lahkoto s pomočjo variante rekombinatnih DNA tehnologij, s končno ekspresijo v transfektiranih celicah, kjer priporočamo uporabo nesmrtnih evkariontskih celic, kakršne so mieloma in hibridoma celice. Polinukleotidi, ki vključujejo prvo sekvenco, ki kodira humano-podobna imunoglobulinska mrežna področja in druga sekvencijska skupina, ki kodira želj ene imunoglobulinske komplementarno določujoča področja, se lahko pridobijo sintetično ali s kombiniranjem ustrezajoče cDNA ali genomskih DNA segmentov.
Imunoglobuline, ki so podobni humanim lahko uporabimo same, v glavnem v čisti obliki ali pa kompleksirane s citotoksičnim agensom, kakršen je radionuklid, ribosomsi inhibitorni protein ali citotoksičen agens, ki je aktiven na površini celic. Vse te združitve so še posebej uporabne pri zdravljenju T-celic, ki povzročajo bolezni. Imunoglobulini, ki so podobni humanim ali njihovi kompleksi se lahko pridobijo v farmacevtsko sprejemljivi obliki in dozi, ki bodo variirale v odvisnosti od načina administracije.
Opisani izum nudi tudi nove postopke za grajenje imunoglobulinskih verig, ki imajo enega ali več komplementarno določujočih področij (CDR) iz donornega imunoglobulina in mrežnega področja humanega imunoglobulina, priporočeni postopki pa vključujejo najprej primerjanje mreže ali amino kislinske sekvence spremenljivega področja donornega imunoglobulina glede na ustrezajoče sekvence v zbirki humano imunoglobulinskih verig, ter izbiranje kakor humanega imunoglobulina ene ali večih homolognih sekvenc iz zbirke. Humano imunoglobulinska ali akceptor imunoglobulinska sekvenca se ponavadi izbere iz zbirke vsaj do 20 imunoglobulinskih sekvenc ter ima navadno najvišjo homologijo glede na donorsko imunoglobulinsko sekvenco nekaterih sekvenc v zbirki. Humana imunoglobulinska mrežna sekvenca ima navadno od 65 do 70% homologijo z donorskimi imunoglobulinskimi mrežnimi sekvencami. Donorski imunoglobulin je lahko težka ali lahka veriga, humana kolekcija pa bo vsebovala isto vrsto verige. Humanizirana težka in lahka veriga se lahko uporabijo za grajenje kompletnega humaniziranega imunoglobulina ali antitelesa ki ima dva para lahkih/težkih verig, z ali brez delnih ali celih humanih konstantnih področij in drugih proteinov.
V drugi realizaciji opisanega izuma bodisi vezano z zgornjo stopnjo primerjanja ali pa posebej, se lahko dodatne amino kisline v akceptorni imunoglobulinski verigi, zamenjajo z amino kislinami iz CDR-donorske imunoglobulinske verige. Natančneje, bodo nadaljnje izborne substitucije humane mrežne amino kisline akceptorega imunoglobulina z ustrezno amino kislino iz donorskega imunoglobulina, narejene na položajih v imunoglobulinih kjer:
a) je amino kislina v humanem mrežnem področju akceptornega imunoglobulina redka za ta položaj, ustrezna amino kislina v donornem imunoglobulinu pa je za tak položaj obča; ali pa
b) se amino kislina nahaja tik ob eni iz CDR;
c) za amino kislino je predviden položaj na okoli 3 χ 1O10 m od CDR-ov v trodimenzionalnem modelu imunoglobulina, ter je sposobna sodelovati s CDR-i humaniziranega imunoglobulina.
Humanizirana imunoglobulinska veriga navadno zajema vsaj okoli 3 amino kisline iz donornega imunoglobulina dodatno na CDR, navadno vsaj en, ki je takoj ob CDR v donornem imunoglobulinu. Težke in lahke verige se lahko nadgradijo z uporabo enega ali vseh treh pozicijskih kriterijev.
Ί
Ko jih združimo v nedotaknjeno antitelo, bodo humanizirane in težke verige tega izuma v glavnem neimunogeni pri ljudeh ter vzdržujejo približno enako afiniteto kakor donorni imunoglobulini za antigen (takem kakor protein ali drugo združevanje, ki vsebuje epitop). Ti afinitetni nivoji lahko variirajo od okoli 108M_1 ali več ter imajo lahko v odnosu z antigenom tudi 4X večjo afiniteto v primerjavi z originalno afiniteto donorskega imunoglobulina.
KRATEK OPIS SLIK
Slika 1: Primerjava sekvenc anti-Tac težke verige (zgornje črte) in Eu težke verige (spodnje črte). Za amino kisline je bila uporabljena 1-črkovna koda. Prva amino kislina v vsaki vrsti je numerirana na levo. Identične amino kisline v dveh sekvencah so povezane s črtami. 3CDR so podčrtane. Druge amino kislinski položaji, za katere se rajši uporablja anti-Tac aminokislina kakor Eu amino kislina, ki je uporabljena v humanizirani anti-Tac težki verigi in je označena z *.
Slika 2: Primerjava sekvenc anti-Tac lahke verige (zgornje črte) in Eu lahke verige (spodnje črte). Za amino kisline je bila uporabljenja eno-črkovna koda.
Prva amino kislina vsake vrste je numerirana na levo. Identične amino kisline v dveh vrstah so povezane z črto. 3CDR so podčrtane. Druge amino kislinske pozicije, za katere je bila namesto Eu amino kisline v humanizirani anti-Tac težki verigi raje uporabljena anti-Tac amino kislina, so označene z *.
Slika 3: Relativne pozicije oligonukleotidov. Puščice so za vsak oligonukleotid postavljene v smeri 3'.
Slika 4: | Relativne pozicije oligonukleotidov. Puščice so postavljene v smeri 3' vsakega oligonukleotida. Prikazan je položaj Hind III mesta v prekrivajočih se JFD2 in JFD3. |
Slika 5: | Shematski prikaz plazmida pHuGTACl, ki ga uporabljamo pri ekspresiji humanizirane anti-Tac težke verige. Ustrezni restrukcijski položaji, ter kodirna področja težke verige so prikazane z okvirji. Smer transkripcije od imunoglobulinskega (Ig) promotorja je prikazana s puščico. EH=ojačevalec težke verige, Hyg=higromicin rezistentni gen. |
Slika 6: | Shematski prikaz plazmida pHuLTAC, ki ga uporabljamo za ekspresijo humanizirane anti-Tac lahke verige. Prikazana so ustrezna restrikcijska mesta, kodirna področja lahke veige pa so prikazana s pomočjo okvirjev. Smer transkripcije od Ig promotorja je prikazana s puščico. |
Slika 7: | Fluorocimetrija HUT-102 in Jurket gelov, obarvanih z anti-Tac antitelesom ali humaniziranim anti-Tac antitelesom, ki jim za tem sledi obeleženje s pomočjo fluorescin-konjugiranim kozjim antimišjim Ig antitelesom ali s kozjim anti-humanim Ig antitelesom. Graf s prekinjeno linijo prikazuje rezultate kadar ni vključeno prvo antitelo, graf z nepretrgano linijo pa prikazuje rezultate, kadar sta vključeni obe antitelesi, prvo in drugo (konjugirano) antitelo. |
Slika 8: | (A) Fluorocimetrija HUT-102 celic, obarvanih u 0-40ng anti-Tac, kakor je bilo naznačeno, ter z nadaljnjim biotinilovanim anti-Tac, ter nadaljnjim |
ficoeritrin-konjigiranim avidinom.
(B) Fluorocimetrija HUT-102 celic, obarvanih z naznačenim antitelesom ter nato z biotinilovanim anti-Tac ter nato s ficoeritrin-konjugiranim avidinom.
PODROBEN OPIS PREDMETNEGA IZUMA
Predmetni izum zagotavlja humano-podobne imunoglobuline, ki so specifično reaktivni z IL-2 receptorjem na humanih Tcelicah. Ti imunoglobulini, katerih afinitete vezave se gibajo med 108 M-1 in prednostno od 109 M'1 do 1O10 M-1 ali močnejše so sposobni, npr. blokirati vezavo IL-2 na humane 11-2 receptorje. Humano-podobni imunoglobulini imajo humanopodobno mrežo in imajo lahko komplementarno določujočega področja (CDR) iz imunoglobulinov, navadno mišjega imunoglobulina, ki so specifično reaktivne z epitopom na p55 Tac proteinu. Imunoglobulini tega izuma, ki jih lahko pridobivamo ekonomično tudi v velikih količinah, se uporabljajo npr. pri zdravljenju T-celic, ki povzročajo bolezni pri humanih pacientih, ob uporabi različnih zdravstvenih tehnik.
Za osnovno strukturno enoto antitelesa je bilo dokazano, da zajema tetramer. Vsak izmed tetramerov je sestavljen iz dveh identičnih parov polipeptidnih verig, kjer ima vsak par eno »lahko« (okoli 25 kD) in eno »težko« (okoli 50-70 kD) verigo. NH2- terminus vsake verige se prične z variabilnim področjem dolgo 100 do 110 ali več amino kislin, ki so v prvi vrsti odgovorne za antigensko prepoznavanje. COOHterminus vsake verige pa definira konstantno področje, ki je primarno odgovorno za efektorsko funkcijo.
Lahke verige so klasificirane kakor kappa ali lambda. Težke verige so klasificirane (ali podklasificirane) kakor gama, mu, delta ali epsilon in kot take definirajo antitelesni izotop kakor IgG, IgM, IgA, IgD in IgE. V lahkih in težkih verigah so spremenljiva in konstantna področja povezana s pomočjo »J« področij, ki so dolgi 12 ali več amino kislin, pri tem pa težka veriga vključuje tudi »D« področje z 12 ali več amino kislinami. (Glej, Fundamental Immunology, Paul, W. ed. del 7, str. 131-166, Raven Press, N. Y. (1984), kar tu navajamo kot referenco).
Spremenljiva področja vsakega lahkega/težkega para verig gradijo mesto vezave antitelesa. Vse verige, ki kažejo isto občo strukturo relativno konzerviranih mrežnih področij, so povezana s pomočjo treh hipervariabilnih področij, ki so prav tako imenovane CDR (glej, »Sequences of Proteins of Imunological Interest«), Kabat E. et al., U.S. Department of Health and Human Services (1983); ter Cholthia and Lesk, J. Mol. Biol. 196: 901-917 (1987), ki jih tu navajamo kakor referenco). CDR gradita 2 verigi iz vsakega para, ki so povezane s pomočjo mrežnih področij, kar omogoča vezavo na specifični epitop.
Kakor je uporabljen v predmetnem opisu izuma, termin »imunoglobulin« označuje protein, ki je sestavljen iz enega ali večih polipeptidov, ki so v glavnem kodirani s pomočjo imunoglobulinskih genov. Znani imunoglobulinski geni vključujejo kapa, lambda, alfa, gama, delta, epsilon in mu konstantna področja gena, kakor tudi obsežno skupino genov spremenljivih področij. Imunoglobulini se lahko najdejo poleg oblike antitelesa še v številnih drugih oblikah; vključene so na primer Fv,Fab in F(ab), kakor tudi enojne verige (npr. Huston, et al., Proč. Nat. Acad. Sci. USA, 85:5879-5883 (1988) ter Bird et al., Science 242: 423-426 (1988), kar navajamo kakor referenco). (glej na splošno,
Hood et al., »Immunology«, Benjamin, Ν.Υ., 2.ed. (1984), ter
Hunkapiller and Hood, Nature, 323: 15-16 (1986), kar navajamo kot referenco).
Himerna antitelesa so tista, katerih geni lahke in težke verige so navadno nadgrajeni z genetskim inženiringom iz imunoglobulinskih genskih segmentov, ki pripadajo različnim vrstam. Na primer, spremenljivi (V) segmenti gena iz mišjega monoklonalnega antitelesa se lahko povežejo na humane konstantne (C) segmente, kakršen je na primer gamai ali gama3. Tipično terapevtsko himerično antitelo je tako hibridni protein, ki je sestavljen iz V ali mesta vezave za antigen mišjega antitelesa in C efektorskega področja iz humanega antitelesa (npr. A.T.C.C. združena št. CRL 9688 izločine anti-Tac himernega antitelesa), čeprav lahko pri tem uporabimo tudi druge vrste sesalcev.
Kakor smo ga uporabljali tu, označuje termin mrežno področje tiste dele lahkih in težkih verig imunoglobulina, ki so relativno konzervirani (npr. drugačne od CDR) med različnimi imunoglobulini ene same vrste, kakor so definirali Kabat et al., cit. Naprej. Humano-podobno mrežno področje pa v tem opisu uporabljamo za označevanje mrežnega področja, ki v vsaki obstoječi verigi vključuje vsaj okoli 70 ali več amino kislinskih ostankov, navadno 75 do 85 ali več, ki so identične tistim v humanem imunoglobulinu.
Izraz humano-podoben imunoglobulin uporabljamo pri imunoglobulinih, ki obsegajo humano-podobno mrežo, ter v kateri je prisotna tudi konstantno področje, ki je v glavnem homologna s konstantnim področjem humanega imunoglobulina, t.j. vsaj okoli 85-90%, najbolje pa okoli 95% identična.
Tako torej, so vsi deli humano-podobnega imunoglobulina z izjemo mogoče CDR, v glavnem homologi eni ali večim sekvencam naravnega humanega imunoglobulina. Npr. humanopodoben imunoglobulin ne vsebuje po potrebi spremenljivega področja antitelesa humane konstantnega področja.
Predstavljeni izum obsega tudi kriterije s pomočjo katerih je bilo omejeno število amino kislin v mreži humano-podobne ali humanizirane imunoglobulinske verige, ki je bil izbran tako, da bo enak kakor amino kisline na tistih položajih prej v donorju in ne v akceptorju, v cilju povečanja afinitete antiteles, ki jih obsega humanizirana imunoglobulinska veriga.
Predmetni izum je osnovan delno na modelu, ki preko dveh doprinosov povzroča izgubljanje afinitete v predhodnih sredstvih proizvodnje humaniziranih antiteles (z uporabljanjem na primer mišjih antiteles kakor izvora CDR):
1) Kadar se mišje CDR mreže vežejo s humano mrežo, postanejo amino kisline v mreži ob CDR humane namesto mišje. Brez kakršnegakoli namena pozivanja na teorijo, pa verjamemo, da lahko te spremembe amino kislin blago izkrivijo CDR zato, ker gradijo različne elektrostatične in hidrofobne sile v primerjavi z mišjim donorskim antitelesom, izkrivljeni CDR pa lahko degradirajo učinkovite kontakte z antigenom, kakor gradijo CDR donorskega antitelesa.
2) Poleg tega lahko amino kisline v originalnemu mišjemu antitelesu, ki so sosednje z, a niso enake CDR (t.j so del mreže) tudi gradijo kontakte z antigenom, kar daje afiniteto. Te amino kisline se izgubljajo pri humanizaciji antitelesa, saj celotna mreža amino kislin postane humana.
Zaradi izogibanja tem problemom in zaradi proizvodnje humaniziranih antiteles, ki imajo danes visoko afiniteto do željenega antigena, uporablja predmetni izum 4 kriterije za grajenje humaniziranih imunoglobulinov. Ti kriteriji se lahko uporabljajo posamično ali v kombinaciji, kadar je potrebno, zaradi doseganja določene željene afinitete in drugih karakteristik.
Kriterij I: Kakor akceptor uporabljamo mrežo določenega humaniega imunoglobulina, ki je nenavadno homologen z donorskim imunoglobulinom, ki ga bomo v postopku humanizirali, ali pa uporabljamo konsenzusno mrežo iz velikega števila humanih antiteles. Npr. primerjava sekvence spremenljivega področja mišje težke (ali lahke) verige glede na humano spremenljivo področje težke (ali lahke) verige, v banki podatkov (npr., The National Biomedical Research Foundation Protein Identification Resource), ki kaže, da stopnja homologije v različnih humanih področjih variira znatno, navadno od 40% do okoli 60-70%. Z izbiro spremenljiva področja težke ali lahke verige humanega imunoglobulina, ki je najbolj homologna s spremenljivim področjem težke (ali lahke) verige donorskega imunoglobulina za akceptorni imunoglobulin, se bo na poti od donorskega imunoglobulina do humaniziranega imunoglobulina spremenilo najmanjše število amino kislin. Torej, zopet brez namena pozivati se na teorijo, verjamemo, da obstajajo manjše možnosti spremembe amino kisline blizu CDR kakor življenje njihove konformacije. Toda, precizna skupna oblika humaniziranega antitelesa, ki obsega humanizirano imunoglobulinsko verigo, lahko pobliže razgradi obliko donorskega antitelesa, kar prav tako zniža možnost krivljenja CDR.
Navadno bo kot akceptor izbrana ena izmed 3-5 najbolj homolognih sekvenc spremenljivega področja težke verige v reprezentativni kolekciji, ki je sestavljena iz 10 do 20 različnih humanih težkih verig, da bi tako zagotovili mrežo težke verige, kar pa je podobno tudi za lahke verige. Priporoča se uporaba ene od 1-3 najbolj homolognih spremenljivih področij. Za izbrano imunoglobulinsko verigo je najboljša vsaj okoli 65% homologija v mrežnemu področju glede na donorski imunoglobulin.
Kakorkoli že izberemo akceptorski imunoglobulin, pa se višja afiniteta lahko doseže z izbiro malega števila amino kislin iz mreže humanizirane imunoglobulinske verige, ki bodo iste kakor amino kisline na tistih položajih v donorju raje kot v akceptorju. Naslednji kriterij pa definira amino kisline, ki jih lahko izberemo na ta način. Priporočeno je, da se na večini ali vseh amino kislinskih mestih, ki zadovoljujejo enega izmed teh kriterijev izbere v bistvu donorska amino kislina.
Kriterij II: Če je amino kislina v mreži humanega akceptornega imunoglobulina nenavadna (t.j. redka, je izraz, ki ga tu uvajamo za amino kisline, ki se na tem položaju pojavlja ne več kakor v 10% humanih težkih (in pripadajočih lahkih) verig V področnih sekvenc v reprezentativni banki podatkov) in če je donorska amino kislina na tem položaju tipična za humane sekvence (t.j. obča, kakor je bilo naznačeno tukaj in označuje amino kislino, ki se pojavlja v vsaj okoli 25% sekvenc v reprezentativni banki podatkov), tedaj lahko izberemo donorsko amino kislino pred akceptorsko. Ta kriterij pomaga pri tem, da atipična amino kislina v humani mreži ne prekine strukture antitelesa. Toda, z zamenjavo nenavadne amino kisline, ki se pojavlja kakor tipična pri različnih antitelesih, pa lahko tako humanizirano antitelo postane manj imunogeno.
Kriterij III: V položajih takoj ob CDR v humanizirani imunoglobulinski verigi, lahko donorsko amino kislino izberemo prej kakor akceptorsko. Te amino kisline so posebej uporabne za sodelovanje z amino kislinami v CDR, pri izbiri iz akceptorja krive donorske CRD pa znižajo afiniteto. Toda, sosedne amino kisline so sposobne reagirati neposredno z antigenom, (Amit et al., Science, 233, 747-753 (1986), kar navajamo kakor referenco), izbor teh amino kislin iz donorja pa je lahko poljubno zaradi vzdrževanja vseh antigenskih kontaktov, ki tvorijo afiniteto v originalnem antitelesu. Kriterij IV: 3-dimenzionalni model tipičnega originalnega donorskega antitelesa kaže, da so določene amino kisline izven CDR sicer bližnje CDR, ter imajo veliko verjetnost za možnost integracije z amino kislinami v CDR s pomočjo vodikove vezi, Van der Waalsovih sil, hidrofobnih interakcij oziroma sodelovanja, ipd. Na teh amino kislinskih pozicijah se donorska amino kislina lahko izbere pred akceptorsko imunoglobulinsko amino kislino. Amino kisline bodo imele glede na ta kriterij navadno bočno atomsko verigo na razdalji okoli 3 x 1O“10 m od mesta v CDR in morajo vsebovati atome, ki lahko sodelujejo s CDR atomi glede na vzpostavljene kemijske sile, kakor je navedeno nadalje.
Računalniški programi za izdelovanje modelov proteinov, kakršni so tudi imunoglobulini, so v glavnem dostopni in dobro poznani strokovnjakom (glej Loew et al., Int. J.
Quant. Chem., Quant. Biol. Symp., 15:55-66 (1988);
Bruccoleri et al., Nature, 335, 564-568 (1988); Chotia et al., Science, 233: 755-758 (1986), ki so tu navedene kakor referenca). Ti ne oblikujejo dela tega izuma. Kakor imajo vsa antitelesa podobne strukture, se lahko znane strukture antiteles, ki jih lahko dobimo na primer v Brookhaven Protein Data Bank, uporabijo, če je tako potrebno, kakor grobi modeli drugih antiteles. Komercialno dostopni računalniški programi se lahko uporabljajo za prikazovanje teh modelov na računalniškem monitorju, da bi tako izračunali razdaljo med posameznimi atomi, ter ocene verjetnosti raznih amino kislinskih integracij (glej, Ferrin et al., J. Mol. Graphics, 6:13-27 (1988).
Humanizirana antitelesa imajo navadno vsaj 3 potencialne prednosti pred mišjimi ali pa v nekaterih primerih himernih antiteles za uporabo v terapijah za ljudi:
1) Zato, ker je efektorski del humani, lahko ta bolje sodeluje z drugimi deli humanega imunskega sistema (npr. razgrajanje celice cilja je učinkoviteje s pomočjo od komplementa odvisne citotoksičnosti (CDC) ali pa od antitelesa odvisne celične citotoksičnosti (ADCC)).
2) Humanemu imunskemu sistemu ni treba prepoznati mrežnega ali konstantnega področja humaniziranega antitelesa kakor tujega in zatorej mora odgovor antitelesa na to vneseno antitelo biti manjši kakor proti povsem tujemu mišjemu antitelesu ali delno tujemu himernemu antitelesu.
3) Za vnešena mišja antitelesa je bilo dokazano, da traja njihova polovična živijenska doba v humani cirkulaciji znatno manj od polovične življenske dobe normalnih antiteles (D. Shaw et al., J. Immunol., 138: 4534-4538 (1987)). Vnešena humanizirana antitelesa bodo imela verjetno polovično živijensko dobo, ki bo podobnejši naravno zastopanim humanim antitelesom, kar bo omogočalo jemanje manjših doz manj pogosto.
Humano-podobna antitelesa imajo vsaj 3 potencialne prednosti pred mišjimi in v nekaterih primerih himernimi antitelesi, kar se tiče uporabe v humani terapiji:
1) Ker je efektorski del humani, lahko ta bolje sodeluje z drugimi deli humanega imunskega sistema (npr. uničevanje celice cilja je bolj učinkovito s pomočjo v celoti odvisne citotoksičnosti (CDC) ali od antitelesa odvisne celične citotoksičnosti (ADCC)).
2) humanemu imunskemu sistemu ni treba prepoznati mrežnega ali C področja humano-podobnega antitelesa kot tujega in zato antitelesni odgovor na tako vneseno antitelo ne bo tako velik, kot na povsem tuje mišje antitelo ali delno tuje himerno antitelo.
3) Za vnesena mišja antitelesa je bilo dokazano, da je njihova polovična živijenska doba v humani cirkulaciji znatno manjša kakor polovična živijenska doba normalnih antiteles (Shaw D. et al., J. Immunol. 138: 4534-4538 (1987)). Vnesena humano-podobna antitelesa bodo imela živijensko dobo, ki bo najbrž podobna tisti v naravno zastopanih humanih antitelesih, kar dovoljuje vnašanje manjših doz manj pogosto.
V enem izmed aspektov je ta izum usmerjen na rekombinantne DNA segment, ki kodirajo CDR težke ali lahke verige iz imunoglobulina in so sposobne za vezanje na želj eni epitop na humanem receptorju, kakršno je na primer anti-Tac monoklonalno antitelo. Dna segmenti, ki kodirajo ta področja, so navadno vezani na DNA segmente, ki kodirajo določene humanim podobne mrežna področja. Želj ene DNA sekvence, ki na ekspresijskem kodu za polipeptidne verige, ki obsegajo hiperspremenljiva področja težke in lahke verige anti-Taca, so prikazane na slikah 1 in 2. Zaradi kodonske degeneracije in nekritičnih amino-kislinskih substitucij, se dajo te sekvence z lahkoto substituirati z drugimi DNA sekvencami, kakor je podroobno opisano nadalje.
DNA segmenti ponavadi nadalje vključujejo tudi ekspresijsko kontrolno DNA sekvenco, ki je operativno vezana na sekvence, ki kodirajo humano-podobna antitelesa, vključno z naravno vezanimi ali heterolohnimi promotorskimi področji. Priporočeno je, da so ekspresijske kontrolne sekvence, evkariontski promotorski sistemi v vektorjih, ki so sposobni za transformiranje ali transfekcijo evkariontskih celic gostiteljev, uporabimo pa lahko tudi prokariontske sekvence. Ko enkrat vgradimo tak vektor v gostitelja, vzdržujemo le tega pod pogoji, ki so ugodni za visok nivo ekspresije nukleotidnih sekvenc in, če želimo, zbiranje in prečiščevanje lahkih verig, težkih verig, dimerov lahka/težka veriga ali nedotaknjenih antiteles, veznih fragmentov ali drugih imunoglobulinskih oblik.
Humana DNA sekvenca konstantnih področij se lahko izolira s pomočjo dobro znanih metod iz različnih humanih celic, najbolje pa iz nesmrtnih B-celic (glej, Kabat vese. cit. In WP87/02671). CDR za pridobivanje imunoglobulinov predmetnega izuma bodo izvedene na podoben naein iz monoklonalnih antiteles, ki so sposobna za vezanje na humani IL-2 receptor in proizvedenih v določenem sesalskem izvoru, vključno z mišimi, podganami, zajci in drugimi vretenčarji, sposobnimi za proizvodnjo antiteles z dobro znanimi postopki. Ustrezen izvor celic za DNA sekvence in celice gostitelja za imunoglobulinsko ekspresijo in izločanje pa se lahko pridobijo iz številnih izvorov, kakršni so tudi American Type Culture Collection (Catalogue of Celi Lines and Hybridomas, 5.izd. (1985), Rockville, Maryland, ZDA, kar navajamo kakor referenco).
Poleg tukaj opisanih humano-podobnih specifičnih imunoglobulinov, se lahko drugi, v glavnem homologno modificirani imunoglobulini nadgradijo in proizvedejo z uporabo različnih rekombinantnih DNA tehnik, ki so strokovnjakom tega področja že znane. Npr. mrežna področja, lahko variirajo od sekvenc SEQ ID NO: 1 in SEQ ID NO 2:, ki so prikazane spodaj na primarnem strukturnem nivoju s pomočjo večjega števila amino kislinskih substanc, terminalnih in imtermediarnih dodajanj, brisanj in podobnega. Toda, varianta različnih humanih mrežnih področij se lahko uporablja tudi sama ali pa v kombinaciji kakor osnova za humano-podobne imunoglobuline predmetnega izuma. V splošnem s modifikacije gena lahko izvedejo s pomočjo dobro znanih tehnik, kakršne so mutageneze usmerjenega mesta (glej, Gillman in Smith, Gene. 8:81-97 (1979) in Roberts S. et al., Nature 328: 731-734 (1987), kar navajamo kakor referenco).
Alternativno, lahko pridobimo polipeptidne fragmente, ki obsegajo le del primarne strukture antitelesa, in sicer na tak način, da posedujejo dobljeni fragmenti eno ali več imunoglobulinskih aktivnosti (npr. komplementarna fiksacijska aktivnost). Poleg tega pa vsebujejo z imunoglobulini povezani geni, zaradi podobnosti mnogih genov, ločena funkcionalna področja, od katerih ima vsaka eno ali več bioloških aktivnosti, geni pa so lahko zlepljeni s funkcijskimi področji iz drugih genov (npr. encimov, glej obče označeni USSN 132 387 od 15.12.1987, kar navajamo kakor referenco), zaradi pridobivanja fuzijskih proteinov (npr. imunotoksina), ki imajo nove lastnosti.
Nukleinsko kislinske sekvence tega izuma, ki so sposobne končnega grajenja humano-podobnih antiteles se lahko tudi nadgradijo iz variant različnih polinukleotidov (genomske ali cDNA, RNA, sintetičnih oligonukleotidov, itd.) in komponent (npr. V, J, D ter C področij), kakor tudi s pomočjo različnih tehnik. Spajanje ustrezajočih genomskih sekvenc je dandanes najbolj obči postopek proizvodnje, uporabljamo pa lahko tudi cDNA sekvence (glej, Evropsko patentno publikacijo št. 0239400 in Reichmann L. et al., Nature 332 : 323-327 (1988), kar navajamo kakor referenco).
Kakor je podano naprej, bodo DNA sekvence ekspresirane v gostiteljih za tem, ko bodo sekvence operativno povezane z (npr. postavljene zato, da bi zagotovili delovanje) sekvenco za nadzor ekspresije. Ti ekspresijski vektorji navadno imajo sposobnost replikacije v gostitelju bodisi v obliki epizonov ali pa kakor integralni del gostiteljeve kromosomske DNA. Govoreč na splošno, bodo ekspresijski vektorji vsebovali markerje, npr. tetraciklin ali neomicin, da bi tako omogočili detektiranje celic, ki so bile transformirane z želj enimi DNA sekvencami (glej, npr. ZDA patent št. 4 707 362, ki ga navajamo kakor referenco).
E. coli je prokariontski gostitelj, ki je koristen predvsem za kloniranje DNA skvenc tega izuma. Drugi mikrobni gostitelji, ki so ustrezni za nase namene pa vključujejo bacile, kakršni so Bacillus subtilus ter druge enterobakteriace, kakršne so Salmonella, Serratia ter različne Pseudomonas vrste. V teh prokariontskih gostiteljih lahko nadgradimo tudi ekspresijske vektorje, ki bodo navadno vsebovali ekspresijske kontrolne sekvence, kompatibilne s celico gostitelja (npr. začetek replikacije). Poleg tega bodo prisotne tudi različne variante dobro znanih promotorjev, kakršni so laktozni promotorski sistem, triptofan (trp), beta-laktamaza promotorski sistem ali pa promotorski sistem iz lambda fagov. Promotorji bodo v teh primerih navadno kontrolirali ekspresijo po izboru z operatorno sekvenco, imajo pa tudi vezna sekvenčna mesta ter podobno, kar služi za začetek in konectranskripcije in translacije.
Za ekspresijo lahko uporabimo tudi druge mikroorganizme, kakršne so na primer kvasovke. Saccharomyces je priporočen gostitelj, z ustreznimi vektorji, ki imaho ekspresijske kontrolne sekvence, kakršni so promotorji, vključno s 3fosfoglicerat kinazo ali drugimi klikolitnimi encimi ter začetek replikacije, terminalne sekvence in podobno, če take pač potrebujemo.
Poleg mikroorganizmov, pa lahko za ekspresijo in proizvodnjo polipeptidov predmetnega izuma uporabljamo tudi kulture celic sesalskega tkiva (glej, Winnacker, From Genes to Clones, VCH Publishers, N. Y., N. Y., (1987), kar navajamo kakor referenco). Evkariontske celice so res priporočene zaradi velikega števila ustreznih celičnih linij gostiteljev, ki so sposobne izločati nedotaknjene imunoglobuline, ki so bili razviti s pomočjo tehnologije znanosti, vključujejo pa CHO celično linijo, različne COS celične linije, HeLa celice, mieloma celične linije, itd., najbolj pa priporočamo transformirane B-celice ali hibridomas. Ekspresijski vektorji za te celice lahko vključujejo ekspresijske kontrolne sekvence, kakršne se uporabljajo za začetek repliciranja, promotor, ojačevalec (Queen C. et al., Immunol. rv. 89: 49-68 (1986), kar navajamo kakor referenco), ter potrebna informacijska mesta, kakršna so vezna mesta za ribosome, RNA vrezna mesta , poliadenilacionska mesta ter transkripcijske terminalne sekvence. Priporočene ekspresijske kontrolne sekvence so promotorji izvedeni iz imunoglobulinskih genov, SV40, Adenovirusa, Govejega Papilloma virusa in podobno.
Vektorji, ki vsebujejo DNA segmente, ki nas zanimajo (npr. kodirne sekvence težke in lahke verige in ekspresijske kontrolne sekvence) se lahko prenesejo v celico gostitelja z dobro znanimi postopki, ki bodo variirali v odvisnosti od tipa celice gostitelja. Npr. kalcij klorovo transfekcijo navadno uporabljamo za prokariontske celice, kalcij fosfatni tretma ali elektroporacijo pa navadno uporabljamo pri drugih celičnih gostiteljih, (glej splošne informacije v Manitatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1982), kar navajamo kakor referenco).
Enkrat izražena, celotna antitelesa, njihovi dimeri, individualne težke in lahke verige ali drugi imunoglobulinske oblike predmetnega izuma, se lahko prečistijo s pomočjo standardnih tehničnih postopkov, vključno z amonij sulfatnim obarjanjem, afinitativno kromatografijo, stolpično kromatografijo, gelno elektroforezo in podobnimi (za splošne informacije glej, Scopes R. Protein Purification, Springer-Verlag, N. Y. (1982)). Za farmacevtsko uporabo je zaželjeno pridobivanje čistih imunoglobulinov z vsaj 90 do 95% homogenostjo, še bolje pa 98-99% ali večjo homogenostjo. Enkrat prečiščen, delno ali do željene homogenosti, se dobljeni polipeptid lahko uporabi terapevtsko (vključno ekstrakorporalno) ali v razvoju in pri opravljanju preizkusnih procedur z imunofluorescentnimi barvami in podobno, (za splošne informacije glej, Immunological methods, vol. I in II, Lefkovits and Pernies, ed. Academic Press, New York, N. Y., (179 in 1981)).
Antitelesa tega izuma bodo svojo uporabo našla navadno v zdravljenju s T-celicami povzročenih bolezni. Navadno so tam, kjer se kot celica povezana z boleznijo identificira nosilec IL-2 receptorjev, uporabimo kot ustrezna antitelesa, humanim podobna antitelesa, ki so sposobna za blokiranje vezanja 11-2 na humani IL-2 receptor (glej, USSN 0 085 707, pod naslovom Treating Human Malignancies and Disorders, kar navajamo kot referenco).
Tipična bolezenska stanja, ki so ustezna za zdravljenje s to metodo, vključujejo na primer presaditev v obolelo osebo in zavračanje transplantata pri pacientih, ki podležejo transplantaciji organov, kakršni so srce, pljuča, ledvice, jetra in podobni. Druge bolezni vključujejo autoimunske bolezni, kakršne so Tip I diabetesa, multipla skleroza, reumatoidni artritis, sistemski lupus aritematozus ter miastenia gravis.
humano-podobna antitelesa tega izuma se laho uporabijo tudi v kombinaciji z drugimi antitelesi, posebej s humanimi monoklonalnimi antitelesi, ki so reaktivna z drugimi markerji za celice, ki so za bolezen odgovorne. Ustrezajoči markerji za T-celice lahko, na primer, vključujejo tiste, ki so bili grupirani v t.i. Clusters of Differentiation, kakor so jih poimenovali na First International Leukocyte Differentiation Workshop, Leukocyte Typing, Bernard et al., ed. Springer-Verlag, N. Y., (1984), kar navajamo kakor referenco.
Antitelesa lahko uporabimo tudi kot posebni preparati, ki jih jemljemo skupaj s heteroterapevtskimi ali imunosupresivnimi agensi. Ti agensi navadno vključujejo ciklosporin A ali purinski analog (npr. metotreksat, 6merkaptopurin ali podobno), uporabimo pa lahko tudi številna druga sredstva, ki so v stroki izkušenim poznana (npr. ciklofosfamid, predniston itd.).
Prednostni farmacevtski preparat predmetnega izuma vključuje uporabo predmetnih antiteles v imunotoksinih. Imunotoksini so značilni po dveh komponentah in so še posebej uporabni za ubijanje določenih celic in vivo ali in vitro. Ena izmed komponent je citotoksični agens, ki je navadno uničujoč za celico, če se nanjo veže ali adsorbira. Druga komponenta, znana kakor izročilni nosilec pa služi kot sredstvo za dostavo toksičnega agensa na določen celični tip, kakršen so na primer celice, ki jih je zajel karcinom. Obe komponenti sta navadno kemično povezani s pomočjo ene izmed različnih oblik, dobro znanih kemijskih procedur. Če je torej citotoksični agens na primer protein, druga komponenta pa je nedotaknjeni imunoglobulin, lahko povezovanje opravimo s pomočjo heterobifunkcionalnih sredstev za omreženje, npr. SPDP, karbodimida, glutaraldehida in podobnih. Proizvodnja različnih imunotoksinov je v tehniki dobro znana in jo lahko najdemo, npr. v Monoclonal Antibody-Toxin Conjugates:
Aiming the Magic Bullet, Thorpe et al., Monoclonal Antibodies in Clinical Medicine, Academic Press, str. 168190 (1982), kar navajamo kot referenco.
Različice citotoksičnih agensov so ugodne za uporabo pri imunotoskinih. Citotoksični agensi lahko vključujejo radionukleotide, kakršni so jod-131, renij-188 ter bizmut23
212; številna hematerapevtska zdravila, kakršna so vindezin metotreksat, adriamicin ter cisplatinum; ter citotoksične proteine, kakršni so ribosom inhibitorni proteini, podobni pokeweed antivirusni protein, Pseudomonas exotoxin A, ricin difteria toksin, ricin A veriga, ipd., ali pa agense, ki so aktivni na površini celice, kakršni so na primer fosfolipazni encimi (npr. fosfolipaza C). (Za splošne informacije glej, objavo USSN 07/290 968 z dne 28.12. 1988) Chimeric Toxins, Olsens and Phill, Pharmac. Ther. 25: 355 381 (1982), ter Monoclonal Antibodies for Cancer Detection and Therapy, ed. Baldwin and Byers, str. 159-179, 224-266, Academic Press (1985), kar je vse navedeno kakor referenca) Izročevalna komponenta imunotoksinov vključuje humanopodobne imunoglobuline predmetnega izuma. Neokrnjeni imunoglobulini in njihovi povezovalni fragmenti, kakršen je na primer Fab, se lahko prosto uporabijo. Navadno bodo antitelesa v imunotoksinih humanega IgM ali IgG izotopa, če pa želimo, pa lahko uporabimo tudi druga konstantna področj sesalcev.
Humano-podobna antitelesa in njihovi farmacevtksi preparati so še posebej uporabni za parenteralno vnašanje, npr. subkutano, intramuskularno ali intravenozno. Preparati za parenteralno vnašanje navadno vključujejo raztopino antiteles ali njihovo mešanico, kjer so raztopljeni v ustreznem nosilcu, priporočen je vodni nosilec. Uporabimo lahko različne vodne nosilce, npr. voda, pufrirana voda, 0.4% slana raztopina, 0.3% glicin in podobne. Te raztopine so sterilne in navadno brez delčkov snovi. Omenjene preparate lahko steriliziramo z že dobro znanimi sterilizacijskimi tehnikami. Preparati lahko vsebujejo farmacevtkso sprejemljive pomožne substance, kakor je bilo zahtevano za približevanje fiziološkim pogojem, kakršni so na primer pH urejevalni in puferski agensi, agensi za uravnavnaje toksičnosti in podobni, npr. natrijev acetat, natrijev klorid, kalijev klorid, natrijev laktat, itd.
Koncentracija antiteles v teh formulacijah lahko znatno niha, npr. od manj kakor 0.5%, navadno vsaj ali manj od okoli 1% do okoi 15-20% mase, izberemo pa jo na osnovi prostornine tekočine, viskoznosti, itd., pač v skladu z določenim načinom, ki je bil izbran za vnašanje v organizem. Tako se lahko tipičen farmacevtski preparat za intramuskularno injekcijo izdela tako, da vebuje 1 ml sterilne pufrirane vode z 50mg antiteles. Tipičen preparat za intravenozno injekcijo pa se lahko naredi tako, da vsebuje do 250 ml sterilnega Ringer-jeve raztopine in 150 mg antiteles. Pravi postopki za izdelavo preparatov za parenteralno vnašanje pa so znani strokovnjakom na tem področju in so podrobno opisani na primer v Remington's Pharmaceutical Science, 15.ed. Mačk Publishing Company, easton, Pensylvania (1980), kar je tu navedeno kakor referenca.
Antitelesa tega izuma se lahko liofilizirajo za spravljanje v skladišča in za ponovno konstituiranje v ustreznem prenašalcu tik pred uporabo. Ta tehnika se je pokazala kot zelo uporabna pri operacijah z navadnimi imunoglobini, uporabimo pa lahko že znane tehnike liofilizacij e in rekonstitucije. V stroki izkušenim bo jasno, da lahko liofilizacija in ponovna rekonstitucija privedeta do izgube aktivnosti antiteles v različnih stopnjah (npr. pri običajnih imunoglobulinih, izgubijo IgM antitelesa več aktivnosti kakor IgG antitelesa), nivoje uporabe pa lahko prilagodimo zaradi kompenzacije tega učinka.
Preparati, ki vsebujejo humano-podobna antitelesa tega izuma se lahko vzemajo v profilaktivne in/ali terapevtske namene.
V terapevtkse namene, vnesemo preparate v pacienta, ki je že bolan, v taki količini, ki je dovolj velika za zdravljenje ali pa vsaj delno zaustavljanje bolezni in njenih komplikacij. Količina, ki je primerna za izvajanje tega načina je označena kot terapevtsko učinkovita doza. Količine, ki so učinkovite pri tem načinu bodo odvisne od resnosti infekcije, stanja pacienta, njegovega imunskega sistema, navadno pa se gibljejo od 1 do okoli 200 mg antiteles na dozo, z doziranjem od 5 do 25 mg na pacienta, ki potrebuje večjo količino zdravila. Vedeti moramo, da se materiali tega izuma navadno lahko uporabljajo tudi pri resnih bolezenskih stanjih, to je življensko nevarnih ali potencialno življenjsko nevarnih situacijah. V takih primerih je mogoče in je tako lahko tudi želj eno, s ciljem minimalizacije tujih substanc in nižanja verjetnosti zavračanja tuje substance, kar dosežemo s pomočjo predmetnih humano-podobnih antiteles tega izuma, po oceni zdravnika vzeti tudi znatne presežke teh antiteles.
V profilaktivne namene pa se preparati, ki vsebujejo prisotna antitelesa ali njihovo mešanico, vnesejo v še ne obolelega pacienta, da bi tako povečali njegovo odpornost. Taka količina je definirana kakor profilaktično učinkovita doza. V tem načinu uporabe pa so precizne količine zdravila ponovno odvisne od zdravstvenega stanja pacienta in občega nivoja imunskega sistema, navadno pa se gibljejo med 0.1 do 25 mg na dozo, prednostno od 0.5 do 2.5 mg na pacienta. Prednostna je profilaktična uporaba za preventivo zavračanja transplantiranih ledvic.
Enkratno ali večkratno vnašanje preparata se lahko izvede z dozami in načinom zdravljenja, ki ga določi sam zdravnik. V vsakem primeru pa morajo farmacevtske formulacije zagotoviti količino antiteles po predmetnem izumu, ki je dovolj velika za učinkovito obravnavanje danega pacienta.
Humano-podobna antitelesa tega izuma se lahko nadalje uporabijo tudi pri in vitro eksperimentih. Tu se na primer, ta antitelesa lahko uporabijo za tipizacijo T-celic, za izolacijo specifičnega IL-2 receptorja, ki ga nosijo celice ali pa za izolacijo fragmenta receptorja, za vakcinski preparat ali podobno.
V diagnostične namene so lahko uporabljena antitelesa označena ali neoznačena. Neoznačena antitelesa se lahko uporabijo v kombinaciji z drugimi označenimi antitelesi (druga antitelesa), ki reagirajo z danimi humano-podobnimi antitelesi, kakršna so na primer antitelesa specifična za humana imunoglobulinska konstantna področja. Alternativno, pa so lahko antitelesa označena tudi neposredno. Uporabimo lahko širok razpon sredstev za označevanje, kakršni so na primer radionuklidi, fluorji, encimi, encimski substrati, encimski kofaktorji, encimski inhibitorji, ligandi (še posebej hapteni), itd. Različne in številne metode imunopreiskav so v stroki izkušenim strokovnjakom poznane.
Opremo, skupaj s predmetnimi antitelesi tega izuma, lahko uporabimo tudi pri raziskavah za zaščito proti ali detekcijo celične aktivnosti ali za detekcijo prisotnosti izbranega antigena. Tako je predmetni preparat antiteles tega izuma lahko podan v najrazličnejših oblikah, kakršne so na primer, v liofilizirani obliki, v posodi, bodisi sam ali v povezavi z ddatnimi antitelesi, ki so specifična za željen tip celice. Antitelesa, ki jih lahko konjugiramo na označevalniku, so vključena v opremo s pufri, kakršen je Tris pufer, fosfat, karbonat, itd., s stabilizatorji, biocidi, inertnimi proteini, npr. serumski albumin ali podobni in s setom navodil za uporabo. Navadno bodo ti materiali prisotni v količinah, ki so manjše od 5 utežnih odstotkov glede na količino aktivnega antitelesa, navadno pa so prisotni v vsaj okoli 0.001 utežnih odstotkov, glede na koncentracijo antiteles. Pogosto bo potrebno vključiti tudi ekscipient, da bi tako blažili aktivne sestavine, kjer je ekscipient lahko prisoten v količinah od 1-90% utežnih odstotkov celotnega preparata. Kjer uporabljamo tudi drugo vrsto antiteles, sposobno za vezanje na himerno antitelo v preiskavi, bo to navadno prisotno v ločeni ampuli. Druga vrsta antiteles je navadno konjugirana na marker in je formulirana na podoben način kakor formulacije antiteles, ki so opisane v nadaljevanju.
Naslednji primeri so opisani zaradi ilustracije, ne pa omejevanja.
EKSPERIMENTALNI DEL
Grajenje genov za humano-podobne lahke in težke verige
Sekvenca humanega antitelesa Eu (Sekvence proteina z imunološkim interesom, Kabat et al., ZDA Dept. of Health and Human Services, 1983) so uporabljane za zagotavljanje mreže humaniziranih antiteles, zato ker je amino kislinska sekvenca težke verige anti-Tac bolj homologna s težko verigo tega antitelesa od druge sekvence težke verige v National Biochemical Foundation Protein Identification Resource. Zaradi izločanja sekvence humanizirane težke verige, je bila anti-Tac sekvenca težke verige (za splošne informacije glej USSN 186 862 in 223 037, kar je navedeno kakor referenca) povezana z Eu sekvenco težke verige (slika 1). Na vsakem položaju je bila za humanizirano sekvenco izbrana Eu amino kislina, z izjemo primerov, ko ta pozicija pade v eno izmed naslednjih kategorij, ko se anti-Tac amino kislina izbira:
1) Pozicija padca v komplementarno določujoče področje (CDR), kakor je to definiral Kabat et al., že cit. (amino kisline 31-35, 50-66, 99-106);
2) Eu amino kislina na tem mestu je neobičajna za humane težke verige, medtem ko je anti-Tac amino kislina tipična za humane težke verige na tem mestu (amino kisline 27,
93, 95, 98, 107-109, 111);
3) Pozicija je bila v amino kislinski sekvenci anti-Tac težke verige tik ob CDR (amino kisline 30 in 67);
4) 3-dimenzionalno modeliranje anti-Tac antiteles sugerira, da je bila amino kislina fizično blizu antigen veznega področja (amino kisline 48 in 68).
Nekatere amino kisline pripadajo več kot le eni kategoriji a so navedene le v eni izmed vseh.
Zaradi izbora sekvence humanizirane lahke verige, se sekvenca anti-Tac lahke verige povezuje s sekvenco Eu lahke verige (Slika 2). Eu amino kislina se izbira na vsakem položaju, razen v primeru, da omenjena pozicija pripada v eno izmed kategorij (1)-(4), (v zamenjavi besed težka veriga z lahka veriga v definiranih kategorijah):
1) CDR (amino kisline 24-34, 50-56, 89-97).
2) Anti-Tac amino kislina je bolj tipična kakor tista od Eu (amino kisline 48 in 63).
3) Ob CDR (ni amino kislin; Eu in Anti-Tac so že iste na vseh položajih).
4) Mogoča 3-dimenzionalna bližina glede na vezna področja (amino kislina 60).
Resnične nukleotidne sekvence genov težke verige (SEQ ID NO:
1) in lahke verige (SEQ ID NO: 2), ki sta prikazani spodaj, so bile izbrane kakor je razvidno:
SEQ ID NO: 1
20 30 40 50 60
TCTAGATGGGATGGAG CTG GATC TT TC TCTTCC TCCTG TC A G GT A CC G C GG GC G TG C A CT
H G W 5 W I F L F L L S G J A G V H
80 90 100 110 120
CTCAGGTCCAGCTTGTCCAGTCTGGGGCTGAAGTCAAGAAACCTGGCTCGAGCGTGAAGG S Q V Q L V 0 S G A E V K K P G S S V K
130 140 150 160 170 180
TCTCCTGCAAGGCTTCTGGCTACACCTTTACTAGCTACAGGATGCMTGGGTAAGGCAGG VSCKASGYTFTSYRMHWVRQ
0 2 0 0 210 220 2 3 0 240
CCCCTGGACAGGGTCTGGAATGGATTGGATATATTAATCCGTCGACTGGGTATACTGAAT A P G Q G L E W I G Υ I N P S T G Y T E
250 260 270 280 290 300
ACAATCAGAAGTTCAAGGACAAGGCAACAATTACTGCAGACGAATCCACCAATACAGCCT
Y N Q K F K D K A T I T A D E $ T N T A
310 320 330 340 350 360
ACATGGAACTGAGCAGCCTGAGATCTGAGGACACCGCAGTCTATTACTGTGCAAGAGGGG
Y M E L S $ L R S E D T A V Υ Y C A R G
370 380 390 400 410 420
GGGGGGTCTTTGACTACTGGGGCCAAGGAACCCTGGTCACAGTCTCCTCAGGTGAGTCCT G G V F D Y W G Q G T L V T V S 5
430
TAAAACCTCTAGA
SEQ ID NO: 1: Nukleotidna sekvenca gena za humanizirani anti-Tac težke verige variabilnega področja gen. Prevedena amino kislinska sekvenca za del gena ki kodira protein, je prikazana pod nukleotidno sekvenco. Nukleotidi TCTAGA na začetku in koncu gena so Xba in I mesta. Zrela sekvenca težke verige se začenja z amino kislinsko ^20 Q.
SEQ ID NO: 2
20 30 40 50 60
TCTAGATGGAGACCGATACCCTCCTGCTATGGGTCCTCCTGCTATGGGTCCCAGGATCAA
METDTLLLWVLLLWVPGS
TO 80 90 100 110 120
CCGGAGATATTCAGATGACCCAGTCTCCATCTACCCTCTCTG CTAGCGTCGGGGATAGGG TGDI OMTOSPSTLSASVGDR
130 140 150 160 170 180
TC ACCATAACCTGCTCT GCCAGCTCAAGTATAAGTTACATGGACTGGTACCAGCAGAAGC VT1TCSASSS I SYMHWYQQK
190 200 210 220 230 240
CAGGCAAAGCTCCCAAGCTTCTAATTTATACCACATGCAACCTGGCTTCTGGAGTCCCTG P G K A P K L L I Y T T S N L A S G V P
250 260 270 280 290 300
CTCGCTTCAGTGGCAGTGGATCTGGGAGCGAGTTCACCCTCACAATCAGCTCTCTGCAGC A R F S G S G $ G T E F T L T I S S L Q
310 320 330 340 350 360
CAGATGATTTCGCCACTTATTACTGCCATCAAAGGA6TACTTAGCCACTGACGTTCGGTC P D D F A T Υ Y C H Q R S T Y P L T F G
370 380 390 400
AGGGGACCAAGGTGGAGGTCAAAC6TAAGTACACTTTTCTAGA OGTKVEVK
SEQ ID NO: 2: Nukleotidna sekvenca gena za humanizirani anti-Tac lahke verige variabilnega področja gen. Prevedena amino kislinska sekvenca za del gena, ki kodira protein je prikazana pod nukleotidno sekvenco. Nukleotidi TCTAGA na začetku in koncu gena so Xba I mesta. Zrela sekvenca lahke verige se začne z amino kislino *21 D.
1) Nukleotidna sekvenčna koda za amino kislinske sekvence je bila izbrana kakor je opisano v nadaljevanju.
2) 5' teh kodirajočih sekvenc, nukleotidne sekvence za vodilno (signalno) sekvenco, torej vodeča sekvenca lahke verige antitelesa MOPC 63 in vodilna sekvenca težke verige antitelesa PCH 108A (Kabat et al., že cit.). Te vodilne sekvence so bile izbrane kakor tipične za antitelo.
3) 3' od kodirajočih sekvenc, nukleotidne sekvence so tiste sekvence, ki spremljajo segment mišje lahke verige J5 in segment mišje težke verige J2, ki sta dela anti-Tac sekvenc. Te sekvence so vključene zato, ker vsebujejo vpletene donorske signale.
4) Na vsakem koncu sekvence je Xba I mesto zaradi omogočanja srečanja na Xba mestih in kloniranja v Xba mesto vektorja.
Gradnja humanizirane lahke in težke verige gena
Za sintezo težke verige so bili sintetizirani štirje oligonukleotidi HES12, HES13, HES14 in HES15 (SEQ ID NO: 3), kjer smo uporabili Applied Biosystems 380B DNA sintetizer.
HESI2 AGCTTCTAGATGGGATGG AGCTGGATCTTTCTCTTCCTCCT-GTCAGG TACCGCGGGCGTG
CACTCTCAGGTCCAG CTTGTCCAGTCTGGGGCTGAAGTCAAGAAACCTGGCTCGAG CGTG AAGGTC
HESI3 CCCAGTCGACGGATTAATATATCCAATGCATTCCAGACCCTGTCCAGGGGCCTGCCTTAC CCAGTGCATCCTGTAGCTAGTAAAGGTGTAGCCAGAAGCCTTGCAGGAGACCTTCACGGT CGAGCCAGG
HESI4 TATATTAATCCGTCGACTGG GTATACTGAATAC AATCAGAAGTTCAAGGACAAGGCAACA ATTACIGCAGACGAATCCACCAATACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAG GAČA
HESI5 ATATCGTCTAGAGGTTTTAAGGACTCACCTGAGGAGACTGTGACCAGGGTTCCTTGGCCC CAGTAGTCAAAGACCCCCCCCCCTCTTGCACAGTAATAGACTGCGGTGTCCTCAGATCTC AGGCTGCT
SEQ ID NO: 3
SEQ ID NO: 3: Sekvence 4 oligonukleotidov, ki se uporabljajo za sintezo anti-Tac težke verige gena, napisane v smeri od 5’ proti 3'.
Dva izmed nukleotidov sta del vsake vijačnice težke verige, vsak oligonukleotid pa prekriva naslednjega z okoli 20 nukleotidi, kar dovoljuje sproščanje (Slika 3). Skupno pa ti oligonukleotidi prekrivajo celotno humanizirano težko verigo (SEQ ID NO: 1) z majhnim številom odvečnih nukleotidov, ki na vsakem koncu omogočajo zarezovanje na Xba in I mestih. Oligonukleotidi so bili prečiščeni iz poliakrilamidnih gelov.
Vsak oligonukleotid je bil fosforiliziran s pomočjo ATP in T4 polinukleotidne kinaze s pomočjo standardnih postopkov (glej Mantitatis, že cit.). Zaradi sproščanja fosforiliranih oligonukleotidov so bili ti suspendirani skupaj v 40 μΐ TA (33mM Tris acetata, pH=7, 9, 66mM kalijevega acetata, lOmM magnezijevega acetata) pri koncentraciji, ki je bila okoli 3.75uM vsak, kjer smo jih greli na 95°C 4 minute, nato pa počasi ohladili na 4°C. Zaradi sinteze celotnega gena iz nukleotidov s pomočjo sintetiziranja nasprotne vijačnice vsakega oligonukleotida (Slika 3), so bile naslednje komponente dodane koncernu volumnu 100 μΐ:
0.16
0.5
0.5
100
3.5 μΐ sproščeni oligonukleotidi mM vsakega deoksiribonukleotida mM ATP mM DTT pg/ml BSA pg/ml T4 g43protein (DNA polimeraza) pg/ml T4 g44/62 protein (polimerazni pomožni protein) pg/ml 45 protein (polimerazni pomožni protein)
Zmes je bila inkubirana na 37°C v trajanju 30 minut. Nato smo dodali lOu T4 DNA ligaze ter ponovili 30 minut trajajočo inkubacijo na 37°C. Polimeraza in ligaza sta bili deaktivirani s pomočjo inkubacije in z reakcijo na 70°C v trajanju 15 minut. Zaradi razgradnje gena z Xba I, smo reakcijski mešanici dodali 50 μΐ 2 x TA, ki je vseboval BSAA na 200 pg/ml in DTT pri lmM, 43 μΐ vode in 50u Xba I v 5μ1. Reakcijo smo nato pustili v inkubaciji 3 ure na 37°C, nakar smo jo postavili na gel. 431 bp Xba I fragment je bil prečiščen iz gela in kloniran v Xba I mestu plazmida pUC19 s standardnimi postopki. 4 plazmidne izolate smo nato prečistili in sekvencirali z uporabo dideoksi metode. Eden izmed teh je imel konkretno sekvenco (SEQ ID NO: 1).
Za sintezo lahke verige smo sintetizirali 4 oligonukleotide JFDI, JFD2, JFD3 in JFD4 (SEQ ID NO: 4).
JFDI CAAATCTAGATGGAGACCGATACCCTCCT6CTATGGGTCCTCCTGCTATGGGTCCCAGGA TCAACCGGAGATATTCAGATGACCCAGTCTCCATCTACCCTCTCTGCTAGCGTCGGGGAT
JFD2 ATAAATTAGAAGCTTGGGAGCTTTGCCTGGCTTCTGCTGGTACCAGTGCATGTAACTTAT ACTTGAGCTGGCAGAGCAGGTTATGGTGACCCTATCCCCGACGCTAGCAGAGAG
JFD3 GCTCCCAAGCTTCTAATTTATACCACATCCAACCTGGCTTCTGGAGTCCCTGCTCGCT TC AGTGGCAGTGGATCTGGGACCGAGTTCACCCTCACAATCAGCTCTCTGCAGCCAGATGAT TTC
JFD4 TATATCTAGAAAAGTGTACTTA CGTTTGACCT CCACCTTGG TCCCCTGACCGAACGTGAG TGGGTAAGTACTCCTTTGATGGCAGTAATAAGTGGCGAAATCATCTGGCTGCAGAGAGCT GA
SEQ ID NO: 4
SEQ ID NO: 4: Sekvence 4 oligonukleotidov, ki so bili uporabljeni pri sintezi humanizirane anti-Tac lahke verige, so napisane v smeri od 5' proti 3'.
Dva izmed nukleotidov sta del vsake vijačnice lahke verige, vsak oligonukleotid pa prekriva naslednjega z okoli 20 nukleotidi in s tem dovoljuje sproščanje (Slika 4). Skupaj pa oligonukleotidi prekrivajo celotno humanizirano lahko verigo (SEQ ID NO: 2) z majhnim številom odvečnih nukleotidov na vsakem koncu, kar omogoča zarezovanje na Xba I mestih. Oligonukleotidi so bili prečiščeni iz poliakrilamidnih gelov.
Gen lahke verige je bil sintetiziran iz teh oligonukleotidov v dveh delih. 0.5 pg vsakega izmed JFD1 in JFD 2 sta bila združena v 20 pl sekuenaznega pufra (40mM Tris-HCl, pH=7.5, 20mM magnezijevega klorida), nakar so bili segreti na 70°C v trajanju 3 minut, nato pa smo jih pustili, da so se počasi ohladili do 23°C s ciljem sproščanja oligonukleotidov. JFD3 in JFD4 sta bila obravnavana na enak način.
Vsaka reakcija se privede na lOmM v DTT ter 0.5mM v vsakem deoksiribonukleotidu, nakar dodamo 6.5 sekvenaze (US Biochemicals) v končno prostornino velikosti 24 μΐ, nakar pustimo celotno stvar inkubirati pri 37°C v trajanju 1 ure, da bi tako sintetizirali nasprotne vijačnice oligonukleotidov. Xbal in Hind III smo dodali vsaki reakciji zaradi razgrajevanja DNA (v področju, kjer se JFD2 in JFD3 prekrivata in zatorej tudi v vsaki DNA, obstaja Hindlll mesto, Slika 4). Reakcije izvajamo na poliakrilamidnih gelih, XbaI-HindIII fragmente prečistimo in kloniramo v pUC18 s pomočjo standardnih metod. Sekvenciramo več plazmidnih izolatov za vsak fragment, kar opravimo s pomočjo dideoksi metode, nato pa izberemo pravilne fragmente.
Izgradnja plazmidov za ekspresijo humaniziranih lahkih in težkih verig
Fragment Xbal težke verige smo izolirali iz pUC19 plazmida, v katerega je bil nameščen, nakar je bil nameščen v Xbal mesto vektorja pVgamal (glej objavo USSN 223 037) v pravilni orientaciji s pomočjo standardnih metod, s čimer smo oblikovali plazmid pHuGTACl (Slika 5). Ta plazmid bo ekspresiral visoke nivoje kompletne težke verige, če ga transfektiramo v ustrezne gostiteljske celice.
Dva fragmenta XbaI-HindIII lahke verige smo izolirali iz pUC18 plazmida v katerega sta bila nameščena. Vektorski plazmid pVkapal (glej, obče označen USSN 223 037) smo zarezali z Xbal, nakar smo ga defosforilizirali in povezali z 2 fragmentoma s pomočjo standardnih metod. Željeni reakcijski produkt je bil krožne oblike: vektor - Xbal fragment 1 - Hindlll - fragment 2-XbaI-vektor. Več plazmidnih izolatov smo analizirali s pomočjo restrikcijskega mapiranja in sekvenciranja, nakar smo izbrali enega s to obliko. Ta plazmid pHuLTAC (Slika 6) zaradi tega vsebuje kompletno lahko verigo (SEQ ID NO: 2) in bo ekspresiral visoke nivoje lahke verige, če ga transfektiramo v ustrezne gostiteljske celice.
Sinteza in afinitet humaniziranih antiteles
Plazmida pHuGTACl in pHuLTAC smo transfektirali v mišje Sp2/0 celice. Celice, ki so plazmid integrirale so bile izbrane na osnovi odpornosti na mikrofenolno kislino in/ali higromicin B, ki so bili preneseni s pomočjo gpt in hyg gena na plazmidih (Sliki 5, 6) s standardnimi metodami. Zaradi potrditve dejstva, da te celice izločajo antitelesa, ki se vežejo na humani IL-2 receptor, je bil supernatant iz celic inkubiran z HUT-102 celicami, ki ekspresirajo IL-2 receptor. Po izpiranju smo celice inkubirali s fluorescin-konjugiranim kozjim anti-humanim antitelesom, nakar smo jih sprali ter analizirali za fluorescenco na FACSCAN citofluorometru. Rezultati (Slika 7A) jasno kažejo, da humanizirano antitelo te celice veže, a se pri tem ne poveže na Jurkat T-celice, ki ne ekspresirajo IL-2 receptorja (Slika 7D). Kot kontrola, so bila za barvanje teh celic uporabljena tudi originalna mišja anti-Tac antitelesa (Slika 7B, C), dobili pa smo podobne rezultate.
Za nadaljnje eksperimente so bile celice, ki proizvajajo humanizirana antitelesa vnesena v miši, nakar smo zbrali dobljene ascite. Humanizirana antitelesa smo iz ascita prečistili do homogenosti s prepuščanjem skozi afinitativni stolpič iz kozjega anti-humanega imunoglobulinskega antitelesa, ki smo ga pripravili na Affigel-10 nosilcu (Bio35
Rad Laboratories, Inc., Richmond, CA), v skladu s standardnimi tehnikami. Zaradi določanja afinitete humaniziranih antiteles glede na originalna anti-Tac antitelesa, smo izvedli primerjalni eksperiment vezave.
Okoli 5 x 105 HUT-102 celic smo inkubirali z znanimi količinami (10-40 ng) anti-Tac antiteles in humaniziranih anti-Tac antiteles 4 min. na 4°C. Nato smo celicam dodali 100 ng biotiniliziranega anti-Tac, celice pa smo nato 30 min. inkubirali na 4°C. Ta količina anti-Taca je bila predhodno določena kot dovolj velika za zasičenj e veznih mest na celicah, ni pa predstavljala velikega presežka. Nato smo celice 2x sprali z 2ml fosfatno pufrirane raztopine soli (PBS), ki je vsebovala 0.1% natrijevega azida. Celice smo nato inkubirali 30 minut na 4°C z 250ng ficoeritrinkonjugiranega avidina, ki se veže na biotinilizirani antiTac, ki je že vezan na celice. Celice smo ponovno sprali kakor prej, ter jih nato fiksirali v PBS, ki je vseboval 1% paraformaldehida, nato pa smo jih analizirali za fluorescenco na FACSCAN citofluorometru.
Uporaba rastočih količin (10-40ng) anti-Tac antiteles, ki so bila uporabljena kot primerjava v prvi stopnji je zmanjšalo količino biotiniliziranega anti-Tac-a, ki se lahko veže na celice v drugi stopnji, zaradi cesar količina ficoeritrinkonjugiranega avidina, ki se veže v zadnji stopnji, zniža fluorescenco (Slika 8A). Ekvivalentne količine (20ng) antiTac-a in humaniziranega anti-Tac-a, ki so bile uporabljene kot primerjave, znižajo fluorescenco za približno enako stopnjo (Slika 8B). To kaže, da imajo ta antitelesa približno enako afiniteto in so učinkovitejša od biotiniliziranega anti-Tac, saj bolj zmanjšujejo fluorescenco.
Biološke lastnosti humaniziranih antiteles
Za optimalno uporabo pri zdravljenju humanih bolezni, mora biti humanizirano antitelo sposobno uničiti T-celice v telesu, ki ekspresira IL-2 receptor. Eden izmed mehanizmov, s pomočjo katerega lahko antitelesa uničijo celice clija je od antiteles odvisna, celično povzročena citotoksičnost, skrajšano ADCC (Fundamental Immunology, Paul W. ed., Raven Press, New York (1984)m str 681), kjer antitelo tvori most med celico cilja in efektorsko celico, kakršne so makrofagi, ki lahko nato razgradi celico clija. Da bi ugotovili, ali humanizirano antitelo in originalno mišje anti-Tac antitelo lahko povzročita ADCC, je bilo izvršena preiskava izločanja kroma s pomočjo standardnih metod. Specifično, so bile celice HUT-102 humane levkemije, ki ekspresirajo IL-2 receptor, inkubirane s 51Cr zaradi adsorbcije tega radionuklida. HUT-102 celice smo nato inkubirali z viškom anti-Tac ali pa z viškom humaniziranih anti-Tac antiteles. HUT-102 celice smo nato inkubirali 4 ure z 30:1 ali 100:1 raztopino efektorskih celic, ki so bile navadne, prečiščene humane periferne krvne mononuklearne celice, ki so bile predhodno aktivirane z inkubacijo v trajanju 20 ur s humanim rekombinantnim IL-2. Izmerili smo osvobajanje 51Cr, ki nakazuje razpadanje HUT-102 celic cilja, nakar smo rezultat zmanjšali za fon (Tabela 1). Rezultati kažejo, da pri kateremkoli odnosu efektorskih celic, anti-Tac ne lizira večjega števila celic cilja (manj od 5%), humanizirano antitelo pa je zmožno veliko večje stopnje razgradnje (več od 20%) . Iz tega je razvidno, da je humanizirano antitelo bolj učinkovito od originalnega antitelesa pri obravnavanju T-celic levkemije ali drugih bolezni, ki jih povzročajo Tcelice.
Tabela 1
Procent 51Cr izločanja po ADCC
Razmerje efektor/tarča
30:1 | 100:1 | |
Antitelo | ||
Anti-Tac | 4% | <1% |
Humanizirano | ||
Anti-Tac | 24% | 23% |
Iz zgornjega je razvidno, da nudijo humanim—podobni imunoglobulini tega izuma niz prednosti nad drugimi humanimi IL-2 specifičnimi antitelesi. Primerjava z anti-Tac mišjimi monoklonalnimi antitelesi kaže, da lahko predmetna humanopodobna antitelesa pridobimo na bolj ekonomičen način, ter da taki vsebujejo tudi manj stranskih amino kislinskih sekvenc. Ta zmanjšana verjetnost antigeničnosti po vnašanju v humanega pacienta predstavlja znatno terapevtsko izbolj sanje.
Čeprav je bil predmetni izum opisan dovolj podrobno s pomočjo ilustracij in primerov, podanih zaradi jasnosti in razumevanja, pa bo v stroki izkušenim jasno, da so določene modifikacije in spremembe znotraj obsega tega izuma možne.
Claims (20)
- PATENTNI ZAHTEVKI1. Novi preparat 11-2 receptor specifičnih humanih imunoglobulinov, značilen po tem, da vključuje v glavnem čist, humano-podoben imunoglobulin, ki je specifično reaktiven z p55 Tac proteinom.
- 2. Preparat, po zahtevku 1 značilen po tem, da vključuje imunoglobulin dva para dimerov lahka/težka veriga, kjer vsaka veriga obsega spremenljivo in konstantno področje.
- 3. Preparat po zahtevku 1, značilen po tem, da obsega v glavnem čist humano-podoben imunoglobulin, ki je sposoben inhibirati vezanje humanega interleukina-2 (IL-2) na humani IL-2 receptor.
- 4. Preparat po zahtevku 1, značilen po tem, da kaže imunoglobulin večjo afiniteto na humani IL-2 receptor od okoli 107 8 M’1 ali več.
- 5. Preparat po zahtevku 1 značilen po tem, da obsega imunoglobulin komplementarno določujoča področja iz enega imunoglobulina ter mrežna področja iz vsaj enega različnega imunoglobulina.
- 6. Rekombinantni imunoglobulinski preparat, značilen po tem, da obsega humanemu podobno in eno ali več tujih komplementarno ustreznih področij, ki niso naravno vezana z mrežo, kjer je omenjeni imunoglobulin sposoben vezanja na humani interleukin-2-receptor.
- 7. Preparat po zahtevku 6 značilen po tem, da je imunoglobulin IgGi imunoglobulinski izotop.
- 8. Preparat po zahtevku 6 značilen po tem, da so zrele lahke in težke proteinske sekvence spremenljivega področja v glavnem homologne s SEQ ID NO: 1 in SEQ ID NO: 2.
- 9. Humano-podoben imunoglobulin, ki ima dva para dimerov lahka/težka veriga in je sposoben specifično reagirati z epitopom na humani interleukin-2 receptor z afiniteto velikosti okoli 108 M-1, značilen po tem, da vključujejo omenjene lahke in težke verige komplementarno določujoča področja (CDR) in humano-podobna mrežna področja, CDR pa so iz imunoglobulinskih molekul različnih od mrežnih področij.
- 10.Imunoglobulin po zahtevku 9 značilen po tem, da blokira vezavo interleukina-2 (IL-2) na humane IL-2 receptorje.
- 11. Humanizirani imunoglobulin, sposoben vezave na humane interleukin-2 receptorje, značilen po tem, da obsega eno ali več komplementarno določujočih področij (CDR) iz anti Tac antiteles v humano-podobni mreži, kjer humano-podobno mrežno področje obsega vsaj eno amino kislino izbrano iz anti-Tac antitelesa.
- 12. Humanizirani imunoglobulin po zahtevku 11, značilen po tem, da ima zrelo spremenljivo sekvenco težke verige, kakor je prikazano v SEQ ID NO: 1, ter sekvenco lahke verige, kakor je prikazano v SEQ ID NO: 2.
- 13. Humanizirani imunoglobulin po zahtevku 11, značilen po tem, da je dodatna amino kislina iz anti-Tac antitelesa postavljena tik ob CDR.
- 14.Imunoglobulin po zahtevku 1, značilen po tem, da se pridobiva v mieloma ali hibridoma celici.
- 15. Polinukleotidna molekula, ki obsega najprej sekvenco, ki kodira humano-podobna imunoglobulinska mrežna področja in drugo sekvenco, ki kodira eno ali več mišjih imunoglobulinskih komplementarno določujočih področij, značilna po tem, da po ekspresiji omenjeni polinukleotid kodira imunoglobulin, ki specifično reagira s p55 Tac proteinom ter blokira vezavo interleukina-2 (IL-2) na IL-2 receptor na humanih celicah.
- 16. Celična linija, značilna po tem, da je transfektirana s polinukleotidom po zahtevku 15.
- 17. Postopek za gradnjo humanizirane imunoglobulinske (Ig) verige, ki ima eno ali več komplementarno določujočih področij (CDR) iz donorja Ig ter mrežno področje iz humanega Ig, značilen po tem, da obsega primerjanje mrežnega ali spremenljivega področja amino kislinske sekvence donorja Ig z ustreznimi sekvencami v kolekciji humanih Ig verig, ter izbiranje zaradi zagotavljanja humane Ig mreže ene izmed okoli 3 najbolj homolognih sekvenc iz kolekcije.
- 18. Postopek gradnje humanizirane imunoglobulinske verige, ki ima mrežno področje iz humanega akceptorskega imunoglobulina in komplementarno določujoče področje iz donorskega imunoglobulina, sposobnega vezave na antigen, značilen po tem, da obsega stopnje substitucije vsaj ene humane mrežne amino kisline akceptornega imunoglobulina z ustrezno amino kislino iz donorskega imunoglobulina na položaju v imunoglobulinu kjer:a) je amino kislina v humanem mrežnem področju redka za omenjeni položaj, ustezna amino kislina v donorskem imunoglobulinu pa je obča za omenjeni položaj v humanih imunoglobulinskih sekvencah; alib) amino kislina je tik ob CDR ali pac) je za amino kislino predvideno, da ima bočno verigo atomov na razdalji 3x 1O~10 m od CDR v 3-dimenzionalnem modelu imunoglobulina, ter je sposobna sodelovati z antigenom ali s CDR humaniziranega imunoglobulina.
- 19. Postopek po zahtevku 18, značilen po tem, da obsega humanizirana imunoglobulinska veriga dodaten CDR vsaj 3 amino kisline iz donorskega imunoglobulina, ki so bile izbrane glede na kriterije opisane pod a), b) ali c).
- 20. Postopek po zahtevku 19, značilen po tem, da je vsaj ena amino kislina, substituirana iz donorja, tik ob CDR.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29097588A | 1988-12-28 | 1988-12-28 | |
US31025289A | 1989-02-13 | 1989-02-13 | |
YU248989A YU48700B (sh) | 1988-12-28 | 1989-12-28 | Postupak za proizvodnju humaniziranog imunoglobulinskog lanca |
Publications (2)
Publication Number | Publication Date |
---|---|
SI8912489A true SI8912489A (sl) | 1999-02-28 |
SI8912489B SI8912489B (sl) | 2000-04-30 |
Family
ID=26966505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI8912489A SI8912489B (sl) | 1988-12-28 | 1989-12-28 | Novi IL-2 receptor specifični humani imunoglobulini |
Country Status (32)
Country | Link |
---|---|
EP (6) | EP0682040B1 (sl) |
JP (6) | JP2828340B2 (sl) |
KR (1) | KR0178385B1 (sl) |
CN (1) | CN1057013C (sl) |
AT (2) | ATE133452T1 (sl) |
AU (1) | AU647383B2 (sl) |
BG (1) | BG61095B2 (sl) |
CA (2) | CA2006865C (sl) |
CZ (1) | CZ418691A3 (sl) |
DD (1) | DD296964A5 (sl) |
DE (14) | DE122005000007I2 (sl) |
DK (2) | DK119191A (sl) |
ES (5) | ES2440825T3 (sl) |
FI (1) | FI108797B (sl) |
FR (1) | FR14C0070I1 (sl) |
HK (1) | HK1014718A1 (sl) |
HR (1) | HRP920500B1 (sl) |
HU (1) | HU211174A9 (sl) |
IE (1) | IE20000331A1 (sl) |
IL (2) | IL162181A (sl) |
LU (8) | LU90411I2 (sl) |
MC (1) | MC2146A1 (sl) |
NL (8) | NL990020I2 (sl) |
NO (9) | NO310473B1 (sl) |
NZ (2) | NZ314793A (sl) |
PT (1) | PT92758B (sl) |
RU (1) | RU2126046C1 (sl) |
SG (1) | SG78258A1 (sl) |
SI (1) | SI8912489B (sl) |
WO (1) | WO1990007861A1 (sl) |
YU (1) | YU48700B (sl) |
ZA (1) | ZA899956B (sl) |
Families Citing this family (972)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800815A (en) * | 1903-05-05 | 1998-09-01 | Cytel Corporation | Antibodies to P-selectin and their uses |
US5851526A (en) * | 1985-04-19 | 1998-12-22 | Ludwig Institute For Cancer Research | Methods of treating colon cancer utilizing tumor-specific antibodies |
US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US7247453B1 (en) * | 1988-12-30 | 2007-07-24 | Oklahoma Medical Research Foundation | Calcium binding recombinant antibody against protein C |
DE3900534A1 (de) * | 1989-01-10 | 1990-07-12 | Boehringer Mannheim Gmbh | Diagnostischer nachweis unter verwendung von chimaeren antikoerpern |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GR1001050B (el) * | 1990-01-09 | 1993-04-28 | Protein Design Labs Inc | Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων. |
HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
GB9020282D0 (en) | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
US5858725A (en) * | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
SK281142B6 (sk) * | 1991-03-06 | 2000-12-11 | Merck Patent Gesellschaft Mit Beschr�Nkter Haftung | Humanizovaná monoklonálna protilátka, expresné vektory a farmaceutický prostriedok |
IL101147A (en) * | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Change of direction of cellular immunity by chimera receptors |
DE69226431T2 (de) * | 1991-04-05 | 1999-04-22 | Univ Washington | Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor |
WO1992019759A1 (en) * | 1991-04-25 | 1992-11-12 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
EP0519596B1 (en) * | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
GB9115010D0 (en) * | 1991-07-11 | 1991-08-28 | Wellcome Found | Antibody |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
US5585103A (en) * | 1991-07-25 | 1996-12-17 | Idec Pharmaceutical Corporation | Induction of cytotoxic T-lymphocyte responses |
US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
US5756096A (en) * | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
US5709860A (en) * | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US6699472B2 (en) | 1991-08-14 | 2004-03-02 | Genentech, Inc. | Method of treating allergic disorders |
US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
ES2145004T3 (es) * | 1991-08-21 | 2000-07-01 | Novartis Ag | Derivados de anticuerpos. |
GB9120467D0 (en) * | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
JP3024311B2 (ja) * | 1991-10-03 | 2000-03-21 | 味の素株式会社 | Il−2受容体重鎖に結合するポリペプチド |
US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
US5817310A (en) | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5869619A (en) * | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5766886A (en) * | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
US5777085A (en) * | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
AU675929B2 (en) * | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
GB9203459D0 (en) * | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5387676A (en) * | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
US6033667A (en) * | 1992-05-05 | 2000-03-07 | Cytel Corporation | Method for detecting the presence of P-selectin |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
US6066718A (en) * | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
GB9223377D0 (en) * | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
DK0669986T3 (da) * | 1992-11-13 | 2003-07-28 | Idec Pharma Corp | Fuldstændigt inaktiverede kozac-sekvenser til ekspression i pattedyr |
EP0752248B1 (en) * | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5648267A (en) * | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
US5804187A (en) * | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen Inc | Rekombinante anti-vla4 antikörpermoleküle |
US5730979A (en) * | 1993-03-05 | 1998-03-24 | Universite Catholique Delouvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
US5951983A (en) * | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
US5817311A (en) * | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
WO1994025067A1 (en) * | 1993-05-04 | 1994-11-10 | Cytel Corporation | Antibodies to p-selectin and their uses |
WO1994028025A1 (en) | 1993-05-28 | 1994-12-08 | The Scripps Research Institute | Methods and compositions for inhibiting cd14 mediated cell activation |
AU6808194A (en) * | 1993-05-31 | 1994-12-20 | Chugai Seiyaku Kabushiki Kaisha | Reconstructed human antibody against human interleukin-6 |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5914110A (en) * | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
ATE286510T1 (de) * | 1993-09-07 | 2005-01-15 | Smithkline Beecham Corp | In der behandlung von il4 auslösenden krankheiten nützliche rekombinante il4 antikörper |
US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
US5928904A (en) * | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
AU7949394A (en) | 1993-11-19 | 1995-06-06 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
AU2185195A (en) * | 1993-11-30 | 1995-06-19 | Protein Design Labs, Inc. | Reperfusion therapy using antibodies to L-selectin |
GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
KR100367948B1 (ko) * | 1994-01-25 | 2003-07-12 | 엘란 파마슈티칼스, 인크. | 백혈구부착분자vla-4에대한인체화된항체 |
ATE240395T1 (de) | 1994-03-29 | 2003-05-15 | Celltech Therapeutics Ltd | Antikörper gegen e-selektin |
US5635597A (en) * | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
USRE39548E1 (en) * | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
US6048972A (en) * | 1994-07-13 | 2000-04-11 | Chugai Pharmaceutical Co., Ltd. | Recombinant materials for producing humanized anti-IL-8 antibodies |
DE4425115A1 (de) * | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
EP0696455A1 (en) * | 1994-08-11 | 1996-02-14 | Cellena (Cell Engineering) A.G. | Transferrin compositions to alleviate the side effects of cytotoxic drugs |
US8771694B2 (en) * | 1994-08-12 | 2014-07-08 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
US5707621A (en) * | 1994-08-31 | 1998-01-13 | Chugai Pharmaceutical Co., Ltd. | Supression of nephritis-induced protein excretion by anti-IL-8 |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
US5693323A (en) * | 1994-12-23 | 1997-12-02 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
WO1996040249A1 (en) * | 1995-06-07 | 1996-12-19 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of ta99 |
US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
GB9600660D0 (en) | 1996-01-12 | 1996-03-13 | Ciba Geigy Ag | Protein |
US6046310A (en) * | 1996-03-13 | 2000-04-04 | Protein Design Labs., Inc. | FAS ligand fusion proteins and their uses |
US5882644A (en) * | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
US6713305B1 (en) | 1996-04-29 | 2004-03-30 | Novartis Ag | Metastasis-associated antigen and antibodies thereto |
DE69724428T3 (de) | 1996-06-07 | 2009-07-23 | Poniard Pharmaceuticals, Inc., Seattle | Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren |
US6833255B1 (en) | 1996-07-24 | 2004-12-21 | Novartis, Ag | Drosophila melanogaster p70 S6 kinase |
US6534311B2 (en) | 1996-07-24 | 2003-03-18 | Novartis Ag | Drosophila melanogaster p70S6 kinase |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
WO1998010070A1 (fr) * | 1996-09-02 | 1998-03-12 | Sumitomo Electric Industries, Ltd. | IMMUNOGLOBULINE HUMANISEE REAGISSANT SPECIFIQUEMENT AVEC UN LIGAND Fas OU L'UN DE SES FRAGMENTS ACTIFS ET REGION D'INDUCTION D'APOPTOSE PRENANT NAISSANCE DANS UN LIGAND Fas |
US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
US6903194B1 (en) | 1996-09-26 | 2005-06-07 | Chungai Seiyaku Kabushiki Kaisha | Antibody against human parathormone related peptides |
UA76934C2 (en) | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
US7883872B2 (en) | 1996-10-10 | 2011-02-08 | Dyadic International (Usa), Inc. | Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose |
US7910096B2 (en) | 1996-11-15 | 2011-03-22 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic uremic syndrome |
US20020160005A1 (en) | 1996-11-15 | 2002-10-31 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic urmec syndrome |
JP4138013B2 (ja) | 1996-12-23 | 2008-08-20 | イミュネックス・コーポレーション | Tnfスーパーファミリーのメンバーであるnf−kappa bの受容体アクティベーターに対するリガンド |
US6262238B1 (en) * | 1997-01-14 | 2001-07-17 | Roche Diagnostic, Gmbh | Process for modifying the stability of antibodies |
US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
US6596850B1 (en) | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
US5986065A (en) | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
US20060235209A9 (en) | 1997-03-10 | 2006-10-19 | Jin-An Jiao | Use of anti-tissue factor antibodies for treating thromboses |
US7749498B2 (en) | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
US20030109680A1 (en) | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
IL123756A0 (en) * | 1997-03-21 | 1998-10-30 | Sankyo Co | Humanized anti-human FAS antibody |
US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
EP1325932B9 (en) | 1997-04-07 | 2006-07-19 | Genentech, Inc. | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US20020165363A1 (en) * | 1997-05-15 | 2002-11-07 | Koh Sato | Cachexia remedy |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
DK1019082T4 (da) | 1997-10-02 | 2008-10-27 | Max Planck Gesellschaft | Fremgangsmåde til moduleringen af neovaskularisering og/eller væksten af kollaterale arterier og/eller andre arterier fra forudeksisterende arteriolære forbindelser |
CA2305712A1 (en) | 1997-10-03 | 1999-04-15 | Chugai Seiyaku Kabushiki Kaisha | Natural humanized antibody |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
EP1745799B1 (en) | 1998-03-04 | 2015-09-02 | The Trustees of The University of Pennsylvania | Compositions and methods of treating tumors |
HUP0101160A2 (hu) | 1998-04-03 | 2001-08-28 | Chugai Seiyaku Kabushiki Kaisha | Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására |
CN1689646A (zh) | 1998-08-11 | 2005-11-02 | 拜奥根Idec公司 | 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法 |
JP4689781B2 (ja) * | 1998-09-03 | 2011-05-25 | 独立行政法人科学技術振興機構 | アミノ酸輸送蛋白及びその遺伝子 |
PL203114B1 (pl) | 1998-09-14 | 2009-08-31 | Regents Board Of | Zastosowania przeciwciała przeciw VLA-4 lub jego fragmentu wiążącego antygen, przeciwciała przeciw integrynie alfa-4/beta7 lub jego fragmentu wiążącego antygen lub przeciwciała przeciw VCAM-1 lub jego fragmentu wiążącego antygen, zastosowania rozpuszczalnych polipeptydów VLA-4 lub VCAM-1, które antagonizują interakcję VLA-4/VCAM-1 |
KR100618495B1 (ko) | 1998-10-06 | 2006-08-31 | 마크 아론 에말파브 | 섬유상의 진균성 숙주 영역에서의 형질전환 시스템:크리소스포륨속에서 |
DE69839740D1 (de) | 1998-10-22 | 2008-08-28 | Univ Montana | Vakzine enthaltend Omp85 Proteine von Neisseria gonorrhoeae und Neisseria meningitidis |
DK2055313T3 (en) | 1998-11-09 | 2015-07-27 | Biogen Inc | Treatment of Hematologic Malignancies Related to Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody |
GB9825632D0 (en) | 1998-11-23 | 1999-01-13 | Novartis Ag | Organic compounds |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
AU767066B2 (en) | 1999-03-03 | 2003-10-30 | Curis, Inc. | Methods of modulating lipid metabolism and storage |
GB9906380D0 (en) * | 1999-03-19 | 1999-05-12 | Melvin William T | Monoclonal antibodies specific for cypibi |
IL145898A0 (en) | 1999-04-22 | 2002-07-25 | Biogen Inc | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
IT1306704B1 (it) * | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
EA011384B1 (ru) | 1999-06-01 | 2009-02-27 | Байоджен Айдек Ма Инк. | Способ лечения воспалительного заболевания |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
TWI255718B (en) | 1999-07-02 | 2006-06-01 | Chugai Pharmaceutical Co Ltd | Ameliorative agent for low vasopressin concentration |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
AU784187B2 (en) * | 1999-09-30 | 2006-02-16 | Kyowa Hakko Kogyo Co. Ltd. | Human type complementarity determining region transplantation antibody against ganglioside GD3 and derivatives of antibody against ganglioside GD3 |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
WO2001039722A2 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
ES2415708T3 (es) | 1999-12-16 | 2013-07-26 | Biogen Idec Ma Inc. | Métodos de tratamiento de la lesión isquémica o hemorrágica del sistema nervioso central mediante el uso de antagonistas anti-integrina alfa4 |
ES2349348T3 (es) | 2000-01-27 | 2010-12-30 | Medimmune, Llc | Anticuerpos neutralizantes de rsv de ultra alta afinidad. |
AU3327701A (en) * | 2000-02-03 | 2001-08-14 | Millennium Pharm Inc | Humanized anti-ccr2 antibodies and methods of use therefor |
WO2001058949A2 (en) | 2000-02-11 | 2001-08-16 | Biogen, Inc. | Heterologous polypeptide of the tnf family |
BRPI0108676B8 (pt) | 2000-02-24 | 2021-05-25 | Lilly Co Eli | anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos |
CA2401652A1 (en) | 2000-03-01 | 2001-09-07 | Medimmune, Inc. | High potency recombinant antibodies and method for producing them |
WO2001070266A2 (en) | 2000-03-17 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2 |
US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
WO2001082968A1 (fr) | 2000-04-28 | 2001-11-08 | Chugai Seiyaku Kabushiki Kaisha | Inhibiteurs de proliferation cellulaire |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
EP1287364B1 (en) | 2000-04-29 | 2008-10-22 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
US7476383B2 (en) | 2000-05-02 | 2009-01-13 | The Uab Research Foundation | Antibody selective for DR4 and uses thereof |
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
EP1717251B1 (en) | 2000-10-02 | 2012-01-18 | Novartis Vaccines and Diagnostics, Inc. | Therapy for B-cell malignancies using human anti-CD40 antibodies |
US6989247B2 (en) | 2000-11-28 | 2006-01-24 | Celltech R & D, Inc. | Compositions and methods for diagnosing or treating psoriasis |
US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
AU2002315271B2 (en) * | 2001-04-06 | 2006-08-03 | University Of Bristol | Use of CD25 binding molecules in steroid-resistant patients |
UA83791C2 (ru) | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 |
YU91403A (sh) * | 2001-05-18 | 2006-05-25 | Boehringer Ingelheim International Gmbh. | Antitela specifična za cd44v6 |
US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
US7541443B2 (en) * | 2001-06-14 | 2009-06-02 | Tolerrx, Inc. | Anti-CD4 antibodies |
JP2005500034A (ja) | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
US20030013081A1 (en) | 2001-06-26 | 2003-01-16 | Olson William C. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
JP4675512B2 (ja) * | 2001-07-10 | 2011-04-27 | 三井化学株式会社 | 熱殺菌方法 |
CA2898314A1 (en) | 2001-07-19 | 2003-07-31 | Perian Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
JP4729717B2 (ja) | 2001-08-03 | 2011-07-20 | 株式会社医学生物学研究所 | GM1ガングリオシド結合型アミロイドβタンパク質を認識する抗体、及び該抗体をコードするDNA |
AU2002329775C1 (en) | 2001-08-17 | 2011-04-07 | Eli Lilly And Company | Assay method for alzheimer's disease |
EP3187592B1 (en) | 2001-09-20 | 2018-12-12 | Immunex Corporation | Selection of cells expressing heteromeric polypeptides |
EP1431310A4 (en) | 2001-09-25 | 2005-03-23 | Immuno Biological Lab Co Ltd | ANTI-OSTEOPONTIN RECOMBINANT ANTIBODY AND USE THEREOF |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
US20030190705A1 (en) * | 2001-10-29 | 2003-10-09 | Sunol Molecular Corporation | Method of humanizing immune system molecules |
US7524502B2 (en) * | 2001-11-12 | 2009-04-28 | Merck Patent Gmbh | Modified anti-TNF alpha antibody |
PL209133B1 (pl) | 2001-11-21 | 2011-07-29 | Univ Pennsylvania | Rekombinowany adenowirus, obejmująca go izolowana komórka gospodarza, oraz kompozycja i zastosowanie |
EP1944043A1 (en) | 2001-11-21 | 2008-07-16 | The Trustees of the University of Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
DK1461300T3 (da) | 2001-11-30 | 2011-10-24 | Biogen Idec Inc | Antistoffer mod kemotaktiske monocytproteiner |
EP1461428B1 (en) * | 2001-12-03 | 2012-03-21 | Alexion Pharmaceuticals, Inc. | Method for producing hybrid antibodies |
US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
EP1519959B1 (en) * | 2002-02-14 | 2014-04-02 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
NZ534947A (en) | 2002-02-22 | 2008-03-28 | Progenics Pharm Inc | Anti-CCR5 antibody that binds to CCR5 on the surface of a human cell. |
AU2003213231A1 (en) | 2002-02-25 | 2003-09-09 | Elan Pharmaceuticals, Inc. | Administration of agents for the treatment of inflammation |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
US20060171940A1 (en) | 2002-03-20 | 2006-08-03 | Celltech R&D Limited | Antibody disulfide isomers, use thereof, and methods of analyzing same |
JP4432031B2 (ja) * | 2002-03-22 | 2010-03-17 | ズィナイス オペレーションズ ピーティーワイ.エルティーディー. | インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体 |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
AU2003241449B2 (en) | 2002-05-14 | 2009-03-05 | Dsm Ip Assets B.V. | Carotene synthase gene and uses therefor |
US7601817B2 (en) | 2002-05-28 | 2009-10-13 | Ucb Pharma S.A. | Antibody peg positional isomers, compositions comprising same, and use thereof |
EP1513554B9 (en) * | 2002-05-30 | 2011-11-09 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
GB0213745D0 (en) | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7544483B2 (en) | 2002-06-14 | 2009-06-09 | Monier Tadros | Method for the production of protamine |
AU2002368055B2 (en) | 2002-06-28 | 2008-09-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist |
US9535076B2 (en) | 2002-09-12 | 2017-01-03 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
KR101329843B1 (ko) | 2002-11-15 | 2013-11-14 | 젠맵 에이/에스 | Cd25에 대한 인간 모노클로날 항체 |
JP2007531505A (ja) | 2002-11-27 | 2007-11-08 | ミネルバ バイオオテクノロジーズ コーポレーション | 癌(muc1)の診断および治療のための技術および組成物 |
BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
WO2004065417A2 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
US7576101B2 (en) | 2003-01-24 | 2009-08-18 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
US7321065B2 (en) | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
CA2523142A1 (en) | 2003-04-23 | 2004-11-04 | Medarex, Inc. | Humanized antibodies to interferon alpha receptor-1 (ifnar-1) |
CN100409897C (zh) | 2003-04-23 | 2008-08-13 | 梅达雷克斯公司 | 1型干扰素拮抗剂在制备治疗患有炎症性肠病的患者的药物中的用途 |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
EP1633189B1 (en) | 2003-05-19 | 2017-07-05 | Prothena Biosciences Limited | Truncated fragments of alpha-synuclein in lewy body disease |
AU2004253868B2 (en) | 2003-06-13 | 2011-06-16 | Biogen Ma Inc. | Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof |
US20060162014A1 (en) | 2003-07-07 | 2006-07-20 | Jaffe Eileen K | Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules |
US8153410B2 (en) | 2003-07-07 | 2012-04-10 | Fox Chase Cancer Center | Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules |
SI2784084T2 (sl) | 2003-07-08 | 2024-02-29 | Novartis Pharma Ag | Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom |
TWI476206B (zh) | 2003-07-18 | 2015-03-11 | Amgen Inc | 對肝細胞生長因子具專一性之結合劑 |
US7834155B2 (en) | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
EP1693385A4 (en) | 2003-11-11 | 2009-11-04 | Chugai Pharmaceutical Co Ltd | ANTI-CD47 ANTIBODIES HUMANIZED |
JP2007514413A (ja) | 2003-11-12 | 2007-06-07 | プロジェニクス・ファーマスーティカルズ・インコーポレイテッド | C型肝炎ウイルス糖タンパク質をコードする新規配列 |
US7700737B2 (en) | 2003-12-05 | 2010-04-20 | Multimmune Gmbh | Therapeutic and diagnostic anti-Hsp70 antibodies |
US7332584B2 (en) | 2003-12-08 | 2008-02-19 | Morphotek, Inc. | Antibodies that specifically bind PMS2 |
US20080025913A1 (en) | 2003-12-15 | 2008-01-31 | Bowdish Katherine S | Novel Anti-Dc-Sign Antibodies |
ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
PL2311873T3 (pl) | 2004-01-07 | 2019-01-31 | Novartis Vaccines And Diagnostics, Inc. | Przeciwciało monoklonalne specyficzne wobec M-CSF i jego zastosowania |
WO2005068504A1 (ja) | 2004-01-19 | 2005-07-28 | Medical And Biological Laboratories Co., Ltd. | 炎症性サイトカイン抑制剤 |
JP2007521811A (ja) | 2004-01-30 | 2007-08-09 | ダナ ファーバー キャンサー インスティテュート | 放射線又は遺伝毒性物質曝露の測定及び定量方法 |
CA2561531C (en) | 2004-02-10 | 2017-05-02 | The Regents Of The University Of Colorado | Inhibition of factor b, the alternative complement pathway and methods related thereto |
US20050232919A1 (en) | 2004-02-12 | 2005-10-20 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
TWI359026B (en) | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
EP1717250A4 (en) | 2004-02-20 | 2008-10-01 | Immuno Biological Lab Co Ltd | MONOCLONAL ANTIBODY AND ITS USE |
WO2005090406A2 (en) | 2004-03-12 | 2005-09-29 | Vasgene Therapeutics, Inc. | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
MXPA06010673A (es) | 2004-03-19 | 2007-06-20 | Amgen Inc | Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v. |
MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
CN1964740A (zh) | 2004-04-02 | 2007-05-16 | 加利福尼亚大学董事会 | 治疗和预防与αVβ5整联蛋白有关的疾病的方法和组合物 |
CA2568201C (en) | 2004-05-24 | 2013-07-30 | Universitat Zu Koln | Identification of ergothioneine transporter and therapeutic uses thereof |
EP1602926A1 (en) | 2004-06-04 | 2005-12-07 | University of Geneva | Novel means and methods for the treatment of hearing loss and phantom hearing |
LT2662390T (lt) | 2004-06-21 | 2017-10-10 | E. R. Squibb & Sons, L.L.C. | Interferono-alfa receptoriaus-1 antikūnai ir jų panaudojimas |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
WO2006033702A2 (en) | 2004-07-26 | 2006-03-30 | Biogen Idec Ma Inc. | Anti-cd154 antibodies |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
CA2478458A1 (en) | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
FI20041204A0 (fi) | 2004-09-16 | 2004-09-16 | Riikka Lund | Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi |
AU2005291486A1 (en) | 2004-10-01 | 2006-04-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel antibodies directed to the mammalian EAG1 ion channel protein |
EP3428191A1 (en) | 2004-10-06 | 2019-01-16 | Mayo Foundation for Medical Education and Research | B7-h1 and pd-1 in treatment of renal cell carcinoma |
AU2005299716B2 (en) | 2004-10-22 | 2012-09-06 | Amgen Inc. | Methods for refolding of recombinant antibodies |
AU2005306997B2 (en) | 2004-10-25 | 2012-07-05 | Merck Sharp & Dohme Corp. | Anti-ADDL antibodies and uses thereof |
CN103169965A (zh) | 2004-11-19 | 2013-06-26 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
KR101404512B1 (ko) | 2005-01-05 | 2015-01-29 | 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. | 상보성 결정부위와 다른 분자의 부위에서 처리된 결합성을갖는 합성 면역글로불린 영역 |
NZ555937A (en) | 2005-01-27 | 2009-05-31 | Childrens Hosp & Res Ct Oak | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
JP2008529536A (ja) | 2005-02-14 | 2008-08-07 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 加齢性黄斑変性を処置および診断するための方法および試薬 |
EP2332408B1 (en) | 2005-02-17 | 2013-11-13 | Biogen Idec MA Inc. | Treating neurological disorders |
AU2006216291B2 (en) | 2005-02-27 | 2011-01-27 | Institute For Antibodies Co., Ltd. | Anti-IgSF4 antibody and utilization of the same |
BRPI0608254A2 (pt) | 2005-03-02 | 2009-12-08 | Biogen Idec Inc | anticorpos kim-1 para o tratamento de condições mediadas por th2 |
AU2006223301B2 (en) | 2005-03-10 | 2010-11-04 | Eisai, Inc. | Anti-mesothelin antibodies |
JP2008532559A (ja) | 2005-03-19 | 2008-08-21 | メディカル リサーチ カウンシル | ウイルス感染の治療及び予防又は治療及び予防の改善 |
DK2343320T3 (da) | 2005-03-25 | 2018-01-29 | Gitr Inc | Anti-gitr-antistoffer og anvendelser deraf |
ES2720288T3 (es) | 2005-03-30 | 2019-07-19 | Minerva Biotechnologies Corp | Proliferación de células que expresan MUC1 |
JP2008543276A (ja) | 2005-03-30 | 2008-12-04 | ミネルバ バイオテクノロジーズ コーポレーション | Muc1発現細胞の増殖 |
WO2006105511A1 (en) | 2005-03-31 | 2006-10-05 | The General Hospital Corporation | Monitoring and modulating hgf/hgfr activity |
CN101351710B (zh) | 2005-04-04 | 2013-06-05 | 生物基因Idecma公司 | 评价对治疗性蛋白质的免疫应答的方法和产品 |
EP2172487A1 (en) | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
JP2008538700A (ja) | 2005-04-22 | 2008-11-06 | モルフォテック、インク. | 免疫エフェクター活性を有するエンドシアリン細胞に内部移行する抗体 |
WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
US8034902B2 (en) | 2005-05-04 | 2011-10-11 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against CD55 and CD59 and uses thereof |
DK2559690T3 (en) | 2005-05-10 | 2016-04-25 | Incyte Holdings Corp | Modulators of indoleamine 2,3-dioxygenase and methods of use thereof |
AU2006247188A1 (en) | 2005-05-18 | 2006-11-23 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against chlamydia infection |
CA2607663C (en) | 2005-05-19 | 2014-08-12 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
JP5707024B2 (ja) | 2005-05-26 | 2015-04-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | 外傷性脳損傷、脊髄損傷および関連状態を治療するために補体副経路を阻害する作用剤 |
ES2507069T3 (es) | 2005-05-27 | 2014-10-14 | Biogen Idec Ma Inc. | Anticuerpos de unión a TWEAK |
EP1899376A2 (en) | 2005-06-16 | 2008-03-19 | The Feinstein Institute for Medical Research | Antibodies against hmgb1 and fragments thereof |
CA2611519A1 (en) | 2005-06-17 | 2006-12-28 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
ES2827247T3 (es) * | 2005-06-21 | 2021-05-20 | Xoma Us Llc | Anticuerpos y fragmentos de los mismos que se unen a IL-1beta |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
JP2009514790A (ja) | 2005-07-22 | 2009-04-09 | プロジェニクス・ファーマスーティカルズ・インコーポレイテッド | Hiv−1−感染患者におけるウイルス負荷を減少させる方法 |
WO2007016285A2 (en) | 2005-07-28 | 2007-02-08 | Novartis Ag | M-csf specific monoclonal antibody and uses thereof |
US8193328B2 (en) | 2005-09-08 | 2012-06-05 | Philadelphia Health & Education Corporation | Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents |
EP1934605B1 (en) | 2005-09-22 | 2014-03-26 | Prosci Incorporated | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
WO2007051077A2 (en) | 2005-10-28 | 2007-05-03 | The Regents Of The University Of California | Methods and compounds for lymphoma cell detection and isolation |
CN101351221A (zh) | 2005-10-28 | 2009-01-21 | 明治制果株式会社 | 绿脓杆菌的外膜蛋白pa5158 |
EP1948235B1 (en) | 2005-11-01 | 2013-08-28 | AbbVie Biotechnology Ltd | Methods for determining efficacy of adalimumab in subjects having ankylosing spondylitis using ctx-ii and mmp3 as biomarkers |
EP1957541A2 (en) | 2005-11-21 | 2008-08-20 | Laboratoires Serono SA | Compositions and methods of producing hybrid antigen binding molecules and uses thereof |
DK1976877T4 (en) † | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
EP2272497B1 (en) | 2006-01-18 | 2012-10-03 | The General Hospital Corporation | Methods of increasing lymphatic function |
JP2009531295A (ja) | 2006-02-22 | 2009-09-03 | ユニバーシティ オブ チューリッヒ | 自己免疫疾患又は脱髄疾患を処置するための方法 |
EP2377887A1 (en) | 2006-03-10 | 2011-10-19 | Zymogenetics Inc | Antibodies that bind both IL-17A and IL-17F and methods of using the same |
EP2006379B1 (en) | 2006-03-23 | 2016-08-31 | Tohoku University | High functional bispecific antibody |
SG170804A1 (en) | 2006-03-30 | 2011-05-30 | Meiji Seika Kaisha | Pseudomonas aeruginosa outer membrane protein pa0427 |
SG170837A1 (en) | 2006-04-05 | 2011-05-30 | Abbott Biotech Ltd | Antibody purification |
EP2007426A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS |
EP2666479A3 (en) | 2006-04-10 | 2014-03-26 | Abbott Biotechnology Ltd | Uses and compositions for treatment of juvenile rheumatoid arthritis |
CA2564435A1 (en) | 2006-04-10 | 2007-10-10 | Abbott Biotechnology Ltd. | Methods for monitoring and treating intestinal disorders |
DK2034830T3 (da) | 2006-05-25 | 2014-10-27 | Biogen Idec Inc | Anti-vla-1-antistof til behandling af slagtilfælde |
CA2653661A1 (en) | 2006-05-31 | 2007-12-06 | Astellas Pharma Inc. | Humanized anti-human osteopontin antibody |
EP2035448A4 (en) | 2006-06-01 | 2010-11-03 | Elan Pharm Inc | NEUROACTIVE FRAGMENTS OF APP |
EP2046384A4 (en) | 2006-06-15 | 2009-12-02 | Fibron Ltd | ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME |
CA2655903A1 (en) | 2006-06-19 | 2008-08-07 | Tolerx, Inc. | Ilt3 binding molecules and uses therefor |
EP2043711A4 (en) | 2006-06-30 | 2017-08-30 | AbbVie Biotechnology Ltd | Automatic injection device |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
EP2292646A3 (en) | 2006-07-07 | 2011-06-08 | Intercell AG | Small Streptococcus pyogenes antigens and their use |
EP2975057A1 (en) | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
AU2007272995B2 (en) | 2006-07-10 | 2013-02-07 | Biogen Idec Ma Inc. | Compositions and methods for inhibiting growth of smad4-deficient cancers |
ES2452067T3 (es) | 2006-08-04 | 2014-03-31 | Novartis Ag | Anticuerpo específico para EPHB3 y usos del mismo |
EP2056709A4 (en) | 2006-08-11 | 2013-05-01 | Univ New Jersey Med | DOUBLE-SENSITIZER WITH LUMINESCENCE COMPOUNDS, CONJUGATES AND USE |
PT2059535E (pt) | 2006-08-18 | 2014-01-29 | Novartis Ag | Anticorpos específicos do prlr e suas utulizações |
EP2500415A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
TW201516149A (zh) | 2006-09-13 | 2015-05-01 | Abbvie Inc | 細胞培養改良 |
JPWO2008032833A1 (ja) | 2006-09-14 | 2010-01-28 | 株式会社医学生物学研究所 | Adcc活性を増強させた抗体及びその製造方法 |
FR2906533B1 (fr) | 2006-09-28 | 2013-02-22 | Pf Medicament | Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations |
US8394927B2 (en) | 2006-11-03 | 2013-03-12 | U3 Pharma Gmbh | FGFR4 antibodies |
CN103073641B (zh) | 2006-11-10 | 2015-01-21 | 株式会社立富泰克 | 在体内具有抗肿瘤活性的抗人Dlk-1抗体 |
CN101553506B (zh) | 2006-11-17 | 2013-08-07 | 诺瓦提斯公司 | Lingo结合分子及其制药用途 |
EP1923069A1 (en) | 2006-11-20 | 2008-05-21 | Intercell AG | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
US8288110B2 (en) | 2006-12-04 | 2012-10-16 | Perkinelmer Health Sciences, Inc. | Biomarkers for detecting cancer |
KR20140119831A (ko) | 2006-12-07 | 2014-10-10 | 노파르티스 아게 | Ephb3에 대한 길항제 항체 |
US8680252B2 (en) | 2006-12-10 | 2014-03-25 | Dyadic International (Usa), Inc. | Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi |
US8440185B2 (en) | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
WO2008083239A2 (en) | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for stimulating an immune response |
JP5694668B2 (ja) | 2006-12-29 | 2015-04-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | 自己免疫疾患の診断上および治療上の標的ならびにその用途 |
SI2436696T1 (sl) | 2007-01-05 | 2017-10-30 | University Of Zurich | Anti-beta-amiloidno protitelo in načini njegove uporabe |
EP2120984A2 (en) | 2007-01-12 | 2009-11-25 | Intercell AG | Protective proteins of s. agalactiae, combinations thereof and methods of using the same |
US8168415B2 (en) | 2007-02-07 | 2012-05-01 | The Regents Of The University Of Colorado | Axl fusion proteins as Axl tyrosine kinase inhibitors |
EP2130044B1 (en) | 2007-02-16 | 2016-10-26 | Genzyme Corporation | Method of identifying risk for thyroid disorder |
EP2118300B1 (en) | 2007-02-23 | 2015-05-27 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
CN104189885A (zh) | 2007-02-23 | 2014-12-10 | 纽约哥伦比亚大学理事会 | 通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径治疗免疫疾病的方法 |
HUE043966T2 (hu) | 2007-02-23 | 2019-09-30 | Prothena Biosciences Ltd | Szinukleinopátiás és amiloidogén betegség megelõzése és kezelése |
HUE035762T2 (en) | 2007-03-13 | 2018-05-28 | Univ Zuerich | Monoclonal Human Tumor-Specific Antibody |
CN103214577B (zh) | 2007-03-22 | 2015-09-02 | 生物基因Ma公司 | 特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途 |
DK2137217T3 (en) | 2007-04-05 | 2014-03-17 | Morphotek Inc | Methods of inhibiting the binding of endosialin to ligands |
WO2008134659A2 (en) | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antagonists to il-17a, il-17f, and il-23p19 and methods of use |
EP2497779A1 (en) | 2007-05-02 | 2012-09-12 | Intercell AG | Klebsiella antigens |
EP3456733A1 (en) | 2007-05-11 | 2019-03-20 | Genzyme Corporation | Methods of producing a secreted protein |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
US7709215B2 (en) | 2007-06-01 | 2010-05-04 | Cytonics Corporation | Method for diagnosing and treating acute joint injury |
WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
MX2009013593A (es) | 2007-06-14 | 2010-01-20 | Biogen Idec Inc | Formulaciones de anticuerpos. |
JP2010530229A (ja) | 2007-06-18 | 2010-09-09 | インターセル アーゲー | クラミジア属の抗原 |
EP3241842B1 (en) | 2007-06-26 | 2024-01-31 | F-star Therapeutics Limited | Display of binding agents |
WO2009001940A1 (ja) | 2007-06-27 | 2008-12-31 | Asubio Pharma Co., Ltd. | ペリオスチンのExon-17部位によりコードされるペプチドに対する抗体を含む癌治療剤 |
EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
EP2175884B8 (en) | 2007-07-12 | 2017-02-22 | GITR, Inc. | Combination therapies employing gitr binding molecules |
AU2008293885A1 (en) | 2007-07-13 | 2009-03-05 | The John Hopkins University | B7-DC variants |
HUE025283T2 (en) | 2007-08-02 | 2016-03-29 | Gilead Biologics Inc | LOX and LOX2 inhibitors and their use |
HUE032301T2 (en) | 2007-08-30 | 2017-09-28 | Daiichi Sankyo Co Ltd | Anti-EPHA2 antibody |
CN101848999A (zh) * | 2007-09-06 | 2010-09-29 | 国立大学法人大阪大学 | 抗-cd20单克隆抗体 |
CA2736661A1 (en) | 2007-09-07 | 2009-03-12 | Dyadic International, Inc. | Novel fungal enzymes |
EP2185592B1 (en) | 2007-09-13 | 2013-01-23 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
JP5963341B2 (ja) | 2007-09-14 | 2016-08-10 | アムジエン・インコーポレーテツド | 均質な抗体集団 |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
SI2206727T1 (sl) | 2007-10-11 | 2015-06-30 | Daiichi Sankyo Company, Limited | Protitelo, ki cilja osteoklast - soroden protein Siglec-15 |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
KR20100115340A (ko) | 2007-10-19 | 2010-10-27 | 이무나스 파마 가부시키가이샤 | Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용 |
WO2009059321A2 (en) | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Rca locus analysis to assess susceptibility to amd and mpgnii |
MY149546A (en) | 2007-11-02 | 2013-09-13 | Novartis Ag | Improved nogo-a binding molecules and pharmaceutical use tereof |
CA2960659C (en) | 2007-11-09 | 2021-07-13 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors |
ES2556214T3 (es) | 2007-11-12 | 2016-01-14 | U3 Pharma Gmbh | Anticuerpos para AXL |
CA2706258C (en) | 2007-11-28 | 2017-06-06 | The Trustees Of The University Of Pennsylvania | Simian subfamily e adenoviruses sadv-39, -25.2, -26, -30, -37, and -38 and uses thereof |
JP5758124B2 (ja) | 2007-11-28 | 2015-08-05 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルサブファミリーCアデノウイルスSAdV−40、−31および−34ならびにそれらの用途 |
EP2229410A4 (en) | 2007-12-05 | 2012-07-04 | Massachusetts Inst Technology | AGLYCOSYLATED IMMUNOGLOBULIN MUTANTS |
WO2009078799A1 (en) | 2007-12-17 | 2009-06-25 | Marfl Ab | New vaccine for the treatment of mycobacterium related disorders |
AU2008342152B2 (en) | 2007-12-25 | 2013-06-27 | Meiji Seika Pharma Co., Ltd. | Component protein PA1698 for type-III secretion system of Pseudomonas aeruginosa |
KR101603076B1 (ko) | 2007-12-28 | 2016-03-14 | 프로테나 바이오사이언시즈 리미티드 | 아밀로이드증의 치료 및 예방 |
CN101918549B (zh) | 2008-01-11 | 2012-11-28 | 财团法人化学及血清疗法研究所 | 改良的人源化的抗-人α9-整联蛋白抗体 |
BRPI0906492A2 (pt) | 2008-01-11 | 2015-12-01 | Synovex Corp | antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações |
JP2011509650A (ja) * | 2008-01-11 | 2011-03-31 | 株式会社ジーンテクノサイエンス | ヒト化抗−α9インテグリン抗体及びその使用 |
CN102936287B (zh) | 2008-02-08 | 2015-09-09 | 伊缪纳斯制药株式会社 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
CN102016011B (zh) | 2008-03-04 | 2013-12-11 | 宾夕法尼亚大学托管会 | 猿猴腺病毒sadv-36、-42.1、-42.2和-44及其应用 |
ES2610327T3 (es) | 2008-03-13 | 2017-04-27 | Biotest Ag | Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias |
BRPI0909180A2 (pt) | 2008-03-13 | 2016-08-09 | Biotest Ag | composição farmacêutica, e, método de tratamento de uma doença autoimune |
AU2009231325B2 (en) | 2008-03-13 | 2014-09-18 | Biotest Ag | Agent for treating disease |
EP2664339A3 (en) | 2008-03-17 | 2013-12-11 | Universitätsklinikum Münster | YopM as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
US8017118B2 (en) | 2008-03-17 | 2011-09-13 | LivTech Inc. — Teikyo University Biotechnology Research Center | Anti-hDlk-1 antibody having an antitumor activity in vivo |
CN101977927A (zh) | 2008-03-17 | 2011-02-16 | 英特塞尔股份公司 | 针对肺炎链球菌保护的肽以及与其有关的组合物、方法和用途 |
EP2260863A1 (en) | 2008-03-27 | 2010-12-15 | Takara Bio, Inc. | Prophylactic/therapeutic agent for infectious disease |
ES2588194T3 (es) | 2008-04-11 | 2016-10-31 | Seattle Genetics, Inc. | Detección y tratamiento de cáncer pancreático, de ovario y otros cánceres |
CA2723197C (en) | 2008-05-02 | 2017-09-19 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
JP2011523560A (ja) | 2008-06-02 | 2011-08-18 | ダナ−ファーバー キャンサー インスティテュート インク. | Xbp1ペプチド、cd138ペプチドおよびcs1ペプチド |
US8575314B2 (en) | 2008-06-20 | 2013-11-05 | National University Corporation Okayama University | Antibody against oxidized LDL/β2GPI complex and use of the same |
KR102007492B1 (ko) | 2008-06-25 | 2019-08-05 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
PL3628686T3 (pl) | 2008-06-25 | 2022-02-28 | Novartis Ag | Humanizowanie przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
HUE039692T2 (hu) | 2008-06-25 | 2019-01-28 | Esbatech Alcon Biomed Res Unit | TNF-et gátló stabil és oldható ellenanyagok |
BRPI0915692B8 (pt) | 2008-07-08 | 2021-05-25 | Incyte Corp | compostos derivados de 1,2,5-oxadiazóis, sua forma sólida, sua composição, bem como seus usos |
US8993728B2 (en) | 2008-07-16 | 2015-03-31 | Medical And Biological Laboratories Co., Ltd. | Anti-human CLCP1 antibody and use thereof |
CA2732715C (en) | 2008-08-01 | 2015-04-07 | Kusuki Nishioka | Treatment agent or preventative agent for osteoarthritis |
US8795981B2 (en) | 2008-08-08 | 2014-08-05 | Molecular Devices, Llc | Cell detection |
US8417011B2 (en) | 2008-09-18 | 2013-04-09 | Molecular Devices (New Milton) Ltd. | Colony detection |
EP2172485A1 (en) | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
US8715654B2 (en) | 2008-10-02 | 2014-05-06 | Celtaxsys, Inc. | Methods of modulating the negative chemotaxis of immune cells |
EP4201421A1 (en) | 2008-10-09 | 2023-06-28 | Minerva Biotechnologies Corporation | Method for inducing pluripotency in cells |
EP2346904B1 (en) | 2008-10-29 | 2017-04-12 | China Synthetic Rubber Corporation | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
JP5809978B2 (ja) | 2008-10-31 | 2015-11-11 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルスSAdV−43、−45、−46、−47、−48、−49および−50ならびにそれらの用途 |
US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
JP5810413B2 (ja) | 2008-12-19 | 2015-11-11 | バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー | ヒト抗アルファシヌクレイン自己抗体 |
US8313915B2 (en) | 2009-01-21 | 2012-11-20 | Gundersen Lutheran Medical Foundation, Inc. | Early detection of canine lyme disease by specific peptides and antibodies |
US20100260752A1 (en) | 2009-01-23 | 2010-10-14 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria |
WO2010089340A2 (en) | 2009-02-05 | 2010-08-12 | Intercell Ag | Peptides protective against e. faecalis, methods and uses relating thereto |
US8617574B2 (en) | 2009-02-13 | 2013-12-31 | Valneva Austria Gmbh | Nontypable Haemophilus influenzae antigens |
US20110306069A1 (en) | 2009-02-19 | 2011-12-15 | Qingyu Wu | Corin As A Marker For Heart Failure |
DK2406288T3 (en) | 2009-03-10 | 2017-03-27 | Baylor Res Inst | ANTIGEN PRESENTING CELL-TARGETED VACCINES |
DK2406286T3 (en) | 2009-03-10 | 2016-08-22 | Baylor Res Inst | Anti-cd40 antibodies and uses thereof |
ES2635080T3 (es) | 2009-03-10 | 2017-10-02 | Baylor Research Institute | Vacunas contra el cáncer dirigidas a células presentadoras de antígenos |
JP5725508B2 (ja) | 2009-03-25 | 2015-05-27 | 国立大学法人東北大学 | Lh型二重特異性抗体 |
US8575316B2 (en) | 2009-04-09 | 2013-11-05 | Daiichi Sankyo Company, Limited | Anti-Siglec-15 antibody |
US20120121706A1 (en) | 2009-04-10 | 2012-05-17 | Tufts Medical Center, Inc. | PAR-1 Activation by Metalloproteinase-1 (MMP-1) |
JP5812418B2 (ja) | 2009-04-17 | 2015-11-11 | イムナス・ファーマ株式会社 | Aβオリゴマーに特異的に結合する抗体およびその利用 |
EP2246364A1 (en) | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
MX2011011541A (es) | 2009-04-29 | 2012-02-28 | Abbott Biotech Ltd | Dispositivo de inyeccion automatico. |
EP2270053A1 (en) | 2009-05-11 | 2011-01-05 | U3 Pharma GmbH | Humanized AXL antibodies |
CN102575232B (zh) | 2009-05-29 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿腺病毒41及其应用 |
EP2260864A1 (en) | 2009-06-10 | 2010-12-15 | University of Melbourne | Therapeutic applications |
TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以dll4拮抗劑與化學治療劑治療癌症之方法 |
BR112012001463A2 (pt) | 2009-07-24 | 2016-03-15 | Univ California | métodos e composições para tratar e prevenir doença associada à integrina alfavbeta5 |
WO2011012646A2 (en) | 2009-07-28 | 2011-02-03 | F. Hoffmann-La Roche Ag | Non-invasive in vivo optical imaging method |
CA2770237A1 (en) | 2009-08-05 | 2011-02-10 | Nexigen Gmbh | Human hcv-interacting proteins and methods of use |
WO2011024114A1 (en) | 2009-08-25 | 2011-03-03 | Ecole Polytechnique Federale De Lausanne (Epfl) | Targeting extracellular matrix molecules for the treatment of cancer |
TWI412375B (zh) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
AU2010286351A1 (en) | 2009-08-31 | 2012-03-15 | Amplimmune, Inc. | B7-H4 fusion proteins and methods of use thereof |
EP2477647B1 (en) | 2009-09-14 | 2016-01-13 | The Regents of the University of Colorado | Modulation of yeast-based immunotherapy products and responses |
EP2305285A1 (en) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Means and methods for treating ischemic conditions |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
EP2308897A1 (en) | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
EP2485762B1 (en) | 2009-10-11 | 2017-12-13 | Biogen MA Inc. | Anti-vla-4 related assays |
WO2011062112A1 (ja) | 2009-11-18 | 2011-05-26 | 国立大学法人東北大学 | ヒト型化抗egfr抗体可変領域の高機能性変異体 |
EP2332929A1 (en) | 2009-11-25 | 2011-06-15 | ArisGen SA | Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
WO2011068870A2 (en) | 2009-12-01 | 2011-06-09 | President And Fellows Of Harvard College | Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186) |
US20110150891A1 (en) | 2009-12-16 | 2011-06-23 | Philip Bosch | Methods of Treating Interstitial Cystitis |
US9221759B2 (en) | 2010-01-13 | 2015-12-29 | Rutgers, The State University Of New Jersey | Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency |
CA2787783A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Anti-ilt5 antibodies and ilt5-binding antibody fragments |
CA2787755A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
KR101684246B1 (ko) | 2010-01-29 | 2016-12-08 | 가부시키가이샤 아크시스 | 변형성 관절증 치료제를 포함하는 주사제 |
JPWO2011093083A1 (ja) | 2010-01-29 | 2013-05-30 | Axis株式会社 | 変形性関節症治療又は予防用医薬組成物及びその製造方法 |
JP2012246222A (ja) | 2010-01-29 | 2012-12-13 | Axis Inc | 変形性関節症治療剤または予防剤を製造するための使用 |
JP2013518590A (ja) | 2010-02-02 | 2013-05-23 | アボツト・バイオテクノロジー・リミテツド | TNF−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物 |
EP2533804B1 (en) | 2010-02-08 | 2018-04-11 | Agensys, Inc. | Antibody drug conjugates (adc) that bind to 161p2f10b proteins |
EP4219560A3 (en) | 2010-02-18 | 2023-08-23 | The Regents of The University of California | Integrin alpha v beta 8 neutralizing antibody |
EP2544688B1 (en) | 2010-03-02 | 2016-09-07 | President and Fellows of Harvard College | Methods and compositions for treatment of angelman syndrome |
EP3056510B1 (en) | 2010-03-03 | 2018-10-03 | The University Of British Columbia | Oligomer-specific amyloid beta epitope and antibodies |
EP2553449A2 (en) | 2010-03-26 | 2013-02-06 | Westfälische Wilhelms-Universität Münster | Substitute therapy for glucocorticoids |
EP2371863A1 (en) | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
RU2625014C2 (ru) | 2010-04-09 | 2017-07-11 | Критикал Кэа Дайэгностикс, Инк. | Антитела против растворимого st-2 человека и способы анализа |
AU2011239512B2 (en) | 2010-04-16 | 2016-01-21 | Biogen Ma Inc. | Anti-VLA-4 antibodies |
RU2695703C2 (ru) | 2010-04-21 | 2019-07-25 | Эббви Байотекнолоджи Лтд. | Носимое устройство для автоматической инъекции для управляемой подачи терапевтических агентов |
KR20130036012A (ko) | 2010-05-07 | 2013-04-09 | 에프. 호프만-라 로슈 아게 | 생체외 세포의 검출을 위한 진단 방법 |
SG10201503904XA (en) | 2010-05-17 | 2015-06-29 | Livtech Inc | Anti-human trop-2 antibody having antitumor activity in vivo |
WO2011146727A1 (en) | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of treating interstitial cystitis |
US9485812B2 (en) | 2010-07-08 | 2016-11-01 | Honda Motor Co., Ltd. | High frequency heating coil |
MX338640B (es) | 2010-07-14 | 2016-04-25 | Merck Sharp & Dohme | Anticuerpo monoclonal anti-ligando difundible derivado de amiloide beta y usos de los mismos. |
KR101695056B1 (ko) | 2010-07-15 | 2017-01-10 | 애드헤론 쎄라퓨틱스, 인코포레이티드 | 카드헤린-11의 ec1 도메인을 표적으로 하는 인간화 항체 및 관련 조성물 및 방법 |
EP3470421B9 (en) | 2010-07-29 | 2023-10-04 | Buzzard Pharmaceuticals AB | Chimeric il-1 receptor type i antagonists |
JP6081356B2 (ja) | 2010-07-30 | 2017-02-15 | エーシー イミューン エス.エー. | 安全で機能的なヒト化抗βアミロイド抗体 |
JP2012034668A (ja) | 2010-08-12 | 2012-02-23 | Tohoku Univ | ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用 |
WO2012027494A1 (en) | 2010-08-24 | 2012-03-01 | Regents Of The University Of Minnesota | Bispecific targeting reagents |
EP2609431B1 (en) | 2010-08-27 | 2017-05-10 | University of Zurich | Method for target and drug validation in inflammatory and/or cardiovascular diseases |
CA2807244A1 (en) | 2010-08-27 | 2012-03-01 | University Of Zurich | A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases |
WO2012028697A1 (en) | 2010-09-01 | 2012-03-08 | Eth Zürich, Institute Of Molecular Biology And Biophysics | Affinity purification system based on donor strand complementation |
US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
WO2012043747A1 (ja) | 2010-09-30 | 2012-04-05 | 独立行政法人理化学研究所 | グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤 |
US8497138B2 (en) | 2010-09-30 | 2013-07-30 | Genetix Limited | Method for cell selection |
EA031698B1 (ru) | 2010-10-11 | 2019-02-28 | Байоджен Интернэшнл Нейросайенз Гмбх | Человеческие анти-тау антитела |
AU2011313847B2 (en) | 2010-10-13 | 2016-07-07 | Janssen Biotech, Inc. | Human oncostatin M antibodies and methods of use |
AU2011317743B2 (en) | 2010-10-18 | 2015-05-21 | Mediapharma S.R.L. | ErbB3 binding antibody |
AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
US9272052B2 (en) | 2010-10-22 | 2016-03-01 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway |
LT3326645T (lt) | 2010-10-25 | 2020-08-10 | Biogen Ma Inc. | Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai |
AU2011322508A1 (en) | 2010-10-27 | 2013-05-02 | Pierre Fabre Medicament | Antibodies for the treatment of HIV |
KR101814852B1 (ko) | 2010-10-29 | 2018-01-04 | 다이이찌 산쿄 가부시키가이샤 | 신규 항 dr5 항체 |
EP2640425A2 (en) | 2010-11-18 | 2013-09-25 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt) |
EP2640744A4 (en) | 2010-11-19 | 2014-05-28 | Eisai R&D Man Co Ltd | NEUTRALIZATION OF ANTIBODIES TO CCL20 |
EP2643465B1 (en) | 2010-11-23 | 2016-05-11 | The Trustees Of The University Of Pennsylvania | Subfamily e simian adenovirus a1321 and uses thereof |
CN103380145B (zh) | 2010-12-17 | 2016-10-12 | 生物控股有限公司 | 人类抗-sod1抗体 |
US9085772B2 (en) | 2010-12-27 | 2015-07-21 | National University Corporation Nagoya University | Method for suppressing receptor tyrosine kinase-mediated pro-survival signaling in cancer cell |
US20130295091A1 (en) | 2011-01-10 | 2013-11-07 | University Of Zurich | Combination therapy including tumor associated antigen binding antibodies |
US9217040B2 (en) | 2011-01-14 | 2015-12-22 | The Regents Of The University Of California | Therapeutic antibodies against ROR-1 protein and methods for use of same |
BR112013018905B1 (pt) | 2011-01-24 | 2021-07-13 | Abbvie Biotechnology Ltd | Dispositivos de injeção automática que têm superfícies de pega sobremoldadas. |
WO2012104824A1 (en) | 2011-02-04 | 2012-08-09 | Ecole polytechnique fédérale de Lausanne (EPFL) | Therapeutic antibodies targeting app-c99 |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
WO2012110843A1 (en) | 2011-02-18 | 2012-08-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for promoting fibrinolysis and thrombolysis |
EP2678026B1 (en) | 2011-02-21 | 2016-05-18 | The University of Zurich | Ankyrin g for use in the treatment of neurodegenerative disorders |
EP2683290B1 (en) | 2011-03-07 | 2018-11-07 | F.Hoffmann-La Roche Ag | Methods for in vivo testing of therapeutic antibodies |
WO2012120004A1 (en) | 2011-03-07 | 2012-09-13 | F. Hoffmann-La Roche Ag | In vivo selection of therapeutically active antibodies |
EP2684045B2 (en) | 2011-03-09 | 2023-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods to characterize patients suffering from hemolysis |
WO2012125680A1 (en) | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
EP2686417B1 (de) | 2011-03-17 | 2016-06-08 | Miltenyi Biotec GmbH | Tcralpha/beta-depletierte zellpräparationen |
WO2012135132A1 (en) | 2011-03-25 | 2012-10-04 | Baylor Research Institute | Compositions and methods to immunize against hepatitis c virus |
TW201249867A (en) | 2011-04-01 | 2012-12-16 | Astellas Pharma Inc | Novel anti-human il-23 receptor antibody |
EP3020428A1 (en) | 2011-04-21 | 2016-05-18 | AbbVie Inc. | Wearable automatic injection device for controlled administration of therapeutic agents |
DK2703486T3 (en) | 2011-04-25 | 2018-05-28 | Daiichi Sankyo Co Ltd | ANTI-B7-H3 ANTIBODY |
UY34054A (es) | 2011-05-02 | 2012-11-30 | Millennium Pharm Inc | FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7 |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
US20140086827A1 (en) | 2011-05-09 | 2014-03-27 | The Cleveland Clinic Foundation | Serum S100B And Uses Thereof |
WO2012163848A1 (en) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of crohn's disease |
EP2530088A1 (en) | 2011-05-30 | 2012-12-05 | Klinikum rechts der Isar der Technischen Universität München | Means and methods for diagnosing and treating multiple sclerosis |
JP2014524891A (ja) | 2011-06-03 | 2014-09-25 | シーティー アトランティック リミテッド | Magea3結合抗体 |
EP2714742A1 (en) | 2011-06-03 | 2014-04-09 | CT Atlantic Ltd. | Magea3 binding antibodies |
EP2718327A1 (en) | 2011-06-06 | 2014-04-16 | Neotope Biosciences Limited | Mcam antagonists and methods of treatment |
WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
US20140120555A1 (en) | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
WO2012177972A1 (en) | 2011-06-23 | 2012-12-27 | Biogen Idec International Neuroscience Gmbh | Anti-alpha synuclein binding molecules |
DE202011103324U1 (de) | 2011-07-12 | 2012-01-02 | Nekonal S.A.R.L. | Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
EP2737083A1 (en) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Methods for diagnosing and treating myhre syndrome |
CA2841181C (en) | 2011-08-11 | 2022-01-25 | Astellas Pharma Inc. | Anti-human ngf antibody |
JP5925783B2 (ja) | 2011-08-12 | 2016-05-25 | 国立感染症研究所長 | アスペルギルスフミガーツス感染症の検査、予防及び治療のための方法並びに組成物 |
EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
MY183989A (en) | 2011-09-19 | 2021-03-17 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
GB2495115A (en) * | 2011-09-29 | 2013-04-03 | Oxford Plastic Sys Ltd | Base for supporting temporary fence panels or posts. |
AR088048A1 (es) | 2011-10-04 | 2014-05-07 | Univ Columbia | Señuelos notch1 humanos |
WO2013050441A1 (en) | 2011-10-05 | 2013-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for inhibiting or preventing platelet aggregation |
EP2764118A1 (en) | 2011-10-05 | 2014-08-13 | University of Bremen | Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
WO2013055911A1 (en) | 2011-10-14 | 2013-04-18 | Dana-Farber Cancer Institute, Inc. | Znf365/zfp365 biomarker predictive of anti-cancer response |
AU2012326137B2 (en) | 2011-10-17 | 2018-11-29 | Minerva Biotechnologies Corporation | Media for stem cell proliferation and induction |
EP2768971A1 (en) | 2011-10-20 | 2014-08-27 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for the detection and the treatment of cardiac remodeling |
EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
CA2854244A1 (en) | 2011-11-22 | 2013-05-30 | Cnrs (Centre National De La Recherche Scientifique) | Methods and pharmaceutical compositions for reducing airway hyperresponse |
JP6082402B2 (ja) | 2011-11-28 | 2017-02-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 加齢に伴う機能障害の処置に使用するための薬学的組成物 |
EP2602621A1 (en) | 2011-12-08 | 2013-06-12 | Julius-Maximilians-Universität Würzburg | LASP-1, a novel urinary marker for transitional cell carcinoma detection |
CN109276713A (zh) * | 2011-12-13 | 2019-01-29 | 诺帝克纳诺维科特股份公司 | 嵌合的治疗性抗-cd37抗体hh1 |
FR2984750B1 (fr) | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
EP2794660A2 (en) | 2011-12-23 | 2014-10-29 | Phenoquest AG | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
CA2861793C (en) | 2011-12-28 | 2023-08-01 | Immunoqure Ag | Method of providing monoclonal auto-antibodies with desired specificity |
CA2858336A1 (en) | 2012-01-01 | 2013-07-04 | Qbi Enterprises Ltd. | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
EP2812702B1 (en) | 2012-02-10 | 2019-04-17 | Seattle Genetics, Inc. | Diagnosis and management of CD30-expressing cancers |
US10160808B2 (en) | 2012-02-16 | 2018-12-25 | Santarus, Inc. | Anti-VLA1 (CD49A) antibody pharmaceutical compositions |
BR112014020666A2 (pt) | 2012-02-23 | 2018-09-25 | U3 Pharma Gmbh | usos de um inibidor de her3 |
PL2821416T3 (pl) | 2012-02-28 | 2019-01-31 | Astellas Pharma Inc. | Nowe przeciwciało przeciwko ludzkiemu receptorowi IL-23 |
JP6487839B2 (ja) | 2012-03-15 | 2019-03-20 | ヤンセン バイオテツク,インコーポレーテツド | ヒト抗cd27抗体、方法、及び使用 |
EP3575311A1 (en) | 2012-03-20 | 2019-12-04 | Biogen MA Inc. | Jcv neutralizing antibodies |
EP2832855A4 (en) | 2012-03-30 | 2016-02-24 | Daiichi Sankyo Co Ltd | NEW ANTI-SIGLEC ANTIBODY-15 |
ES2660472T3 (es) | 2012-03-30 | 2018-03-22 | Daiichi Sankyo Company, Limited | Anticuerpo anti-Siglec-15 modificado con CDR |
CN103382223B (zh) | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
EP2833900B1 (en) | 2012-04-01 | 2018-09-19 | Technion Research & Development Foundation Limited | Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies |
AU2013243560A1 (en) | 2012-04-02 | 2014-10-23 | Gundersen Lutheran Health System, Inc. | Reagents, methods, and kits for the classification of cancer |
JP6188681B2 (ja) | 2012-04-09 | 2017-08-30 | 第一三共株式会社 | 抗fgfr2抗体 |
AU2013254313B2 (en) | 2012-04-27 | 2017-03-30 | Daiichi Sankyo Company, Limited | Anti-ROBO4-antibody |
US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
US9416189B2 (en) | 2012-05-11 | 2016-08-16 | Microbial Chemistry Research Foundation | Anti-CXADR antibody |
EP2849786B1 (en) | 2012-05-15 | 2019-11-06 | Eisai Inc. | Methods for treatment of gastric cancer |
CN105473723A (zh) | 2012-05-18 | 2016-04-06 | 宾夕法尼亚大学托管会 | 亚家族e猿腺病毒a1302、a1320、a1331和a1337及其用途 |
JP2015520373A (ja) | 2012-05-22 | 2015-07-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 巣状分節性糸球体硬化症を診断及び処置するための方法 |
MX369626B (es) | 2012-05-24 | 2019-11-13 | Mountgate Group Ltd | Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia. |
DK3338794T3 (da) | 2012-07-13 | 2020-05-04 | Univ Pennsylvania | Toksicitetsstyring til antitumoraktivitet af CARS |
US20150184155A1 (en) | 2012-07-18 | 2015-07-02 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for preventing and treating chronic kidney disease (ckd) |
EP3539563A1 (en) | 2012-07-19 | 2019-09-18 | Redwood Bioscience, Inc. | Antibody specific for cd22 and methods of use thereof |
WO2014021339A1 (ja) | 2012-07-30 | 2014-02-06 | 国立大学法人名古屋大学 | ヒトミッドカインに対するモノクローナル抗体 |
EP2888283B1 (en) | 2012-08-24 | 2018-09-19 | The Regents of The University of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗mcam抗體及相關使用方法 |
WO2014042251A1 (ja) | 2012-09-13 | 2014-03-20 | 中外製薬株式会社 | 遺伝子ノックイン非ヒト動物 |
EP2711016A1 (en) | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
PL2905335T3 (pl) | 2012-10-03 | 2018-06-29 | Chiome Bioscience Inc. | Przeciwciało anty-hdlk-1 wykazujące aktywność przeciwnowotworową in vivo |
AU2013329372B2 (en) | 2012-10-08 | 2018-07-12 | St. Jude Children's Research Hospital | Therapies based on control of regulatory T cell stability and function via a Neuropilin-1:Semaphorin axis |
KR102584005B1 (ko) | 2012-10-11 | 2023-09-27 | 다이이찌 산쿄 가부시키가이샤 | 글리신아미드 화합물의 제조 방법 |
DE102012020496A1 (de) | 2012-10-18 | 2014-04-24 | Charité - Universitätsmedizin Berlin | Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1 |
JP6272230B2 (ja) | 2012-10-19 | 2018-01-31 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート |
EP2911681A1 (en) | 2012-10-26 | 2015-09-02 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
EP2914630B1 (en) | 2012-11-05 | 2021-03-03 | Pierre Fabre Medicament | Novel antigen binding proteins and their use as addressing product for the treatment of cancer |
EP2917347B1 (en) | 2012-11-08 | 2019-01-02 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for the treatment of bone metastases |
TW201438736A (zh) | 2012-11-14 | 2014-10-16 | Regeneron Pharma | 以dll4拮抗劑治療卵巢癌之方法 |
KR102344907B1 (ko) | 2012-12-10 | 2021-12-28 | 바이오젠 엠에이 인코포레이티드 | 항-혈액 수지상 세포 항원 2 항체 및 이의 용도 |
EP3514175A1 (fr) | 2012-12-17 | 2019-07-24 | Laboratoire Français du Fractionnement et des Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
WO2014100602A1 (en) | 2012-12-20 | 2014-06-26 | Hospital For Special Surgery | Treatment of egf-receptor dependent pathologies |
US9598484B2 (en) | 2012-12-21 | 2017-03-21 | Biogen Ma Inc. | Human anti-tau antibodies |
EP2938631B1 (en) | 2012-12-31 | 2018-12-19 | Neurimmune Holding AG | Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases |
EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
EP2949675B1 (en) | 2013-01-28 | 2021-03-31 | Evec Inc. | Humanized anti-hmgb1 antibody or antigen-binding fragment thereof |
EP2951589A1 (en) | 2013-02-01 | 2015-12-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting and preventing metastasis in triple negative breast cancers |
JP6357113B2 (ja) | 2013-02-08 | 2018-07-11 | 株式会社医学生物学研究所 | ヒトnrg1タンパク質に対する抗体 |
RU2015139095A (ru) | 2013-02-15 | 2017-03-21 | ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи | Акцепторный каркасный участок для пересадки cdr |
RU2015139890A (ru) | 2013-02-20 | 2017-03-27 | ИЭсБиЭйТЕК - Э НОВАРТИС КОМПАНИ ЭлЭлСи | Акцепторный каркасный участок для пересадки cdr |
FR3004184B1 (fr) | 2013-02-26 | 2016-03-18 | Agronomique Inst Nat Rech | Anticorps anti-gluten desamide et utilisations. |
US9429584B2 (en) | 2013-02-28 | 2016-08-30 | National Cancer Center | Antibody against insoluble fibrin |
WO2014136910A1 (ja) | 2013-03-08 | 2014-09-12 | 国立大学法人大阪大学 | ペリオスチンのExon-21部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物 |
RU2015143521A (ru) | 2013-03-13 | 2017-04-19 | Илэвэн Байотерапьютикс, Инк. | Лекарственные формы химерных цитокинов для глазной доставки |
US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
EP2968550B1 (en) | 2013-03-14 | 2018-11-14 | Ffe Therapeutics LLC | Compositions and methods for treating angiogenesis-related disorders |
US20160017041A1 (en) | 2013-03-15 | 2016-01-21 | Biogen Ma Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
WO2014143739A2 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
WO2014144466A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
BR112015023862A2 (pt) | 2013-03-18 | 2017-10-24 | Biocerox Prod Bv | anticorpo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, método de realçar uma resposta imune, método de tratar câncer, composição farmacêutica, e, anticorpo agonístico isolado |
EP2981554B1 (en) | 2013-04-01 | 2020-07-29 | The Regents of The University of California | Methods and compositions for treating and preventing disease associated with avb8 integrin |
WO2014174596A1 (ja) | 2013-04-23 | 2014-10-30 | 株式会社医学生物学研究所 | ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体 |
US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
CN107460201A (zh) | 2013-05-08 | 2017-12-12 | 科济生物医药(上海)有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
JP6652916B2 (ja) | 2013-06-20 | 2020-02-26 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 膵臓がんを診断するための方法 |
KR102402973B1 (ko) | 2013-07-03 | 2022-05-27 | 이뮤노큐어 아게 | 인간 항-ifn-알파 항체 |
US9803017B2 (en) | 2013-07-05 | 2017-10-31 | University Of Washington Through Its Center For Commercialization | Soluble MIC neutralizing monoclonal antibody for treating cancer |
WO2015001082A1 (en) | 2013-07-05 | 2015-01-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof |
RU2689528C2 (ru) | 2013-08-09 | 2019-05-28 | Астеллас Фарма Инк. | Новое антитело к tslp-рецептору человека |
EP3055695A1 (en) | 2013-09-12 | 2016-08-17 | Institut National de la Santé et de la Recherche Médicale | Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies |
WO2015040215A1 (en) | 2013-09-20 | 2015-03-26 | Westfaelische Wilhelms-Universitaet Muenster | Cell-penetrating bacterial e3-ubiqitin-ligases for use in immunotherapy |
JP6615100B2 (ja) | 2013-09-24 | 2019-12-04 | ザ ファインスタイン インスティチュート フォー メディカル リサーチ | 低温誘導性rna結合タンパク質活性を阻害するペプチド |
ES2894333T3 (es) | 2013-09-26 | 2022-02-14 | Beth Israel Deaconess Medical Ct Inc | Inhibidores de SGK1 en el tratamiento del síndrome de QT Largo |
MX2016003643A (es) | 2013-09-30 | 2016-12-20 | Daiichi Sankyo Co Ltd | Anticuerpo anti-lps o11. |
EP3470081A1 (en) | 2013-10-01 | 2019-04-17 | Mayo Foundation for Medical Education and Research | Methods for treating cancer in patients with elevated levels of bim |
TWI664977B (zh) | 2013-10-08 | 2019-07-11 | 第一三共股份有限公司 | 抗fgfr2抗體及其與其他藥劑之組合 |
EP3070167A4 (en) | 2013-11-06 | 2017-06-07 | Osaka University | Antibody having broad neutralizing activity in group 1 influenza a virus |
AU2014346770B2 (en) | 2013-11-06 | 2020-05-21 | Janssen Biotech, Inc. | Anti-CCL17 antibodies |
WO2015071701A1 (en) | 2013-11-15 | 2015-05-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of pancreatic cancers |
WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
CN109535254B (zh) | 2013-12-24 | 2022-06-24 | 安斯泰来制药株式会社 | 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物 |
RU2743077C2 (ru) | 2013-12-25 | 2021-02-15 | Дайити Санкио Компани, Лимитед | Конъюгат анти-trop2 антитело-лекарственное средство |
ES2902835T3 (es) | 2014-01-09 | 2022-03-30 | Hadasit Med Res Service | Composiciones celulares mejoradas y métodos para la terapia contra el cáncer |
CN106103483A (zh) | 2014-01-13 | 2016-11-09 | 贝勒研究院 | 抗hpv和hpv相关的疾病的新疫苗 |
CN104774264B (zh) | 2014-01-15 | 2018-09-14 | 上海易乐生物技术有限公司 | 抗人proBDNF单克隆抗体及其在疼痛中的作用 |
CN105829346B (zh) | 2014-01-31 | 2019-08-23 | 第一三共株式会社 | 抗her2抗体-药物偶联物 |
WO2015124570A1 (en) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of influenza a virus infection |
WO2015124588A1 (en) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway |
EP2915543B1 (en) | 2014-03-04 | 2018-05-09 | Albert-Ludwigs-Universität Freiburg | Polypeptides derived from Enterococcus and their use for vaccination and the generation of therapeutic antibodies |
WO2015140351A1 (en) | 2014-03-21 | 2015-09-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for enhancing myelination |
WO2015145449A2 (en) | 2014-03-27 | 2015-10-01 | Yeda Research And Development Co. Ltd. | T-cell receptor cdr3 peptides and antibodies |
ES2859648T3 (es) | 2014-04-10 | 2021-10-04 | Daiichi Sankyo Co Ltd | Conjugado anticuerpo-fármaco anti-HER3 |
EP3134546A4 (en) | 2014-04-24 | 2017-12-06 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
RU2685259C2 (ru) | 2014-04-25 | 2019-04-17 | Пьер Фабр Медикамент | Конъюгат антитела и лекарственного средства и его применение для лечения рака |
SI3134124T1 (sl) | 2014-04-25 | 2019-06-28 | Pierre Fabre Medicament | Konjugat protitelesa zdravila IGF-1R in uporaba le-tega za zdravljenje raka |
JP6835591B2 (ja) | 2014-04-25 | 2021-02-24 | ピエール、ファーブル、メディカマン | Igf−1r抗体および癌処置のためのアドレッシングビヒクルとしてのその使用 |
KR102452349B1 (ko) | 2014-04-27 | 2022-10-11 | 페임웨이브 리미티드 | Ceacam1에 대한 인간화 항체 |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
CA2953807A1 (en) | 2014-06-26 | 2015-12-30 | Yale University | Compositions and methods to regulate renalase in the treatment of diseases and disorders |
US20170227541A1 (en) | 2014-07-17 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Methods for using exosomes to monitor transplanted organ status |
CN105315375B (zh) | 2014-07-17 | 2021-04-23 | 恺兴生命科技(上海)有限公司 | 靶向cld18a2的t淋巴细胞及其制备方法和应用 |
EP3171896A4 (en) | 2014-07-23 | 2018-03-21 | Mayo Foundation for Medical Education and Research | Targeting dna-pkcs and b7-h1 to treat cancer |
SG10201902850TA (en) | 2014-09-30 | 2019-04-29 | Neurimmune Holding Ag | Human-derived anti-dipeptide repeats (dprs) antibody |
SG10201902924RA (en) | 2014-10-03 | 2019-05-30 | Massachusetts Inst Technology | Antibodies that bind ebola glycoprotein and uses thereof |
EP3204516B1 (en) | 2014-10-06 | 2023-04-26 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
EP3204119B1 (en) | 2014-10-09 | 2021-06-09 | Dana-Farber Cancer Institute, Inc. | Multiple-variable il-2 dose regimen for treating immune disorders |
EP3220900B1 (en) | 2014-11-21 | 2020-09-23 | University of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
WO2016087889A1 (en) | 2014-12-03 | 2016-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions using orexins (oxa, oxb) for the treatment of prostate cancers |
US20180031579A1 (en) | 2015-02-12 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
WO2016144673A1 (en) | 2015-03-06 | 2016-09-15 | Dana-Farber Cancer Institute, Inc. | Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers |
EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
KR20180026659A (ko) | 2015-03-18 | 2018-03-13 | 더 존스 홉킨스 유니버시티 | 포타슘 채널 kcnk9를 표적화하는 신규한 모노클로날 항체 억제제 |
US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
US10214591B1 (en) | 2015-04-03 | 2019-02-26 | Alienor Farma | Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject |
US10851176B2 (en) | 2015-04-13 | 2020-12-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of administering neutralizing anti-protease nexin-1 antibodies to treat hemophilia A |
WO2016170027A1 (en) | 2015-04-22 | 2016-10-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of th17 mediated diseases |
US10858760B2 (en) | 2015-06-01 | 2020-12-08 | Medigene Immunotherapies Gmbh | T cell receptor library |
MX2017015619A (es) | 2015-06-01 | 2018-08-15 | Medigene Immunotherapies Gmbh | Anticuerpos especificos de receptor de celulas t. |
CN108137688A (zh) | 2015-06-01 | 2018-06-08 | 基因医疗免疫疗法有限责任公司 | 产生抗t细胞受体的抗体的方法 |
ES2909486T3 (es) | 2015-06-19 | 2022-05-06 | Centurion Biopharma Corp | Sistemas de administración para liberación controlada de fármaco |
US20180161429A1 (en) | 2015-06-26 | 2018-06-14 | Beth Israel Deaconess Medical Center Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
ES2938186T3 (es) | 2015-06-29 | 2023-04-05 | Daiichi Sankyo Co Ltd | Procedimiento de fabricación selectiva de un conjugado anticuerpo-fármaco |
MX2018001522A (es) | 2015-08-05 | 2018-03-15 | Janssen Biotech Inc | Anticuerpos anti-cd154 y metodos de uso de estos. |
EP3350212A1 (en) | 2015-09-18 | 2018-07-25 | INSERM - Institut National de la Santé et de la Recherche Médicale | T cell receptors (tcr) and uses thereof for the diagnosis and treatment of diabetes |
US10647752B2 (en) | 2015-09-22 | 2020-05-12 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1 |
TWI836305B (zh) | 2015-09-24 | 2024-03-21 | 日商第一三共股份有限公司 | 抗garp抗體及其製造方法及用途 |
ES2906823T3 (es) | 2015-09-30 | 2022-04-20 | Janssen Biotech Inc | Anticuerpos agonistas que se unen específicamente a CD40 humano y métodos de uso |
EP3360961B1 (en) | 2015-10-08 | 2023-11-22 | National University Corporation Tokai National Higher Education and Research System | Method for preparing genetically-modified t cells which express chimeric antigen receptor |
WO2017064716A1 (en) | 2015-10-13 | 2017-04-20 | Rappaport Family Institute For Research | Heparanase-neutralizing monoclonal antibodies |
WO2017064302A1 (en) | 2015-10-16 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
AU2016344663B2 (en) | 2015-10-26 | 2023-09-07 | Pierre Fabre Medicament | Composition for the treatment of IGF-1R expressing cancer |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
ITUB20155272A1 (it) | 2015-11-02 | 2017-05-02 | Scuola Normale Superiore | Intracellular antibody |
WO2017079215A1 (en) | 2015-11-03 | 2017-05-11 | Glycomimetics, Inc. | Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same |
MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
ITUB20155097A1 (it) | 2015-11-05 | 2017-05-05 | Biouniversa Srl | Anticorpi umanizzati anti-BAG3 |
WO2017097889A1 (en) | 2015-12-10 | 2017-06-15 | Katholieke Universiteit Leuven | Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device |
WO2017106684A2 (en) | 2015-12-17 | 2017-06-22 | Janssen Biotech, Inc. | Antibodies specifically binding hla-dr and their uses |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
KR102319839B1 (ko) | 2015-12-23 | 2021-11-01 | 메디진 이뮤노테라피스 게엠바하 | 항원-특이적 tcr의 신규 생성 |
KR102507685B1 (ko) | 2015-12-31 | 2023-03-08 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 난소암의 검출 및 치료를 위한 조성물 및 방법 |
BR112018013268A2 (pt) | 2015-12-31 | 2018-12-11 | Progastrine Et Cancers S A R L | composições e métodos para detectar e tratar câncer gástrico |
BR112018013272A2 (pt) | 2015-12-31 | 2018-12-11 | Progastrine Et Cancers S A R L | composições e métodos para detectar e tratar câncer esofágico |
EP3202788A1 (en) | 2016-02-05 | 2017-08-09 | MediaPharma S.r.l. | Endosialin-binding antibody |
EP3205663A1 (en) | 2016-02-15 | 2017-08-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for inhibiting gene expression |
US11484577B2 (en) | 2016-02-15 | 2022-11-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction |
CA3015619A1 (en) | 2016-03-01 | 2017-09-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human poliovirus receptor (pvr) |
US11340233B2 (en) | 2016-03-07 | 2022-05-24 | Pierre Fabre Medicament | Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples |
WO2017156263A1 (en) | 2016-03-09 | 2017-09-14 | Memorial Sloan-Kettering Cancer Center | Enigma and cdh18 as companion diagnostics for cdk4 inhibitors |
JP6903680B2 (ja) | 2016-03-15 | 2021-07-14 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法 |
WO2017158396A1 (en) | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cytidine deaminase inhibitors for the treatment of pancreatic cancer |
WO2017162604A1 (en) | 2016-03-21 | 2017-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and treatment of solar lentigo |
WO2017161976A1 (en) | 2016-03-23 | 2017-09-28 | Mabspace Biosciences (Suzhou) Co., Ltd | Novel anti-pd-l1 antibodies |
EP3436461B1 (en) | 2016-03-28 | 2023-11-01 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
ITUA20162242A1 (it) | 2016-04-01 | 2017-10-01 | St Biochimico Italiano Giovanni Lorenzini Spa | Un nuovo anticorpo anti-erbb2 |
BR112018070302A2 (pt) | 2016-04-18 | 2019-01-29 | Faron Pharmaceuticals Oy | agentes que reconhecem o epítopo de clever-1 e usos dos mesmos |
EP3452512B1 (en) | 2016-05-03 | 2023-03-08 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of tissue lesions |
AU2017263454B2 (en) | 2016-05-11 | 2023-02-09 | Amgen Inc. | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors |
WO2017198811A1 (de) | 2016-05-20 | 2017-11-23 | Christoph Karl | Pharmazeutische zusammensetzungen mit anti-rankl-antikörpern, kalzium und vitamin d, geeignet zur behandlung und/oder prophylaxe von erkrankungen des knochenstoffwechsels und von therapiebedingten nebenwirkungen wie hypokalzämien |
WO2017202813A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections |
WO2017202814A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons |
CA3026778A1 (en) | 2016-06-07 | 2017-12-14 | Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
EP3482210B1 (en) | 2016-07-06 | 2021-06-23 | Prothena Biosciences Limited | Assay for detecting total and s129 phosphorylated alpha-synuclein |
JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
MA45715A (fr) | 2016-07-25 | 2019-05-29 | Biogen Ma Inc | Anticorps anti-hspa5 (grp78) et leurs utilisations |
EP3491387A1 (en) | 2016-07-28 | 2019-06-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods of treatement of cancer disease by targetting tumor associated macrophage |
JP7178342B2 (ja) | 2016-08-12 | 2022-11-25 | ヤンセン バイオテツク,インコーポレーテツド | アゴニズム及びエフェクター機能が増強した改変抗体、及び他のFcドメイン含有分子 |
CA3033665A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
EP3515559A4 (en) | 2016-09-20 | 2020-07-15 | Dana-Farber Cancer Institute, Inc. | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS |
US20190330368A1 (en) | 2016-10-07 | 2019-10-31 | Daiichi Sankyo Company, Limited | Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate |
JPWO2018070390A1 (ja) | 2016-10-12 | 2019-08-22 | 第一三共株式会社 | 抗robo4抗体と他剤を含む組成物 |
CU20210030A7 (es) | 2016-10-13 | 2021-11-04 | Massachusetts Inst Technology | Anticuerpos que se unen a la proteína de envoltura del virus zika |
IT201600111877A1 (it) | 2016-11-07 | 2018-05-07 | Biouniversa Srl | Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use |
ES2913401T3 (es) | 2016-11-18 | 2022-06-02 | Astellas Pharma Inc | Nuevo fragmento Fab de anticuerpo anti-MUC1 humana |
CA3046293A1 (en) | 2016-12-12 | 2018-06-21 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
MX2019006897A (es) | 2016-12-13 | 2019-08-22 | Astellas Pharma Inc | Anticuerpo anti cd73 humana. |
WO2018109770A1 (en) | 2016-12-15 | 2018-06-21 | The National Institute for Biotechnology in the Negev Ltd. | Anti-pcna monoclonal antibodies and use thereof |
US11618785B2 (en) | 2016-12-22 | 2023-04-04 | Daiichi Sankyo Company, Limited | Anti-CD3 antibody and molecules comprising the antibody |
US20180179490A1 (en) | 2016-12-27 | 2018-06-28 | Miltenyi Biotec Gmbh | CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS |
US11773182B2 (en) | 2017-01-05 | 2023-10-03 | The Johns Hopkins University | Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) |
EP3572428A4 (en) | 2017-01-17 | 2020-12-30 | Daiichi Sankyo Company, Limited | ANTI-GPR20 ANTIBODY AND ANTI-GPR20 ANTIBODY MEDICINAL CONJUGATE |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
AU2018218753A1 (en) | 2017-02-07 | 2019-09-26 | Daiichi Sankyo Company, Limited | Anti-GPRC5D antibody and molecule containing same |
EP3363459A1 (en) | 2017-02-17 | 2018-08-22 | Alexander Klimka | Polypeptide epitopes of s. aureus and respective monoclonal antibodies for the treatment of infections and immune-diagnosis |
JP7325045B2 (ja) | 2017-02-27 | 2023-08-14 | カイロス セラピューティクス, インコーポレイテッド | 癌を処置する抗体コンストラクトおよび方法 |
TW201834696A (zh) | 2017-02-28 | 2018-10-01 | 學校法人近畿大學 | 藉由投予抗her3抗體-藥物複合體之egfr-tki抗性之非小細胞肺癌的治療方法 |
CN114940713B (zh) | 2017-03-15 | 2024-04-30 | 清华大学 | 抗trkb抗体 |
JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
WO2018167283A1 (en) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling |
ES2926532T3 (es) | 2017-03-30 | 2022-10-26 | Progastrine Et Cancers S A R L | Composiciones y métodos para tratar el cáncer de pulmón |
TWI782000B (zh) | 2017-03-30 | 2022-11-01 | 日商第一三共股份有限公司 | 抗gpr20抗體、其製造方法及其應用 |
KR102317805B1 (ko) | 2017-03-30 | 2021-10-27 | 이씨에스-프로가스트린 에스에이 | 전립선암을 검출하기 위한 조성물 및 방법 |
US10722589B2 (en) | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
EP3610264A1 (en) | 2017-04-13 | 2020-02-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
WO2018189403A1 (en) | 2017-04-14 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancer |
CN111201034A (zh) | 2017-05-11 | 2020-05-26 | 西托戴恩股份有限公司 | 涉及施用抗ccr5受体试剂的治疗或预防移植物抗宿主病的方法 |
TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
CA3065516A1 (en) | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Antibodies that specifically bind pd-1 and methods of use |
WO2018226685A2 (en) | 2017-06-06 | 2018-12-13 | Dana-Farber Cancer Institute, Inc. | Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways |
US20210145828A1 (en) | 2017-06-29 | 2021-05-20 | Rutgers, The State University Of New Jersey | Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy |
JP7181535B2 (ja) | 2017-06-30 | 2022-12-01 | 国立大学法人北海道大学 | 成長障害を生じない小児骨粗鬆症治療薬 |
TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
BR112020001255A2 (pt) | 2017-07-21 | 2020-07-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | composições imunogênicas de neisseria meningitidis |
SG11202000759XA (en) | 2017-07-27 | 2020-02-27 | Daiichi Sankyo Co Ltd | Anti-cd147 antibody |
WO2019020734A1 (en) | 2017-07-28 | 2019-01-31 | Biouniversa S.R.L. | ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENTS IN CARDIOVASCULAR DISEASES |
US11680110B2 (en) | 2017-07-31 | 2023-06-20 | Hoffmann-La Roche Inc. | Three-dimensional structure-based humanization method |
EP3444272A1 (en) | 2017-08-17 | 2019-02-20 | International-Drug-Development-Biotech | Treatment of ck8 positive cancers in relation with k-ras gene status |
EP3673918A4 (en) | 2017-08-23 | 2021-05-19 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PREPARATION AND ASSOCIATED LYOPHILIZATION |
CN111094349A (zh) | 2017-08-23 | 2020-05-01 | 马克思-德布鲁克-分子医学中心亥姆霍兹联合会 | 嵌合抗原受体和结合cxcr5的car-t细胞 |
WO2019044947A1 (ja) | 2017-08-31 | 2019-03-07 | 第一三共株式会社 | 抗体-薬物コンジュゲートの改良製造方法 |
CN117838881A (zh) | 2017-08-31 | 2024-04-09 | 第一三共株式会社 | 制备抗体-药物缀合物的新方法 |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
TWI820044B (zh) | 2017-09-29 | 2023-11-01 | 日商第一三共股份有限公司 | 抗體-吡咯并苯二氮呯衍生物複合體 |
WO2019069561A1 (ja) | 2017-10-03 | 2019-04-11 | 公益財団法人東京都医学総合研究所 | インフルエンザに対する医薬 |
TW201927336A (zh) | 2017-10-05 | 2019-07-16 | 日商第一三共股份有限公司 | 細胞毒性t細胞耗竭用組成物 |
KR101966362B1 (ko) * | 2017-10-20 | 2019-04-05 | 주식회사 녹십자 | 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
JP2021502125A (ja) | 2017-11-09 | 2021-01-28 | ピンテオン セラピューティクス インコーポレイテッド | ヒト化コンホメーション特異的リン酸化タウ抗体の作製および使用のための方法および組成物 |
CN111712263A (zh) | 2017-11-30 | 2020-09-25 | 森托瑞恩生物制药公司 | 基于美登木素生物碱的药物递送系统 |
PT3717503T (pt) | 2017-11-30 | 2024-01-16 | Ladrx Corp | Profármacos de ligação a albumina de derivados de auristatina e |
WO2019106126A1 (en) | 2017-12-01 | 2019-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mdm2 modulators for the diagnosis and treatment of liposarcoma |
CA3084687C (en) | 2017-12-05 | 2024-01-02 | Progastrine Et Cancers S.A R.L. | Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer |
WO2019121872A1 (en) | 2017-12-20 | 2019-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of liver cancer |
US20190225689A1 (en) | 2018-01-22 | 2019-07-25 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-pd-1 antibodies |
TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ecs前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
WO2019155474A1 (en) | 2018-02-12 | 2019-08-15 | Hadasit Medical Research Services & Development Ltd. | Modulation of slamf6 splice variants for cancer therapy |
WO2019158512A1 (en) | 2018-02-13 | 2019-08-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the prognosis and the treatment of glioblastoma |
CN112384515A (zh) | 2018-02-27 | 2021-02-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶 |
AU2019228339A1 (en) | 2018-02-27 | 2020-09-10 | Ecs-Progastrin Sa | Progastrin as a biomarker for immunotherapy |
CA3093205A1 (en) | 2018-03-05 | 2019-09-12 | Saitama Medical University | Pharmaceutical composition for treating or preventing heterotopic ossification |
EP3775206A1 (en) | 2018-03-28 | 2021-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
US20210164984A1 (en) | 2018-04-13 | 2021-06-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting outcome and treatment of patients suffering from prostate cancer or breast cancer |
US20210230245A1 (en) | 2018-04-20 | 2021-07-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor and car-t cells that bind a herpes virus antigen |
WO2019207066A1 (en) | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of sjögren's syndrome |
WO2019211369A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
WO2019211370A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
JP2021522801A (ja) | 2018-05-09 | 2021-09-02 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | ヒトネクチン4に特異的な抗体 |
CN112105735A (zh) | 2018-05-11 | 2020-12-18 | 安斯泰来制药株式会社 | 用于螨过敏治疗的核酸 |
EP3792361A4 (en) | 2018-05-11 | 2022-01-26 | Astellas Pharma Inc. | NUCLEIC ACID FOR TREATMENT OF CRUSTACEANS ALLERGY |
MX2020012351A (es) | 2018-05-17 | 2021-01-29 | Astellas Pharma Inc | Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando. |
US11168089B2 (en) | 2018-05-18 | 2021-11-09 | Incyte Corporation | Fused pyrimidine derivatives as A2A / A2B inhibitors |
MX2020012589A (es) | 2018-05-24 | 2021-01-29 | Janssen Biotech Inc | Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos. |
SG11202011633SA (en) | 2018-05-24 | 2020-12-30 | Janssen Biotech Inc | Psma binding agents and uses thereof |
SG11202011270QA (en) | 2018-05-24 | 2020-12-30 | Janssen Biotech Inc | Anti-cd3 antibodies and uses thereof |
EP3804764A4 (en) | 2018-05-28 | 2022-04-06 | Daiichi Sankyo Company, Limited | TREATMENT OF HER2 MUTANT CANCER BY ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
KR20210018192A (ko) | 2018-05-31 | 2021-02-17 | 다이이찌 산쿄 가부시키가이샤 | 항인간 tlr7 항체 |
BR112020024351A2 (pt) | 2018-06-01 | 2021-02-23 | Novartis Ag | moléculas de ligação contra bcma e usos das mesmas |
WO2019234099A1 (en) | 2018-06-06 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction |
WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
SG11202012671QA (en) | 2018-06-20 | 2021-01-28 | Incyte Corp | Anti-pd-1 antibodies and uses thereof |
TW202016144A (zh) | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | 包括cd3抗原結合片段之組成物及其用途 |
CN113164398B (zh) | 2018-06-29 | 2023-11-03 | 因赛特公司 | Axl/mer抑制剂的制剂 |
WO2020007898A1 (en) | 2018-07-04 | 2020-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating brain injury or neurodegenerative disease |
GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
AU2019311557A1 (en) | 2018-07-25 | 2021-02-04 | Daiichi Sankyo Company, Limited | Effective method for manufacturing antibody-drug conjugate |
US20210308170A1 (en) | 2018-07-27 | 2021-10-07 | Osaka University | Composition for suppression of aging, prevention, amelioration, or treatment of an age-related disease or symptom, or extension of lifespan |
EP3831853A4 (en) | 2018-07-27 | 2022-06-01 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE PROTEIN-RECOGNIZING DRUG UNIT |
BR112021001509A2 (pt) | 2018-07-31 | 2021-04-27 | Daiichi Sankyo Company, Limited | agente terapêutico para um tumor de cérebro metastásico |
CN112512587A (zh) | 2018-08-06 | 2021-03-16 | 第一三共株式会社 | 抗体药物缀合物和微管蛋白抑制剂的组合 |
JP7254818B2 (ja) | 2018-09-06 | 2023-04-10 | 第一三共株式会社 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
KR20210062005A (ko) | 2018-09-20 | 2021-05-28 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘쥬게이트 투여에 의한 her3 변이암의 치료 |
JP7475687B2 (ja) | 2018-09-21 | 2024-04-30 | 国立大学法人 東京医科歯科大学 | ヒトhmgb1に特異的に結合するヒトモノクローナル抗体、及びそれを含有するアルツハイマー病を治療又は予防するための医薬組成物 |
US12011485B2 (en) | 2018-09-27 | 2024-06-18 | Pierre Fabre Medicament | Sulfomaleimide-based linkers and corresponding conjugates |
WO2020065096A1 (en) | 2018-09-28 | 2020-04-02 | Pierre Fabre Medicament | New immunocytokines for the treatment of cancer |
JP7374544B2 (ja) | 2018-10-10 | 2023-11-07 | アステラス製薬株式会社 | 標識部-抗ヒト抗体Fabフラグメント複合体を含む医薬組成物 |
UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
CN112955462B (zh) | 2018-10-18 | 2024-05-07 | 国家医疗保健研究所 | 用于治疗实体瘤的βIG-H3拮抗剂和免疫检查点抑制剂的组合 |
MA54097A (fr) | 2018-10-31 | 2022-02-09 | Astellas Pharma Inc | Anticorps anti-fn14 humain |
WO2020099235A1 (en) | 2018-11-12 | 2020-05-22 | Mediapharma S.R.L. | Bispecific antibodies directed against human 90k and either endosialin or her3 |
SG11202104993SA (en) | 2018-11-14 | 2021-06-29 | Daiichi Sankyo Co Ltd | Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate |
KR20210102341A (ko) | 2018-12-11 | 2021-08-19 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 컨쥬게이트와 parp 저해제의 조합 |
US20220096518A1 (en) | 2018-12-21 | 2022-03-31 | Aim Immunotech Inc. | Compositions and methods for cancer therapy |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
JOP20210180A1 (ar) | 2019-01-07 | 2023-01-30 | Astellas Pharma Inc | مادة اقتران تشتمل على ربيطة، فاصل، رابط ببتيدي وجزيء حيوي |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
KR20210117277A (ko) | 2019-01-13 | 2021-09-28 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 인간 넥틴-2에 특이적인 항체 |
CA3125697A1 (en) | 2019-01-29 | 2020-08-06 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Treating the causative agent in adhesiogenesis |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
CA3130103A1 (en) | 2019-02-13 | 2020-08-20 | The Brigham And Women's Hospital, Inc. | Anti-peripheral lymph node addressin antibodies and uses thereof |
WO2020178193A1 (en) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of sarcoidosis |
EP3942026A1 (en) | 2019-03-22 | 2022-01-26 | Université de Paris | New inhibitors of lrrk2/pp1 interaction |
JPWO2020196474A1 (sl) | 2019-03-25 | 2020-10-01 | ||
EP3949987A4 (en) | 2019-03-25 | 2023-02-22 | Daiichi Sankyo Company, Limited | ANTI-HER2 ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
ES2967879T3 (es) | 2019-03-25 | 2024-05-06 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Mejora de la actividad de los linfocitos T citolíticos mediante la inhibición de EBAG9 |
EP3949988A4 (en) | 2019-03-27 | 2022-11-16 | Daiichi Sankyo Company, Limited | COMBINATION OF AN ANTIBODY-DERIVATIVE CONJUGATE OF PYRROLOBENZODIAZEPINE AND A PARP INHIBITOR |
TW202104259A (zh) | 2019-04-01 | 2021-02-01 | 日商凱依歐姆 生物科學股份有限公司 | 癌治療用醫藥 |
CN113692413A (zh) | 2019-04-02 | 2021-11-23 | 肯乔克蒂生物技术股份有限公司 | 外排泵-癌症抗原多特异性抗体以及与其相关的组合物、试剂、试剂盒和方法 |
AR118720A1 (es) | 2019-04-19 | 2021-10-27 | Janssen Biotech Inc | Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 |
CN114007642A (zh) | 2019-04-30 | 2022-02-01 | 森迪生物科学公司 | 嵌合受体及其使用方法 |
US20220289854A1 (en) | 2019-04-30 | 2022-09-15 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
US20220259561A1 (en) | 2019-05-14 | 2022-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof |
AU2020285681A1 (en) | 2019-05-29 | 2022-01-27 | Daiichi Sankyo Company, Limited | Dosage of an antibody-drug conjugate |
WO2020261093A1 (en) | 2019-06-24 | 2020-12-30 | Novartis Ag | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
EP4004057A1 (en) | 2019-07-26 | 2022-06-01 | Janssen Biotech, Inc. | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses |
JPWO2021020282A1 (sl) | 2019-07-26 | 2021-02-04 | ||
WO2021019706A1 (ja) | 2019-07-31 | 2021-02-04 | 国立大学法人信州大学 | Car発現免疫細胞を含む細胞集団の製造方法 |
EP4007602A1 (en) | 2019-08-01 | 2022-06-08 | Incyte Corporation | A dosing regimen for an ido inhibitor |
CA3146474A1 (en) | 2019-08-02 | 2021-02-11 | Denis BURGER | Methods for treating or preventing cancers involving the administration of anti-ccr5 receptor agents |
WO2021028921A1 (en) | 2019-08-12 | 2021-02-18 | Biond Biologics Ltd. | Antibodies against ilt2 and use thereof |
EP3792632A1 (en) | 2019-09-16 | 2021-03-17 | Vito NV | Immunotherapy markers |
CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
US11760801B2 (en) | 2019-09-27 | 2023-09-19 | Janssen Biotech, Inc. | Anti-CEACAM antibodies and uses thereof |
WO2021058744A1 (en) | 2019-09-27 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of müllerian inhibiting substance inhibitors for treating cancer |
EP4049675A4 (en) | 2019-10-25 | 2023-11-22 | Daiichi Sankyo Company, Limited | COMBINATION OF ANTI-GARP ANTIBODY AND IMMUNOREGULATOR |
MX2022005904A (es) | 2019-11-15 | 2022-09-07 | Pliant Therapeutics Inc | Composiciones y metodos para la activacion de integrinas. |
AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
IL293736A (en) * | 2019-12-10 | 2022-08-01 | Coa Therapeutics Hangzhou Co Ltd | Humanized anti-glycoprotein ib alpha (gpibalpha) antibodies |
JP2023509373A (ja) | 2019-12-20 | 2023-03-08 | ノヴァロック バイオセラピューティクス, リミテッド | 抗インターロイキン-23 p19抗体およびそれの使用方法 |
WO2021138512A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors |
WO2021140173A1 (en) | 2020-01-10 | 2021-07-15 | Biouniversa S.R.L. | Methods and uses for treating fibrotic solid tumors with bags inhibitors |
WO2021156329A1 (en) | 2020-02-05 | 2021-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment of cancer disease by targeting an epigenetic factor |
TW202140012A (zh) | 2020-02-12 | 2021-11-01 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑 |
TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
AU2021229611A1 (en) | 2020-03-03 | 2022-10-27 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
EP4115909A1 (en) | 2020-03-06 | 2023-01-11 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
WO2021178779A1 (en) | 2020-03-06 | 2021-09-10 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
JP2023517889A (ja) | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | NPM1c陽性がんの免疫療法のための組成物および方法 |
IL302349A (en) | 2020-03-13 | 2023-06-01 | Janssen Biotech Inc | Materials and methods for binding SIGLEC-3/CD33 |
US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
EP4130036A4 (en) | 2020-03-30 | 2024-05-15 | National Cancer Center | ANTIBODY-DRUG CONJUGATE |
EP3889183A1 (en) | 2020-04-01 | 2021-10-06 | Pierre Fabre Medicament | A protein complex comprising an immunocytokine |
CA3179348A1 (en) | 2020-04-06 | 2021-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies to nkp46 and constructs thereof for treatment of cancers and infections |
US20230174670A1 (en) | 2020-05-14 | 2023-06-08 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof |
JP2023526529A (ja) | 2020-05-19 | 2023-06-21 | アンスティテュ・クリー | サイトカイン放出症候群の診断及び処置の方法 |
CR20220594A (es) | 2020-05-27 | 2023-01-17 | Janssen Biotech Inc | Proteins comprising cd3 antigen binding domains and uses thereof |
EP4159859A1 (en) | 2020-05-27 | 2023-04-05 | Arialys Therapeutics, Inc. | Anti-human nr1 antibody derivative |
AU2021283080A1 (en) | 2020-06-04 | 2022-12-15 | Kenjockety Biotechnology, Inc. | ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
WO2021260578A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and cdk9 inhibitor |
JP2023539715A (ja) | 2020-06-24 | 2023-09-19 | アストラゼネカ ユーケー リミテッド | 抗体-薬物コンジュゲートとatm阻害剤との組合わせ |
KR20230043109A (ko) | 2020-06-24 | 2023-03-30 | 아스트라제네카 유케이 리미티드 | 항체-약물 접합체 및 atr 억제제의 조합 |
WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
US20230305023A1 (en) | 2020-06-25 | 2023-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment and diagnostic of pathological conditions associated with intense stress |
KR20230041023A (ko) | 2020-07-17 | 2023-03-23 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 제조 방법 |
KR20230042055A (ko) | 2020-07-20 | 2023-03-27 | 다이이찌 산쿄 가부시키가이샤 | 항 her2 항체-약물 콘주게이트와 her 이량체화 저해제의 조합 |
US11827708B2 (en) | 2020-07-29 | 2023-11-28 | Janssen Biotech, Inc. | Proteins comprising HLA-G antigen binding domains and their uses |
RU2764216C1 (ru) * | 2020-08-10 | 2022-01-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" | Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения |
JP2023537396A (ja) | 2020-08-12 | 2023-08-31 | ビオンド バイオロジクス リミテッド | Ilt2に対する抗体およびその使用 |
JP2023540023A (ja) | 2020-08-24 | 2023-09-21 | シャリテ-ウニベルジテーツメディツィン ベルリン | Ceaを認識するキメラ抗原受容体(car)発現細胞 |
EP4199959A1 (en) | 2020-08-24 | 2023-06-28 | Charité - Universitätsmedizin Berlin | A chimeric antigen receptor construct encoding a checkpoint inhibitory molecule and an immune stimulatory cytokine and car-expressing cells recognizing cd44v6 |
JP2023540526A (ja) | 2020-09-04 | 2023-09-25 | ノヴァロック バイオセラピューティクス, リミテッド | ネクチン-4抗体およびそれの使用 |
US20230340149A1 (en) | 2020-09-07 | 2023-10-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment of inflammatory bowel diseases |
KR20230066094A (ko) | 2020-09-12 | 2023-05-12 | 아스트라제네카 유케이 리미티드 | 항-her2 항체-약물 접합체 치료법을 위한 채점 방법 |
EP4226945A1 (en) | 2020-10-05 | 2023-08-16 | Chiome Bioscience, Inc | Medicine for treating cancer |
US20230372527A1 (en) | 2020-10-09 | 2023-11-23 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
EP4228693A1 (en) | 2020-10-13 | 2023-08-23 | Janssen Biotech, Inc. | Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii |
WO2022084399A1 (en) | 2020-10-21 | 2022-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | C-terminal sparc fragments for treating cancer |
KR20230110523A (ko) | 2020-10-22 | 2023-07-24 | 얀센 바이오테크 인코포레이티드 | 델타-유사 리간드 3(dll3) 항원 결합 영역을 포함하는 단백질 및 그의 용도 |
WO2022097090A1 (en) | 2020-11-05 | 2022-05-12 | Novartis Ag | Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors |
JP2023548421A (ja) | 2020-11-06 | 2023-11-16 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | 多のう胞性卵巣症候群(pcos)を診断および処置するための方法 |
WO2022102634A1 (ja) | 2020-11-11 | 2022-05-19 | 第一三共株式会社 | 抗体-薬物コンジュゲートと抗SIRPα抗体の組み合わせ |
EP4245322A1 (en) | 2020-11-12 | 2023-09-20 | Daiichi Sankyo Company, Limited | Treatment for mesothelioma through administration of anti-b7-h3 antibody-drug conjugate |
KR20230108288A (ko) | 2020-11-16 | 2023-07-18 | 아스텔라스세이야쿠 가부시키가이샤 | 항tspan8-항cd3 이중 특이성 항체 및 항tspan8 항체 |
EP4251282A1 (en) | 2020-11-27 | 2023-10-04 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for diagnosis and monitoring of toxic epidermal necrolysis |
JP2023551519A (ja) | 2020-11-30 | 2023-12-08 | インサイト・コーポレイション | 抗cd19抗体とパルサクリシブの組み合わせ療法 |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
JPWO2022124247A1 (sl) | 2020-12-09 | 2022-06-16 | ||
AU2021411952A1 (en) | 2020-12-29 | 2023-08-10 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
WO2022153212A1 (en) | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Antibodies neutralizing sars-cov-2 |
JP2024503657A (ja) | 2021-01-13 | 2024-01-26 | メモリアル スローン-ケタリング キャンサー センター | 抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
MX2023008285A (es) | 2021-01-13 | 2023-09-12 | Memorial Sloan Kettering Cancer Center | Conjugado de anticuerpo anti-dll3-farmaco. |
BR112023015097A2 (pt) | 2021-01-28 | 2023-10-03 | Janssen Biotech Inc | Proteínas de ligação a psma e usos das mesmas |
JP2024505049A (ja) | 2021-01-29 | 2024-02-02 | ノバルティス アーゲー | 抗cd73及び抗entpd2抗体のための投与方式並びにその使用 |
TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
CA3206413A1 (en) | 2021-02-11 | 2022-08-18 | Pinchas TSUKERMAN | Antibodies against cd112r and uses thereof |
CN116848136A (zh) | 2021-02-12 | 2023-10-03 | 勃林格殷格翰国际有限公司 | 补体c3抗原结合蛋白 |
US20220378929A1 (en) | 2021-02-25 | 2022-12-01 | MediBoston Limted | Anti-her2 antibody-drug conjugates and uses thereof |
EP4301777A1 (en) | 2021-03-02 | 2024-01-10 | Dana-Farber Cancer Institute, Inc. | Methods of treating red blood cell disorders |
WO2022189632A1 (en) | 2021-03-12 | 2022-09-15 | Fibrosys S.R.L. | Monoclonal antibodies for the treatment of viral infections |
JPWO2022191313A1 (sl) | 2021-03-12 | 2022-09-15 | ||
IL306103A (en) | 2021-03-24 | 2023-11-01 | Janssen Biotech Inc | The antibody targets CD22 and CD79B |
JP2024513172A (ja) | 2021-03-26 | 2024-03-22 | ヤンセン バイオテツク,インコーポレーテツド | 対らせん状細線維タウに対するヒト化抗体及びその使用 |
WO2022218998A1 (en) | 2021-04-13 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating hepatitis b and d virus infection |
CR20230523A (es) | 2021-04-14 | 2024-01-23 | Villaris Therapeutics Inc | Anticuerpos anti-cd122 y usos de estos |
TW202309083A (zh) | 2021-04-22 | 2023-03-01 | 日商安斯泰來製藥股份有限公司 | 抗cldn4-抗cd137雙特異性抗體 |
WO2022261183A2 (en) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating and/or identifying an agent for treating intestinal cancers |
CN113361141B (zh) * | 2021-07-11 | 2022-02-18 | 西南石油大学 | 一种dna图谱算法的改进试验方法 |
IL311070A (en) | 2021-08-27 | 2024-04-01 | Janssen Biotech Inc | Anti-PSMA antibodies and uses thereof |
WO2023042097A1 (en) | 2021-09-15 | 2023-03-23 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer |
WO2023041744A1 (en) | 2021-09-17 | 2023-03-23 | Institut Curie | Bet inhibitors for treating pab1 deficient cancer |
WO2023046322A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceutica Nv | Proteins comprising cd20 binding domains, and uses thereof |
WO2023052541A1 (en) | 2021-09-30 | 2023-04-06 | Imcheck Therapeutics | Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy |
AU2022368385A1 (en) | 2021-10-18 | 2024-04-11 | Daiichi Sankyo Company, Limited | Anti-cd37 antibody-drug conjugate |
WO2023073084A1 (en) | 2021-10-27 | 2023-05-04 | Imcheck Therapeutics | Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders |
EP4177266A1 (en) | 2021-11-05 | 2023-05-10 | Katholieke Universiteit Leuven | Neutralizing anti-sars-cov-2 human antibodies |
CA3238116A1 (en) | 2021-11-18 | 2023-05-25 | Matthew Simon SUNG | Combination of antibody-drug conjugate and parp1 selective inhibitor |
WO2023089032A1 (en) | 2021-11-19 | 2023-05-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
WO2023097119A2 (en) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Methods and compositions to modulate riok2 |
WO2023099763A1 (en) | 2021-12-03 | 2023-06-08 | Institut Curie | Sirt6 inhibitors for use in treating resistant hrd cancer |
WO2023105528A1 (en) | 2021-12-12 | 2023-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to ceacam1 |
TW202334231A (zh) | 2021-12-22 | 2023-09-01 | 德商莫菲西斯公司 | 抗cd19抗體療法的治療範例 |
TW202333800A (zh) | 2021-12-28 | 2023-09-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及rasg12c抑制劑之組合 |
TW202339805A (zh) | 2021-12-28 | 2023-10-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atr抑制劑之組合 |
WO2023152581A1 (en) | 2022-02-09 | 2023-08-17 | Janssen Biotech, Inc. | Method of treating cancer with psmaxcd3 antibody |
WO2023166081A1 (en) | 2022-03-02 | 2023-09-07 | Heidelberg Immunotherapeutics Gmbh | Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody |
WO2023175614A1 (en) | 2022-03-15 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof |
WO2023175483A1 (en) | 2022-03-16 | 2023-09-21 | Astrazeneca Uk Limited | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
WO2023218378A1 (en) | 2022-05-11 | 2023-11-16 | Daiichi Sankyo Company, Limited | Combination of an antibody specific for a tumor antigen and a cd47 inhibitor |
WO2023228095A1 (en) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Dosage regimen of an anti-cdh6 antibody-drug conjugate |
WO2024013724A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody-drug conjugates |
WO2024023750A1 (en) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
WO2024072893A1 (en) | 2022-09-28 | 2024-04-04 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
WO2024074498A1 (en) | 2022-10-04 | 2024-04-11 | Imcheck Therapeutics | Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer |
WO2024116094A1 (en) | 2022-11-30 | 2024-06-06 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugates and dnmt inhibitors |
WO2024121380A1 (en) | 2022-12-08 | 2024-06-13 | Pierre Fabre Medicament | Vaccinal composition and adjuvant |
WO2024127366A1 (en) | 2022-12-16 | 2024-06-20 | Pheon Therapeutics Ltd | Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
JPS6033453B2 (ja) * | 1978-08-17 | 1985-08-02 | 富士電機株式会社 | 魚切断加工自動化装置 |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6014678A (ja) * | 1983-07-04 | 1985-01-25 | Taiheiyo Kogyo Kk | 電磁弁 |
GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB2188941B (en) * | 1986-04-14 | 1990-06-06 | Bayer Ag | Monoclonal antibodies recognizing human interleukin-2-receptor |
DK554986A (da) * | 1986-11-19 | 1988-07-18 | Novo Industri As | Human-human hybride cellelinier samt dermed producerede monoklonale cancerantistoffer |
GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
EP0328404B1 (en) * | 1988-02-12 | 1993-09-29 | Btg International Limited | Modified antibodies |
EP0362371A4 (en) * | 1988-04-15 | 1990-10-24 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
JP5598363B2 (ja) | 2011-02-15 | 2014-10-01 | ソニー株式会社 | 記憶装置およびその動作方法 |
-
1989
- 1989-11-27 IL IL162181A patent/IL162181A/en not_active IP Right Cessation
- 1989-12-27 IL IL92904A patent/IL92904A0/xx not_active IP Right Cessation
- 1989-12-28 CN CN89109618A patent/CN1057013C/zh not_active Expired - Lifetime
- 1989-12-28 AU AU51532/90A patent/AU647383B2/en not_active Expired
- 1989-12-28 ES ES04076438.3T patent/ES2440825T3/es not_active Expired - Lifetime
- 1989-12-28 DE DE122005000007C patent/DE122005000007I2/de active Active
- 1989-12-28 ES ES95105609T patent/ES2136760T3/es not_active Expired - Lifetime
- 1989-12-28 CA CA002006865A patent/CA2006865C/en not_active Expired - Lifetime
- 1989-12-28 DE DE68925536T patent/DE68925536T3/de not_active Expired - Lifetime
- 1989-12-28 ES ES04076439.1T patent/ES2523810T3/es not_active Expired - Lifetime
- 1989-12-28 MC MC@@@@D patent/MC2146A1/xx unknown
- 1989-12-28 EP EP95105609A patent/EP0682040B1/en not_active Revoked
- 1989-12-28 EP EP04076438.3A patent/EP1491556B1/en not_active Expired - Lifetime
- 1989-12-28 SI SI8912489A patent/SI8912489B/sl unknown
- 1989-12-28 DE DE200712000037 patent/DE122007000037I1/de active Pending
- 1989-12-28 EP EP98204240.0A patent/EP0939127B1/en not_active Expired - Lifetime
- 1989-12-28 DE DE1989625536 patent/DE122006000036I1/de active Pending
- 1989-12-28 AT AT90903576T patent/ATE133452T1/de active
- 1989-12-28 ZA ZA899956A patent/ZA899956B/xx unknown
- 1989-12-28 ES ES90903576T patent/ES2081974T5/es not_active Expired - Lifetime
- 1989-12-28 ES ES98204240.0T patent/ES2492815T3/es not_active Expired - Lifetime
- 1989-12-28 EP EP10185689A patent/EP2341080A1/en not_active Withdrawn
- 1989-12-28 DE DE04076439.1T patent/DE04076439T1/de active Pending
- 1989-12-28 PT PT92758A patent/PT92758B/pt active IP Right Grant
- 1989-12-28 DE DE122009000071C patent/DE122009000071I1/de active Pending
- 1989-12-28 EP EP04076439.1A patent/EP1477497B1/en not_active Expired - Lifetime
- 1989-12-28 DE DE04076438.3T patent/DE04076438T1/de active Pending
- 1989-12-28 RU SU4895847/13A patent/RU2126046C1/ru active
- 1989-12-28 DE DE122005000057C patent/DE122005000057I2/de active Active
- 1989-12-28 JP JP2503677A patent/JP2828340B2/ja not_active Ceased
- 1989-12-28 KR KR1019900701939A patent/KR0178385B1/ko not_active IP Right Cessation
- 1989-12-28 DE DE2000175038 patent/DE10075038I2/de active Active
- 1989-12-28 DE DE2000175005 patent/DE10075005I2/de active Active
- 1989-12-28 DE DE68925536A patent/DE68925536D1/de not_active Expired - Lifetime
- 1989-12-28 IE IE20000331A patent/IE20000331A1/en unknown
- 1989-12-28 CA CA002328851A patent/CA2328851C/en not_active Expired - Lifetime
- 1989-12-28 AT AT95105609T patent/ATE183753T1/de not_active IP Right Cessation
- 1989-12-28 YU YU248989A patent/YU48700B/sh unknown
- 1989-12-28 WO PCT/US1989/005857 patent/WO1990007861A1/en active IP Right Grant
- 1989-12-28 DE DE98204240.0T patent/DE98204240T1/de active Pending
- 1989-12-28 DE DE19975047C patent/DE19975047I2/de active Active
- 1989-12-28 DE DE68929061T patent/DE68929061T2/de not_active Expired - Lifetime
- 1989-12-28 EP EP90903576A patent/EP0451216B9/en not_active Expired - Lifetime
-
1990
- 1990-01-04 NZ NZ314793A patent/NZ314793A/xx unknown
- 1990-01-04 NZ NZ231984A patent/NZ231984A/en unknown
- 1990-01-17 DD DD90337159A patent/DD296964A5/de unknown
-
1991
- 1991-05-20 FI FI912436A patent/FI108797B/fi active Protection Beyond IP Right Term
- 1991-06-19 DK DK119191A patent/DK119191A/da not_active Application Discontinuation
- 1991-06-19 NO NO19912385A patent/NO310473B1/no not_active IP Right Cessation
- 1991-12-31 CZ CS914186A patent/CZ418691A3/cs unknown
-
1992
- 1992-01-20 BG BG95784A patent/BG61095B2/xx unknown
- 1992-09-26 HR HRP-2489/89A patent/HRP920500B1/xx not_active IP Right Cessation
-
1995
- 1995-06-16 HU HU95P/P00236P patent/HU211174A9/hu active Protection Beyond IP Right Term
-
1996
- 1996-04-13 SG SG1996007855A patent/SG78258A1/en unknown
-
1998
- 1998-01-12 JP JP00433498A patent/JP3604058B2/ja not_active Expired - Lifetime
- 1998-07-16 DK DK199800941A patent/DK174317B1/da not_active IP Right Cessation
- 1998-12-28 HK HK98115967A patent/HK1014718A1/xx not_active IP Right Cessation
-
1999
- 1999-07-02 LU LU90411C patent/LU90411I2/fr unknown
- 1999-07-14 NL NL990020C patent/NL990020I2/nl unknown
-
2000
- 2000-02-11 NL NL300005C patent/NL300005I2/nl unknown
- 2000-02-11 LU LU90528C patent/LU90528I2/fr unknown
- 2000-11-03 NL NL300023C patent/NL300023I2/nl unknown
- 2000-11-09 LU LU90676C patent/LU90676I2/fr unknown
-
2001
- 2001-12-17 NO NO2001026C patent/NO2001026I2/no unknown
- 2001-12-17 NO NO2001025C patent/NO2001025I2/no unknown
- 2001-12-17 NO NO2001024C patent/NO2001024I1/no unknown
-
2003
- 2003-01-20 JP JP2003011706A patent/JP2003245091A/ja not_active Withdrawn
- 2003-01-20 JP JP2003011705A patent/JP2003245090A/ja not_active Withdrawn
-
2005
- 2005-02-04 LU LU91139C patent/LU91139I2/fr unknown
- 2005-02-10 NL NL300173C patent/NL300173I2/nl unknown
- 2005-02-18 NO NO2005005C patent/NO2005005I2/no unknown
- 2005-12-02 LU LU91208C patent/LU91208I2/fr unknown
- 2005-12-07 NO NO2005026C patent/NO2005026I2/no unknown
- 2005-12-12 NL NL300213C patent/NL300213I2/nl unknown
-
2006
- 2006-08-07 NO NO2006009C patent/NO2006009I2/no unknown
- 2006-08-07 LU LU91272C patent/LU91272I2/fr unknown
- 2006-08-07 NL NL300239C patent/NL300239I2/nl unknown
-
2007
- 2007-03-02 JP JP2007053539A patent/JP2007145863A/ja not_active Withdrawn
- 2007-04-11 LU LU91333C patent/LU91333I2/fr unknown
- 2007-04-18 NL NL300279C patent/NL300279I2/nl unknown
- 2007-04-18 NO NO2007006C patent/NO2007006I2/no unknown
-
2009
- 2009-04-21 JP JP2009103471A patent/JP2009165488A/ja not_active Withdrawn
- 2009-11-12 NO NO2009026C patent/NO2009026I1/no unknown
- 2009-11-19 NL NL300426C patent/NL300426I1/nl unknown
- 2009-12-09 LU LU91627C patent/LU91627I2/fr unknown
-
2014
- 2014-09-17 FR FR14C0070C patent/FR14C0070I1/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI8912489A (sl) | Novi IL-2 receptor specifični humani imunoglobulini | |
EP0566647B1 (en) | Improved humanized immunoglobulins | |
US5997867A (en) | Method of using humanized antibody against CD18 | |
AU631545B2 (en) | Il-2 receptor-specific chimeric antibodies | |
US20080160018A1 (en) | Humanized immunoglobulins | |
WO1993001289A1 (en) | Humanized interleukin-2 receptors antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date | ||
SP73 | Change of data on owner |
Owner name: PROTEIN DESIGN LABS, INC.; US Effective date: 20051207 |
|
SP73 | Change of data on owner |
Owner name: PDL BIOPHARMA, INC.; US Effective date: 20061207 |
|
SP73 | Change of data on owner |
Owner name: PDL BIOPHARMA, INC.; US Effective date: 20081022 |
|
SP73 | Change of data on owner |
Owner name: PDL BIOPHARMA, INC.; US Effective date: 20090806 |